


Systematic review of the effectiveness of preventing and treating *Staphylococcus aureus* carriage in reducing peritoneal catheter-related infections

K McCormack, K Rabindranath, M Kilonzo,
L Vale, C Fraser, L McIntyre, S Thomas,
H Rothnie, N Fluck, IM Gould and N Waugh



July 2007

Health Technology Assessment
NHS R&D HTA Programme
www.hta.ac.uk





INAHTA

How to obtain copies of this and other HTA Programme reports.

An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (<http://www.hta.ac.uk>). A fully searchable CD-ROM is also available (see below).

Printed copies of HTA monographs cost £20 each (post and packing free in the UK) to both public **and** private sector purchasers from our Despatch Agents.

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.

You can order HTA monographs from our Despatch Agents:

- fax (with **credit card** or **official purchase order**)
- post (with **credit card** or **official purchase order** or **cheque**)
- phone during office hours (**credit card** only).

Additionally the HTA website allows you **either** to pay securely by credit card **or** to print out your order and then post or fax it.

Contact details are as follows:

HTA Despatch
c/o Direct Mail Works Ltd
4 Oakwood Business Centre
Downley, HAVANT PO9 2NP, UK

Email: orders@hta.ac.uk
Tel: 02392 492 000
Fax: 02392 478 555
Fax from outside the UK: +44 2392 478 555

NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30–40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume.

Payment methods

Paying by cheque

If you pay by cheque, the cheque must be in **pounds sterling**, made payable to *Direct Mail Works Ltd* and drawn on a bank with a UK address.

Paying by credit card

The following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email.

Paying by official purchase order

You can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK.

How do I get a copy of HTA on CD?

Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. *HTA on CD* is currently free of charge worldwide.

The website also provides information about the HTA Programme and lists the membership of the various committees.



INAHTA

How to obtain copies of this and other HTA Programme reports.

An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (<http://www.hta.ac.uk>). A fully searchable CD-ROM is also available (see below).

Printed copies of HTA monographs cost £20 each (post and packing free in the UK) to both public **and** private sector purchasers from our Despatch Agents.

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.

You can order HTA monographs from our Despatch Agents:

- fax (with **credit card** or **official purchase order**)
- post (with **credit card** or **official purchase order** or **cheque**)
- phone during office hours (**credit card** only).

Additionally the HTA website allows you **either** to pay securely by credit card **or** to print out your order and then post or fax it.

Contact details are as follows:

HTA Publications
PO Box 642
YORK YO31 7WX
UK

Email: orders@hta.ac.uk
Tel: 0870 1616662
Fax: 0870 1616663

NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30–40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume.

Payment methods

Paying by cheque

If you pay by cheque, the cheque must be in **pounds sterling**. Please see our website for details.

Paying by credit card

The following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email.

Paying by official purchase order

You can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK.

How do I get a copy of HTA on CD?

Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact our despatch agents (see contact details above) by email, post, fax or phone. *HTA on CD* is currently free of charge worldwide.

The website also provides information about the HTA Programme and lists the membership of the various committees.

Systematic review of the effectiveness of preventing and treating *Staphylococcus aureus* carriage in reducing peritoneal catheter-related infections

K McCormack,^{1*} K Rabindranath,² M Kilonzo,³
L Vale,^{1,3} C Fraser,¹ L McIntyre,⁴ S Thomas,⁴
H Rothnie,⁴ N Fluck,⁵ IM Gould⁶ and N Waugh⁷

¹ Health Services Research Unit, Institute of Applied Health Sciences, University of Aberdeen, UK

² Department of Renal Medicine, Churchill Hospital, Oxford, UK

³ Health Economics Research Unit, Institute of Applied Health Sciences, University of Aberdeen, UK

⁴ Systematic Reviewer, Orkney, UK

⁵ Department of Renal Medicine, Aberdeen Royal Infirmary, UK

⁶ Medical Microbiology, Aberdeen Royal Infirmary, UK

⁷ Department of Public Health, University of Aberdeen, UK

* Corresponding author

Declared competing interests of authors: none

Published July 2007

This report should be referenced as follows:

McCormack K, Rabindranath K, Kilonzo M, Vale L, Fraser C, McIntyre L, et al. Systematic review of the effectiveness of preventing and treating *Staphylococcus aureus* carriage in reducing peritoneal catheter-related infections. *Health Technol Assess* 2007; **11**(23).

Health Technology Assessment is indexed and abstracted in *Index Medicus/MEDLINE*, *Excerpta Medica/EMBASE* and *Science Citation Index Expanded (SciSearch®)* and *Current Contents®/Clinical Medicine*.

NIHR Health Technology Assessment Programme

The Health Technology Assessment (HTA) programme, now part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.

The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'.

The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects.

First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, the public and consumer groups and professional bodies such as royal colleges and NHS trusts. These suggestions are carefully prioritised by panels of independent experts (including NHS service users). The HTA Programme then commissions the research by competitive tender.

Secondly, the HTA Programme provides grants for clinical trials for researchers who identify research questions. These are assessed for importance to patients and the NHS, and scientific rigour.

Thirdly, through its Technology Assessment Report (TAR) call-off contract, the HTA Programme commissions bespoke reports, principally for NICE, but also for other policy-makers. TARs bring together evidence on the value of specific technologies.

Some HTA research projects, including TARs, may take only months, others need several years. They can cost from as little as £40,000 to over £1 million, and may involve synthesising existing evidence, undertaking a trial, or other research collecting new data to answer a research problem.

The final reports from HTA projects are peer-reviewed by a number of independent expert referees before publication in the widely read monograph series *Health Technology Assessment*.

Criteria for inclusion in the HTA monograph series

Reports are published in the HTA monograph series if (1) they have resulted from work for the HTA Programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

The research reported in this monograph was commissioned by the HTA Programme as project number 05/29/01. The contractual start date was in September 2005. The draft report began editorial review in May 2006 and was accepted for publication in February 2007. As the funder, by devising a commissioning brief, the HTA Programme specified the research question and study design. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the referees for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

The views expressed in this publication are those of the authors and not necessarily those of the HTA Programme or the Department of Health.

Editor-in-Chief:

Professor Tom Walley

Series Editors:

Dr Aileen Clarke, Dr Peter Davidson, Dr Chris Hyde,
Dr John Powell, Dr Rob Riemsma and Dr Ken Stein

Managing Editors:

Sally Bailey and Sarah Llewellyn Lloyd

ISSN 1366-5278

© Queen's Printer and Controller of HMSO 2007

This monograph may be freely reproduced for the purposes of private research and study and may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising.

Applications for commercial reproduction should be addressed to: NCCHTA, Mailpoint 728, Boldrewood, University of Southampton, Southampton, SO16 7PX, UK.

Published by Gray Publishing, Tunbridge Wells, Kent, on behalf of NCCHTA.

Printed on acid-free paper in the UK by St Edmundsbury Press Ltd, Bury St Edmunds, Suffolk.



Abstract

Systematic review of the effectiveness of preventing and treating *Staphylococcus aureus* carriage in reducing peritoneal catheter-related infections

K McCormack,^{1*} K Rabindranath,² M Kilonzo,³ L Vale,^{1,3} C Fraser,¹ L McIntyre,⁴ S Thomas,⁴ H Rothnie,⁴ N Fluck,⁵ IM Gould⁶ and N Waugh⁷

¹ Health Services Research Unit, Institute of Applied Health Sciences, University of Aberdeen, UK

² Department of Renal Medicine, Churchill Hospital, Oxford, UK

³ Health Economics Research Unit, Institute of Applied Health Sciences, University of Aberdeen, UK

⁴ Systematic Reviewer, Orkney, UK

⁵ Department of Renal Medicine, Aberdeen Royal Infirmary, UK

⁶ Medical Microbiology, Aberdeen Royal Infirmary, UK

⁷ Department of Public Health, University of Aberdeen, UK

* Corresponding author

Objectives: To determine the clinical effectiveness and cost-effectiveness of (1) alternative strategies for the prevention of *Staphylococcus aureus* carriage in patients on peritoneal dialysis (PD) and (2) alternative strategies for the eradication of *S. aureus* carriage in patients on PD.

Data sources: Major electronic databases were searched up to December 2005 (MEDLINE Extra up to 6 January 2006).

Review methods: Electronic searches were undertaken to identify published and unpublished reports of randomised controlled trials and systematic reviews evaluating the effectiveness of preventing and treating *S. aureus* carriage on peritoneal catheter-related infections. The quality of the included studies was assessed and data synthesised. Where data were not sufficient for formal meta-analysis, a qualitative narrative review looking for consistency between studies was performed.

Results: Twenty-two relevant trials were found. These fell into several groups: the first split is between prophylactic trials, aiming to prevent carriage, and trials which aimed to eradicate carriage in those who already had it; the second split is between antiseptics and antibiotics; and the third split is between those that included patients having the catheter inserted before dialysis started and people already on dialysis. Many of the trials were small or short-term. The quality was often not good by today's standards. The body of evidence suggested a reduction in exit-site infections,

but this did not seem to lead to a significant reduction in peritonitis, although to some extent this reflected insufficient power in the studies and a low incidence of peritonitis in them. The costs of interventions to prevent or treat *S. aureus* carriage are relatively modest. For example, the annual cost of antibiotic treatment of *S. aureus* carriage per identified carrier of *S. aureus* was estimated at £179 (£73 screening and £106 cost of antibiotic). However, without better data on the effectiveness of the interventions, it is not clear whether such costs are offset by the cost of treating infections and averting changes from peritoneal dialysis to haemodialysis. Although treatment is not expensive, the lack of convincing evidence of clinical effectiveness made cost-effectiveness analysis unrewarding at present. However, consideration was given to the factors needed in a hypothetical model describing patient pathways from methods to prevent *S. aureus* carriage, its detection and treatment and the detection and treatment of the consequences of *S. aureus* (e.g. catheter infections and peritonitis). Had data been available, the model would have compared the cost-effectiveness of alternative interventions from the perspective of the UK NHS, but as such it helped identify what future research would be needed to fill the gaps.

Conclusions: The importance of peritonitis is not in doubt. It is the main cause of people having to switch from peritoneal dialysis to haemodialysis, which then leads to reduced quality of life for patients

and increased costs to the NHS. Unfortunately, the present evidence base for the prevention of peritonitis is disappointing; it suggests that the interventions reduce exit-site infections, but not

peritonitis, although this may be due to trials being in too small numbers for too short periods. Trials are needed with larger numbers of patients for longer durations.



Contents

List of abbreviations	vii	References	33
Executive summary	ix	Appendix 1 Search strategies	37
1 Objectives of the review	1	Appendix 2 Study eligibility form	41
2 Background	3	Appendix 3 Data abstraction and quality assessment form	43
Description of the problem	3	Appendix 4 List of included studies	47
Descriptions of interventions	3	Appendix 5 Detailed quality assessment results for included trials	49
Recommendations according to various guidelines	3	Appendix 6 Detailed description of included studies	51
3 Efficacy and safety	5	Appendix 7 Proposed methods for parameterising the economic model	59
Methods for reviewing effectiveness	5	Appendix 8 Treatment of clinical infections	65
Results	6	Health Technology Assessment reports published to date	67
4 Economic evaluation	21	Health Technology Assessment Programme	81
Introduction	21		
The economic approach	21		
Hypothetical economic model	22		
Summary	26		
5 Discussion	27		
Volume of evidence	27		
Other reviews	27		
Research needs	28		
6 Conclusions	29		
Acknowledgements	31		



List of abbreviations

CEAC	cost-effectiveness acceptability curve	MRSA	methicillin-resistant <i>Staphylococcus aureus</i>
CI	confidence interval	MSSA	methicillin-sensitive <i>Staphylococcus aureus</i>
EPO	erythropoietin	NICE	National Institute for Health and Clinical Excellence
EURODICE	European Dialysis and Cost Effectiveness	PD	peritoneal dialysis
HCHS	Hospital and Community Health Services	QALY	quality-adjusted life-year
HD	haemodialysis	RCT	randomised controlled trial
ITT	intention-to-treat	RR	relative risk
		SA	<i>Staphylococcus aureus</i>

All abbreviations that have been used in this report are listed here unless the abbreviation is well known (e.g. NHS), or it has been used only once, or it is a non-standard abbreviation used only in figures/tables/appendices in which case the abbreviation is defined in the figure legend or at the end of the table.



Executive summary

Objectives

The objectives of this review were to determine the clinical effectiveness and cost-effectiveness of alternative strategies for the prevention and eradication of *Staphylococcus aureus* carriage in patients on peritoneal dialysis (PD). The aim was to prevent, or reduce, the frequency of peritonitis. The review does not cover treatment of peritonitis itself.

Background and intervention

In chronic renal failure, dialysis is used to replace the kidneys' function in removing impurities and unwanted products of metabolism from the blood. Peritoneal dialysis is a form of ambulatory dialysis in which fluid is fed into the abdominal cavity via a catheter through the abdominal wall. The fluid collects the substances normally excreted by the kidney. After an interval the fluid is drained out again.

The main complication of peritoneal dialysis in the short term is infection of the peritoneal cavity, peritonitis. In the longer term, recurrent episodes of peritonitis can impair diffusion across the peritoneal membrane, so that peritoneal dialysis is no longer feasible, which means that patients have to attend hospital for haemodialysis, usually three times per week.

One of the organisms which cause peritonitis is *Staphylococcus aureus*. It can colonise parts of the body without symptoms, but may cause infection where the peritoneal catheter passes through the skin of the abdomen. These are known as exit-site infections. It may also contaminate the tip of the catheter. In both situations, peritonitis may be a consequence.

Various measures have been used to try to prevent or eradicate colonisation, in the hope that this will prevent, or reduce, the frequency of peritonitis. These include antiseptics and antibiotics. The antibiotics can be applied locally or given systemically, by mouth.

S. aureus can develop resistance to commonly used antibiotics, and is then known as methicillin-resistant *Staphylococcus aureus* (MRSA).

Epidemiology

End-stage renal failure can be a consequence of a number of diseases, the commonest being glomerulonephritis, diabetes, renal vascular disease, pyelonephritis and polycystic kidney disease.

Methods

Electronic searches were undertaken to identify published and unpublished reports of randomised controlled trials (RCTs) and systematic reviews evaluating the effectiveness of preventing and treating *S. aureus* carriage on peritoneal catheter-related infections. The main databases searched were MEDLINE (1966–2005), EMBASE (1980–2005), CINAHL (1982–2005), BIOSIS (1985–2005), Science Citation Index (SCI) (1980–2005), MEDLINE Extra (6 January 2006), Cochrane Library (Issue 4 2005), Database of Abstracts of Reviews of Effectiveness (December 2005) and HTA Database (December 2005). The quality of the included studies was assessed and data synthesised. Where data were not sufficient for formal meta-analysis, a qualitative narrative review looking for consistency between studies was performed.

Results

Number and quality of studies and summary of benefits

Twenty-two trials were found. These fell into several groups: the first split is between prophylactic trials, aiming to prevent carriage, and trials which aimed to eradicate carriage in those who already had it; the second split is between antiseptics and antibiotics; and the third split is between those that included patients having the catheter inserted before dialysis started and people already on dialysis. Many of the trials were small or short-term. The quality was often not good by today's standards. The body of evidence suggested a reduction in exit-site infections but this did not seem to lead to a significant reduction in peritonitis, although to some extent this reflected insufficient power in the studies and a low incidence of peritonitis in them.

Costs

The costs of interventions to prevent or treat *S. aureus* carriage are relatively modest. For example, the annual cost of antibiotic treatment of *S. aureus* carriage per identified carrier of *S. aureus* was estimated at £179 (£73 screening and £106 cost of antibiotic). However, without better data on the effectiveness of the interventions, it is not clear whether such costs are offset by the cost of treating infections and averting changes from peritoneal dialysis to haemodialysis.

Cost-effectiveness

Although treatment is not expensive, the lack of convincing evidence of clinical effectiveness made cost-effectiveness analysis unrewarding at present. However, consideration was given to the factors needed in a hypothetical model describing patient pathways from methods to prevent *S. aureus* carriage, its detection and treatment and the detection and treatment of the consequences of *S. aureus* (e.g. catheter infections and peritonitis). Had data been available, the model would have compared the cost-effectiveness of alternative interventions from the perspective of the UK NHS, but as such it helped identify what future research would be needed to fill the gaps.

Conclusions

The importance of peritonitis is not in doubt. It is the main cause of people having to switch from peritoneal dialysis to haemodialysis, which leads to

reduced quality of life for patients and increased costs to the NHS. Unfortunately, the present evidence base for the prevention of peritonitis is disappointing; it suggests that the interventions reduce exit-site infections but not peritonitis, although this may be due to trials being in too small numbers for too short periods.

Recommendations for research

The study identified key research questions that need to be addressed. These are given below.

- What is the natural history of carriage of *S. aureus*? What are the links between carriage and exit-site infection, and between exit-site infection and peritonitis? What factors predict carriage?
- Is the problem mainly with MRSA, with methicillin-sensitive *Staphylococcus aureus* (MSSA) being relatively harmless?
- Does decolonisation work, or is recolonisation rapid?
- Apart from antibiotic and antiseptic use, what other options for reducing peritonitis are there? Would more training help?
- Should measures to eradicate carriage be intermittent or chronic; antiseptics versus antibiotics?
- Is vaccination worth revisiting?
- Given the common use of mupirocin in renal units, research into that drug and resistance to it should be a priority.

Trials are needed with larger numbers of patients for longer durations.

Chapter I

Objectives of the review

The objectives of this review were to determine the clinical effectiveness and cost-effectiveness of alternative strategies for the prevention and eradication of *Staphylococcus aureus* carriage in

patients on peritoneal dialysis (PD). The aim was to prevent, or reduce, the frequency of peritonitis. The review does not cover treatment of peritonitis itself.

Chapter 2

Background

Description of the problem

S. aureus is a bacterium that lives completely harmlessly on the skin and in the nose of about one-third of normal healthy people. This situation can be called colonisation or carriage. Other *S. aureus* carriage sites include the axillae, vagina, perineum and occasionally the gastrointestinal tract.

However, although colonisation of those sites may not cause any problems there, the presence of the organism means that more vulnerable parts of the body may be first contaminated and then infected. In PD, a catheter is inserted into the abdominal cavity through the skin of the abdominal wall and exits through a subcutaneous tunnel. Whenever the skin is broken, there is a risk of infection. Hence people on PD are at increased risk because of the break in the skin. Some may also be at increased risk of all infections because of the diseases which lead to renal failure, such as diabetes.

PD is used more in the UK than in other countries. Almost one-third of the dialysis population in the UK are on PD¹ and 50% of PD patients are known to be *S. aureus* carriers.² Some studies have reported that nasal carriage of *S. aureus* is more frequent in diabetic and immunosuppressed PD patients.^{3,4}

PD catheter-related infections are an important cause of morbidity and mortality in the PD population. Such infections are classified into exit-site, tunnel infections and peritonitis. An exit-site infection is defined as purulent drainage at the catheter exit site with or without erythema. A tunnel infection is an infection of the tissues overlying the subcutaneous portion of the catheter.⁵ Peritonitis is inflammation of the peritoneal membrane. Exit-site or tunnel infections cause significant morbidity as they can lead to refractory or recurrent peritonitis.⁶ Peritonitis is associated with several adverse consequences. It accounts for the majority of occasions when the PD catheter has to be removed, leading to transfer to haemodialysis (HD).^{7,8} Peritonitis is one of the most common causes for hospitalisation in PD patients.⁹ It contributes to the decline of peritoneal

membrane function, which means that PD may become impossible. It may also lead to a more rapid decline in residual renal function (i.e. some patients still have a little function left in their kidneys) and is an important predictor of survival.¹⁰

Although there can be many different causes of PD catheter-related infections, *S. aureus* is an important cause. It is believed to be the leading cause of PD catheter exit-site infection^{11,12} and one of the most frequent causes of PD-related peritonitis.¹³ It has been estimated that the peritonitis rates due to *S. aureus* are 0.09–0.22 per dialysis year.^{2,14} The cost of *S. aureus* infections in the dialysis population in the USA has been estimated to be over US\$200 million annually.¹⁵

Several studies have shown a strong link between *S. aureus* carriage and PD catheter exit-site and tunnel infections^{16–18} and peritonitis.^{19,20} *S. aureus* carriers, have a two- to six-fold higher risk of *S. aureus* peritonitis than non-carriers.^{2,19}

Peritonitis due to *S. aureus* tends to be more severe than that due to other organisms, with patients more likely to have fever and hypotension.²¹ Hospital admission may be prolonged with *S. aureus* peritonitis⁹ and it also increases mortality.^{22,23} Furthermore, removal of the PD catheter is required more often in *S. aureus* peritonitis than with peritonitis due to other bacteria, to resolve the peritonitis or prevent recurrence.²⁴ Removal of the catheter means that PD has to be replaced by HD, requiring at least temporary attendance at hospital dialysis sessions, usually three times per week.

Descriptions of interventions

Studies comparing carriage and infecting *S. aureus* isolates have shown that patients are infected with their 'own' organism, that is, the one they carry on skin or nose.^{2,25,26} Although *S. aureus* is found in the body in areas other than the nose, elimination of nasal carriage also leads to loss of carriage in other sites such as hands and skin,²⁷ implying that the other parts are being reinfected from the nose. In addition, the PD catheter exit site is reported to be most important colonising site of *S. aureus*

strains that cause peritonitis.²⁸ These important observations underpin strategies that aim to reduce *S. aureus*-related PD catheter infections and peritonitis.

S. aureus is normally susceptible to a variety of antibiotics, the most commonly used of which is mupirocin, given as an ointment.

Recommendations according to various guidelines

Various bodies have made recommendations, although these are not necessarily followed in practice.

- Renal Association (UK):²⁹ Peritonitis rates should be less than one episode per 18 patient months. Mupirocin should be applied to the exit site either daily or on alternate days. Nasal carriage of *S. aureus* should be treated with mupirocin twice daily for five consecutive days every 4 weeks.
- European Renal Association–European Dialysis and Transplantation Association (ERA–EDTA):³⁰ Mupirocin should be applied

either at the exit site or intranasally especially in patients who are *S. aureus* carriers.

- International Society of Peritoneal Dialysis:³¹ Several options are recommended: exit-site mupirocin daily in all patients or in *S. aureus* carriers only or in response to positive *S. aureus* culture; intranasal mupirocin every month in those identified as carriers or only in response to positive nose culture; exit-site gentamicin in all patients.
- Caring for Australians with Renal Impairment (CARI guidelines):^{32–34} Prophylactic therapy using mupirocin ointment, especially for *S. aureus* carriage intranasally, is recommended to decrease the risk of *S. aureus* catheter exit site/tunnel infections and peritonitis.

It is clear that although all guidelines recommend mupirocin for *S. aureus* nasal carriers, there is considerable variation with other recommendations. There has been no systematic review of evidence for the effectiveness of interventions for prevention and treatment of *S. aureus* carriage in PD patients. It was against this background that the NHS Research and Development Programme for Health Technology Assessment (HTA) commissioned this study.

Chapter 3

Efficacy and safety

Methods for reviewing effectiveness

Search strategy

Electronic searches were undertaken to identify published and unpublished reports of randomised controlled trials (RCTs) and systematic reviews evaluating the effectiveness of preventing and treating *S. aureus* carriage on peritoneal catheter-related infections.

The main databases searched were MEDLINE (1966–2005), EMBASE (1980–2005), CINAHL (1982–2005), BIOSIS (1985–2005), Science Citation Index (SCI) (1980–2005), MEDLINE Extra (6 January 2006), Cochrane Library (Issue 4 2005), Database of Abstracts of Reviews of Effectiveness (December 2005) and HTA Database (December 2005). Searching was restricted to English language publications only. In addition, recent conference proceedings, tables of contents of two key PD journals and reference lists of all included studies were scanned to identify additional potentially relevant studies. Full details of the search strategies used are documented in Appendix 1.

All titles and abstracts identified in these ways were assessed to identify potentially eligible studies. Two reviewers independently assessed them for inclusion, using a study eligibility form developed for this purpose (Appendix 2). Any disagreements were resolved by consensus or arbitration. Systematic reviews were used to identify RCTs but were not otherwise included in this review.

Inclusion and exclusion criteria

Types of studies

All published RCTs and quasi-RCTs (e.g. allocation by alternation) of patients receiving PD for end-stage renal disease in whom alternative interventions were compared for the prevention and treatment of *S. aureus* carriage were included. For the purposes of this review, studies comparing alternative interventions for the treatment of clinical infections and studies which did not report outcomes separately for *S. aureus* were excluded.

Types of participants

The trials included patients on PD for end-stage renal disease from any cause.

Types of outcomes

The following measures of outcomes were sought:

Primary outcome:

1. number of patients with peritonitis caused by *S. aureus*.

Secondary outcomes:

1. number of patients with *S. aureus* carriage
2. time to *S. aureus* carriage
3. peritonitis rate (number of episodes over total patient months on PD) caused by *S. aureus*
4. time to first peritonitis episode caused by *S. aureus*
5. peritonitis relapse (number and specify time to) caused by *S. aureus*
6. number of patients requiring catheter removal caused by *S. aureus*
7. number of patients switching to HD caused by *S. aureus*
8. number of patients requiring catheter replacement caused by *S. aureus*
9. number of patients with exit-site and/or tunnel infections caused by *S. aureus*
10. exit-site and/or tunnel infection rate caused by *S. aureus*
11. side-effects
12. death due to peritonitis caused by *S. aureus*
13. hospitalisation rates
14. quality of life
15. development of antibiotic resistance.

Data extraction strategy

The titles and abstracts of all papers identified by the search strategy were screened. Full text copies of all potentially relevant studies were obtained and assessed for inclusion. Reviewers were not blinded to the names of studies' authors, institutions or sources of the reports. Any disagreements were resolved by consensus or arbitration.

A data extraction form was developed to record details of trial methods, participants, interventions, patient characteristics and outcomes (Appendix 3).

Two reviewers independently extracted data from the included studies. Any differences that could not be resolved through discussion were referred to an arbiter.

Quality assessment strategy

Two reviewers, working independently, assessed the methodological quality of the included studies. Again, any disagreements were resolved by consensus or arbitration. The system for classifying methodological quality of controlled trials was based on an assessment of four principal potential sources of bias: selection bias caused by inadequate concealment of allocation of treatments; attrition bias caused by losses to follow-up without appropriate intention-to-treat (ITT) analysis; detection bias caused by biased ascertainment of outcome where knowledge of the allocation might have influenced the measurement of outcome; and selection bias in analysis (Appendix 3).

Data synthesis

For trials with multiple publications, only the most up-to-date data for each outcome were included. Dichotomous outcome data were combined using the Mantel–Haenszel relative risk (RR) method and 95% confidence intervals (CIs) and *p*-values were calculated for the estimates. The results were all reported using a fixed-effects model. χ^2 tests and I^2 statistics were used to explore statistical heterogeneity across studies and, when present, random effects methods were applied. Other possible reasons for heterogeneity were explored using sensitivity analyses. The meta-analyses were conducted using the standard Cochrane software RevMan 4.2.

Where data were not sufficient for formal meta-analysis, a qualitative narrative review looking for consistency between studies was performed.

Results

Quantity and quality of research available

Number of studies identified

The results of the searches are summarised in *Table 1*. The numbers retrieved from the searches in CINAHL, SCI, Biosis and CENTRAL and screening of full text journals include only the additional reports found after excluding those identified from the MEDLINE/EMBASE multifile search.

A total of 498 titles and abstracts were identified from the various searches, of which 394 were

TABLE 1 Search results

Database	No. retrieved
MEDLINE/EMBASE/MEDLINE Extra multifile search (after deduplication in Ovid)	381
CINAHL	23
SCI	56
BIOSIS	12
CENTRAL	2
CDSR	1
DARE	7
HTA database	2
NRR	1
CCT	0
Clinical Trials	0
SCI Proceedings	2
Selected from conference abstracts	2
Selected from full text journals	9
Total	498

TABLE 2 Papers selected for full assessment

Assessment	No. of papers
Included in review	25
Systematic reviews	7
Retained for background information	26
Excluded – not RCTs	17
Excluded – treatment of clinical infections	7
Excluded – outcomes not reported separately for <i>S. aureus</i> carriage	22
Unobtainable papers	0
Total	104

clearly outwith the scope of this review. The remaining 104 reports (90 full text papers and 14 abstracts) were selected for full assessment. *Table 2* details the numbers of these that were included and excluded.

Number and type of studies included

Twenty-five reports (21 full text papers and four abstracts) describing 22 RCTs met the inclusion criteria for the review and were included in the review of clinical effectiveness. The majority of these reports were identified from the MEDLINE/EMBASE search (20), with two each identified from SCI and the full text journals and one from BIOSIS. The list of included studies and associated references are listed in Appendix 4. No studies were identified only from CINAHL.

Trials fell into several groups. The first split is between prophylactic trials, aiming to prevent

carriage, and between trials which aimed to eradicate carriage in those who already had it. The second split is between antiseptics and antibiotics. The third split is between those that included patients having the catheter inserted before dialysis started and those where the people were already on dialysis.

Number and type of studies excluded, with reasons for specific exclusions

A total of 46 reports were obtained but subsequently were excluded because they failed to meet one or more of the inclusion criterion. Of these, 17 were not RCTs, seven were concerning the treatment of clinical infections and in 22 the authors did not report outcomes separately for participants with *S. aureus* carriage (18 primary reports and four secondary reports).

Study quality, characteristics and evidence rating

A summary of the quality assessment of the 22 RCTs is presented in *Table 3* and the detailed quality assessment for each of the included studies is reported in Appendix 5. The method of randomisation used was stated explicitly for 11 of 22 trials: a central randomisation service was used in one study, consecutively numbered, sealed envelopes were used in one study, computer-generated random numbers were used in one study, there was consecutive allocation in two, by random numbers table in three, by date of follow-up in one, assigned by a third party in one and random selection by cards in one. By modern standards, most of these methods are unsatisfactory, but some of the trials were done some time ago. In 11 trials, the allocation was said to be 'randomised' but the method was not specified. Concealment of allocation was adequate in only one trial, suboptimal in four and unclear in 17.

In the majority of trials, it was unclear whether studies blinded the care provider, participant, outcome assessor or data analyst (but it is questionable if this is possible given the nature of the treatments compared). Five studies included an ITT analysis but it was unclear if this were the case for the remaining 25 studies.

Eligibility criteria were clearly specified in 21 studies. The mean or median duration of follow-up ranged from at least 48 hours to 1 year. This was not reported for three studies.

Characteristics of included studies

The comparisons made and characteristics of the RCTs are summarised in *Table 4* and a detailed description for each of the included studies is reported in Appendix 6. Within the 22 eligible RCTs, there were 30 relevant comparisons (four trials had three arms). Three trials took place in the UK, eight in the USA, two in Hong Kong, two in Brazil and one each in Spain, Turkey, Singapore and Canada. There were two multi-centre European trials and one multi-centre Australia and New Zealand trial. Across the trials recruitment dates ranged from May 1987 to August 2003. Eleven trials failed to provide information on recruitment dates. The number of participants randomised ranged from 15 to 267. Two trials had more than 200 participants, eight more than 100 participants and 12 fewer than 100 participants. Eighteen trials gave details of the numbers of men and women in each trial group. Seventeen trials gave details of participants' ages. One trial included children only.

Assessment of effectiveness

Table 5 gives a summary of the outcomes reported in the included studies.

Prophylaxis amongst all patients

Eighteen trials evaluated prophylaxis amongst all patients regardless of their *S. aureus* status at trial entry. Four trials evaluated prophylaxis at the time of catheter insertion and the remaining trials considered prophylaxis given once dialysis had commenced. Five trials compared antibiotic treatment with no antibiotic treatment, four trials compared two different antibiotic regimes, one three-armed trial compared two different antibiotic regimes with no antibiotic treatment, three trials compared antiseptic treatment with no antiseptic treatment, one trial compared two different types of antiseptics, one trial compared a vaccination with combined staphylococcus

TABLE 3 Summary of the quality assessment of the included RCTs

Allocation concealment	Blinding of investigators	Blinding of participants	Blinding of assessor	Blinding of data analysis	ITT	Lost to follow-up
Adequate: 1	Yes: 1	Yes: 2	Yes: 1	Yes: 0	Stated: 3	Yes: 12
Inadequate: 4	No: 5	No: 4	No: 2	No: 1	Not stated: 19	No: 0
Unclear: 17	Unclear: 17	Unclear: 16	Unclear: 19	Unclear: 21		Unclear: 10

TABLE 4 Summary of the comparisons made and baseline characteristics

Study	Comparison	No. of participants	Age (years) ^a	Male/female
Prophylaxis amongst all patients				
Antibiotic versus no antibiotic				
<i>Catheter insertion:</i>				
Bennett-Jones, 1988 ³⁵	I.v. gentamicin	13	52.7 ± 18.6 ^b	8/5
	No treatment	13	52.7 ± 18.6 ^b	9/4
Lye, 1992 ³⁶	I.v. cefazolin and gentamicin	25	56.0 ± 14.3	8/17
	No treatment	25	52.3 ± 14.0	15/10
<i>During dialysis:</i>				
Sharma, 1971 ³⁷	Neomycin by mouth or nasogastric tube	48 dialysates	–	–
	Placebo	41 dialysates	–	–
Wong, 2003 ³⁸	Mupirocin ointment	78 (73 analysed)	60 ± 12 ^c	32/41
	No treatment	88 (81 analysed)	59 ± 13 ^c	47/34
Zimmerman, 1991 ³⁹	Rifampin	32	53 ± 3	17/15
	No treatment	32	55 ± 4	24/8
Antibiotic versus antibiotic				
<i>During dialysis:</i>				
Bernardini, 1996 ⁴⁰	Mupirocin ointment	41	–	49%/51%
	Oral rifampin	41	–	59%/41%
Bernardini, 2005 ^{41,42}	Mupirocin ointment	66	51 ± 15	38/28
	Gentamicin ointment	67	51 ± 15	34/33
Cavdar, 2004 ⁴³	Mupirocin ointment applied once weekly	18	55.3 ± 1.8 ^c	10/8
	Mupirocin ointment applied thrice weekly	18	55.0 ± 2.3 ^c	11/7
Antibiotic versus antibiotic versus no antibiotic				
<i>Catheter insertion:</i>				
Gadallah, 2000 ^{44,45}	I.v. vancomycin	90 (103 procedures)	46 (15 to 72) ^b	38/52
	I.v. cefazolin	88 (102 procedures)	47 (20 to 81) ^b	43/45
	No treatment	87 (100 procedures)	45 (19 to 76) ^b	38/49
Antiseptic versus no antiseptic				
<i>Catheter insertion:</i>				
Waite, 1997 ⁴⁶	Povidone–iodine ointment	61	54.4 ± 15.1	33/28
	No treatment	56	53.2 ± 14.5	30/26
<i>During dialysis:</i>				
Luzar, 1990 ³	Povidone–iodine	74	–	63%/37%
	Non-disinfectant soap	53	–	59%/41%
Sesso, 1988 ⁴⁷	Chlorhexidine	20	–	–
	Neutral soap	19	–	–
Wilson, 1997 ⁴⁸	Povidone–iodine spray	77 catheters	53 (18–82) ^e	55/22
	No treatment	72 catheters	51 (21–76) ^e	43/29
Wong, 2002 ⁴⁹	Chlorhexidine liquid soap	69	59.0 ± 11.50 ^b	34/35
	Pure liquid soap	48	56.3 ± 11.7 ^b	23/25
Antiseptic versus antiseptic				
<i>During dialysis:</i>				
Fuchs, 1990 ⁵⁰	Chlorhexidine	18	46 ^c	7/11
	Sodium hypochlorite	13	47 ^c	7/6
	Povidone–iodine swabsticks plus povidone ointment	20	55 ^c	13/7
Other				
<i>During dialysis:</i>				
Poole-Warren, 1991 ⁵¹	Vaccination	65	54 ± 11	1.5 (ratio)
	Placebo	59	52 ± 14	0.7 (ratio)

continued

TABLE 4 Summary of the comparisons made and baseline characteristics (cont'd)

Study	Comparison	No. of participants	Age (years) ^a	Male/female
Turner, 1992 ⁵²	Catheter immobiliser	22	45 ± 15.51	–
	Tape	23	40 ± 14.26	–
	Non-immobilisation	21	43 ± 15.8	–
Warady, 2003 ⁵³	'Flush before fill'	62	11.4 ± 5.6 ^d	54.8%/45.2%
	Flushing with 15 ml of sterile dialysate	59	11.2 ± 6.0 ^d	59.3%/40.7%
Treatment of <i>S. aureus</i> carriage				
Antibiotic versus no antibiotic				
<i>During dialysis:</i>				
Blowey, 1994 ⁵⁴	Oral rifampin plus bacitracin	7	–	–
	No treatment	8	–	–
Mupirocin Study Group, 1996 ^{55,56}	Mupirocin ointment	134	60.3 ^c	60.4%/39.6%
	Placebo ointment	133	60.3 ^c	60.2%/39.8%
Antibiotic versus antibiotic				
<i>During dialysis:</i>				
Perez-Fontan, 1992 ⁵⁷	Mupirocin nasal ointment	12	51 ± 15 ^b	5/7
	Neomycin sulphate ointment	10	48 ± 21 ^b	5/5
Antibiotic versus antibiotic versus no antibiotic				
<i>During dialysis:</i>				
Sesso, 1994 ⁵⁸	Sodium fusidate ointment	9	46.1 ± 3.8 (33–69) ^e	6/3
	Oral ofloxacin	9	36.6 ± 4.6 (22–61) ^e	6/3
	Placebo tablets	13	42.1 ± 4.6 (17–68) ^e	9/4

^a Data are expressed as mean ± standard deviation (SD) unless stated otherwise.
^b Measure unclear.
^c Mean.
^d Mean ± standard error of the mean (SEM).
^e Mean ± standard error (range).

toxoid/whole killed staphylococci formulation with a placebo, one three-armed trial compared a catheter immobiliser with the use of tape and non-immobilisation and one trial compared the 'flush before fill' technique with standard practice.

Table 6 provides details, where reported, of the results for the following outcomes: number of patients with *S. aureus* carriage (at trial entry); number of patients with peritonitis; peritonitis rate (number of episodes over total patient months on PD); number of patients requiring catheter removal; number of patients with exit-site and/or tunnel infections; and the exit-site and/or tunnel infection rate.

Time to *S. aureus* carriage

One trial, comparing vaccination with a combined staphylococcus toxoid/whole killed staphylococci formulation (SB) given intramuscularly with placebo,⁵¹ also reported the number of *S. aureus*-positive nasal swabs relative to the total nasal swabs taken at each time point (Table 7).

Time to the first peritonitis episode

One trial comparing intravenous vancomycin approximately 12 hours before catheter placement with intravenous cefazolin approximately 3 hours before catheter placement with no antibiotics for at least 1 week before procedure, reported the time to the first peritonitis episode.⁴⁴ There was one case of peritonitis at 6 days in the intravenous cefazolin and two cases of peritonitis at 1 and 4 days in the group allocated to receive no antibiotics at least 1 week before surgery.

Side-effects

Three trials reported side-effects of antibiotic prophylaxis: Bernardini and colleagues⁴⁰ reported that four out of 41 patients experienced nausea and vomiting in the oral rifampin group and one other required liver function tests. There were no reported side-effects in the mupirocin group. Bernardini and colleagues⁴¹ reported exit-site irritation in seven out of 66 patients in the mupirocin group and seven out of 67 patients in the gentamicin group. Wilson and colleagues⁴⁸

TABLE 5 Summary of outcomes reported in the included studies

Study ID	Outcomes															
	No. of patients with <i>S. aureus</i> carriage	Time to <i>S. aureus</i> carriage	No. of patients with peritonitis	Peritonitis rate	Time to first peritonitis episode	Peritonitis relapse	No. of patients requiring catheter removal	No. of patients switching to haemodialysis	No. of patients requiring catheter replacement	No. of patients with exit-site and tunnel infections	Exit-site and tunnel infection rate	Side-effects of antibiotics	Death due to peritonitis	Hospitalisation rates	Quality of life	Development of antibiotic resistance
Propylaxis amongst all patients																
Bennett-Jones, 1988 ³⁵	✓			✓						✓	✓	✓				
Bernardini, 1996 ⁴⁰	✓			✓						✓	✓	✓				
Bernardini, 2005 ^{41,42}	✓			✓						✓	✓	✓				
Cavdar, 2004 ⁴³	✓			✓						✓	✓	✓				
Fuchs, 1990 ⁵⁰	✓			✓						✓	✓	✓				
Gadallah, 2000 ^{44,45}	✓			✓						✓	✓	✓				
Luzar, 1990 ³	✓			✓						✓	✓	✓				
Lye, 1992 ³⁶	✓			✓						✓	✓	✓				
Poole-Warren, 1991 ⁵¹	✓			✓						✓	✓	✓				
Sesso, 1988 ⁴⁷	✓			✓						✓	✓	✓				
Sharma, 1971 ³⁷	✓			✓						✓	✓	✓				
Turner, 1992 ⁵²	✓			✓						✓	✓	✓				
Waite, 1997 ⁴⁶	✓			✓						✓	✓	✓				
Warady, 2003 ⁵³	✓			✓						✓	✓	✓				
Wilson, 1997 ⁴⁸	✓			✓						✓	✓	✓				
Wong, 2002 ⁴⁹	✓			✓						✓	✓	✓				
Wong, 2003 ³⁸	✓			✓						✓	✓	✓				
Zimmerman, 1991 ³⁹	✓			✓						✓	✓	✓				
Treatment of <i>S. aureus</i> carriage																
Blowey, 1994 ⁵⁴	✓			✓						✓	✓	✓				
Muriprocin Study Group, 1996 ^{55,56}	✓			✓						✓	✓	✓				
Perez-Fontan, 1992 ⁵⁷	✓			✓						✓	✓	✓				
Sesso, 1994 ⁵⁸	✓			✓						✓	✓	✓				✓

TABLE 6 Outcomes results for prophylaxis amongst all patients

Study	Comparison	<i>S. aureus</i> carriage at trial entry (no.)	Peritonitis (no.)	Peritonitis rate	Catheter removal (no.)	ESI and/or TI (no.)	ESI and/or TI rate
Antibiotic versus no antibiotic							
<i>Catheter insertion:</i>							
Bennett-Jones, 1988 ³⁵	i.v. gentamicin	–	–	–	–	0/13	–
	No treatment	–	–	–	–	4/13	–
Lye, 1992 ³⁶	i.v. ceftazolin and gentamicin	3/25	2/25	–	–	2/25	–
	No treatment	6/25	0/25	–	–	4/25	–
<i>During dialysis:</i>							
Sharma, 1971 ³⁷	Neomycin	–	0/48	–	–	–	–
	Placebo	–	2/41	–	–	–	–
Wong, 2003 ³⁸	Mupirocin ointment	16/73	1/78 (MSSA)	–	0/78	0/78 ^b	–
	No treatment	14/81	1/88 (MRSA)	–	0/88	10/88 ^b	–
Zimmerman, 1991 ³⁹	Rifampin	9/32	3/32	0.11 mean episodes/patient year	–	3/32 ^c	0.22 mean infections/patient year
	No treatment	8/32	3/32	0.16 mean episodes/patient year	–	12/32 ^c	0.65 mean infections/patient year
Antibiotic versus antibiotic							
<i>During dialysis:</i>							
Bernardini, 1996 ⁴⁰	Mupirocin ointment	44%	–	0.04 episodes/dialysis year	–	–	0.13 episodes/dialysis year
	Oral rifampin	44%	–	0.02 episodes/dialysis year	–	–	0.15 episodes/dialysis year
Bernardini, 2005 ⁴¹	Mupirocin ointment	9/66	0/66	0 episodes/patient year	–	3/66	0.06 episodes/patient year
	Gentamicin ointment	9/67	2/67	0.03 episodes/patient year	–	5/67	0.08 episodes/patient year
Cavdar, 2004 ⁴³	Mupirocin ointment once weekly	3/18	0/18	–	–	0/18	–
	Mupirocin ointment thrice weekly	0/18	0/18	–	–	0/18	–
Antibiotic versus antibiotic versus no antibiotic							
<i>Catheter insertion:</i>							
Gadallah, 2000 ⁴⁴	i.v. vancomycin	–	0/90	–	0/90	–	–
	i.v. ceftazolin	–	1/88	–	1/88	–	–
	No treatment	–	2/87	–	1/87	–	–
Antiseptic versus no antiseptic							
<i>Catheter insertion:</i>							
Waite, 1997 ⁴⁶	Povidone-iodine ointment	22/61	0/61	–	1/61	2/61	–
	No treatment	14/56	2/56	–	2/56	8/56	–

continued

TABLE 6 Outcomes results for prophylaxis amongst all patients (cont'd)

Study	Comparison	<i>S. aureus</i> carriage at trial entry (no.)	Peritonitis (no.)	Peritonitis rate	Catheter removal (no.)	ESI and/or TI (no.)	ESI and/or TI rate
<i>During dialysis:</i> Luzar, 1990 ³	Povidone iodine Non-disinfectant soap	— —	8/74 ^a 3/53 ^a	— —	— —	15/74 ^a 16/53 ^a	— —
Sesso, 1988 ⁴⁷	Chlorhexidine Neutral soap	— —	6/19 ^d 4/16 ^d	— —	— —	— —	— —
Wilson, 1997 ⁴⁸	Povidone-iodine spray No treatment	— —	2/77 3/72	— —	— —	9/77 22/72	— —
Wong, 2002 ⁴⁹	Chlorhexidine liquid soap Pure liquid soap	— —	— —	— —	— —	0/69 4/48	— —
Antiseptic versus antiseptic							
<i>During dialysis:</i> Fuchs, 1990 ⁵⁰	Chlorhexidine Sodium hypochlorite Povidone-iodine/povidone ointment	— — —	— — —	— — —	— — —	1/18 2/13 0/20	1/134 per patient month 1/41 per patient month —
Other							
<i>During dialysis:</i> Poole-Warren, 1991 ⁵¹	Vaccination Placebo	13/40 11/36	8/60 8/51	— —	— —	29/44 ^e 25/25 ^e	— —
Turner, 1992 ⁵²	Catheter immobiliser Tape Non-immobilisation	10/22 11/23 6/21	— — —	— — —	— — —	4/22 ^e 4/23 ^e 4/21 ^e	— — —
Warady, 2003 ⁵³	'Flush before fill' Flushing with 15 ml of sterile dialysate	— —	7/62 ^a 15/59 ^a	— —	— —	— —	— —

ESI, exit-site infection; MRSA, methicillin-resistant *Staphylococcus aureus*; MSSA, methicillin-sensitive *Staphylococcus aureus*; TI, timed infection.^a Denominators are unclear therefore numbers randomised are reported.^b 5 × MSSA; 5 × MRSA.^c Catheter infections.^d Episodes.^e Microorganisms.

TABLE 7 *S. aureus* nasal carriage versus weeks following vaccination, expressed as number of carriers/group total⁵¹

No. of weeks	Vaccination	Placebo
Pre-study	13/40	11/36
7	19/50	14/44
19	11/51	14/46
32	9/29	5/20
44	2/22	6/25
57	10/20	6/22

reported a rash and pruritus at the catheter exit site in five patients allocated to use the povidone-iodine spray. There were no reported side-effects in the group which received no treatment.

Death due to peritonitis caused by *S. aureus*

Only one trial reported this outcome.³⁷ This trial compared neomycin 0.5 g by mouth or nasogastric tube every 6 hours with a placebo and reported that there were no deaths due to peritonitis caused by *S. aureus*.

Development of antibiotic resistance

One trial⁴³ comparing mupirocin applied to the exit site once weekly with mupirocin applied three times weekly reported no difference between the groups (one out of seven isolations were resistant to mupirocin in the group applying mupirocin

once weekly and one isolation resistant to mupirocin and methicillin in the group applying mupirocin three times weekly).


No data were reported for the following outcomes: peritonitis relapse, number of patients requiring catheter replacement, hospitalisation rates and quality of life.

Oral antibiotics versus no antibiotics

Four trials compared an oral antibiotic with no antibiotics and one trial compared two different types of oral antibiotics with no antibiotic. When considering all oral antibiotics together, there were fewer cases of peritonitis caused by *S. aureus* in the groups which received antibiotics (Figure 1: 6/283 versus 7/185: RR 0.69, 95% CI 0.28 to 1.72; $p = 0.43$), but this was not a statistically significant difference. There were also fewer cases of exit-site and/or tunnel infections caused by *S. aureus* (Figure 2, 5/70 versus 20/70: RR 0.27, 95% CI 0.11 to 0.65; $p = 0.003$). The direction of effect was similar when considering subcategories (catheter insertion and during dialysis).

Topical antibiotics versus no antibiotics

Only one trial³⁸ compared the use of a topical antibiotic with no antibiotics. There was no difference in the number of patients with peritonitis caused by *S. aureus*. However, there were 0/78 cases of exit-site and/or tunnel

**FIGURE 1** Oral antibiotic prophylaxis amongst all patients: number of patients with peritonitis caused by *S. aureus*




FIGURE 2 Oral antibiotic prophylaxis amongst all patients: number of patients with exit-site and/or tunnel infections caused by *S. aureus*




FIGURE 3 Antiseptic prophylaxis amongst all patients: number of patients with peritonitis caused by *S. aureus*

infections in the group allocated to use a topical antibiotic compared with 10/88 cases in the no treatment group [five of which were methicillin-resistant *Staphylococcus aureus* (MRSA) and five were methicillin-sensitive *Staphylococcus aureus* (MSSA)].

Antiseptic versus no antiseptic

When considering all antiseptics together, there were more cases of peritonitis caused by *S. aureus* in the groups allocated to antiseptic use (Figure 3: 16/231 versus 12/197: RR 1.08, 95% CI 0.54 to 2.16; $p = 0.84$), but this was not statistically significant.




FIGURE 4 Antiseptic prophylaxis among all patients: number of patients with exit-site and/or tunnel infections caused by *S. aureus*

However, when considering antiseptic use at the time of catheter insertion, there were fewer cases of peritonitis (one trial). There were fewer cases of exit-site and/or tunnel infections caused by *S. aureus* in the groups allocated to antiseptic use (Figure 4, 26/281 versus 50/229; RR 0.43, 95% CI 0.28 to 0.66; $p = 0.0001$). The direction of effect was similar when considering subcategories (catheter insertion and during dialysis).

Treatment of *S. aureus* carriage

Four trials evaluated treatment of *S. aureus* carriage, all during dialysis. Two compared antibiotic treatment with no antibiotic treatment, one trial compared two different antibiotic regimes and one three-armed trial compared two different antibiotic regimes with no antibiotic treatment.

Table 8 provides details, where reported, of the results for the following outcomes: number of patients with *S. aureus* carriage; number of patients with peritonitis; peritonitis rate (number of episodes over total patient months on PD); number of patients requiring catheter removal; number of patients with exit-site and/or tunnel infections; and the exit-site and/or tunnel infection rate.

Time to *S. aureus* carriage

One trial⁵⁷ reported time to recolonisation after initial treatment and the results are presented in Table 9.

Side-effects

Two trials reported side-effects: the Mupirocin Study Group⁵⁵ reported six episodes of side-effects in six patients (one withdrew due to rhinitis) using mupirocin ointment and eight episodes in seven patients (one withdrew due to rhinorrhea and sneezing) using the placebo ointment; and Sesso and colleagues³⁸ reported that one patient using sodium fusidate ointment discontinued use due to nasal irritation.

Death due to peritonitis caused by *S. aureus*

One trial reporting this outcome⁵⁸ reported that there were no deaths due to peritonitis caused by *S. aureus*.

Development of antibiotic resistance

One trial⁵⁸ reported that no patient developed ofloxacin-resistant organisms.

There were no data reported for the following outcomes: time to first peritonitis episode; peritonitis relapse; number of patients requiring catheter replacement; hospitalisation rates; and quality of life.

Oral antibiotics versus no antibiotics

Two trials compared oral antibiotics with no antibiotics. When considering all oral antibiotics together, there were fewer cases of peritonitis caused by *S. aureus* in the groups which received

TABLE 8 Outcomes results for treatment of *S. aureus* carriage

Study	Comparison	<i>S. aureus</i> carriage (no.)	Peritonitis (no.)	Peritonitis rate	Catheter removal (no.)	ESI and/or TI (no.)	ESI and/or TI rate
Antibiotic versus no antibiotic							
<i>During dialysis:</i>							
Blowey, 1994 ⁵⁴	Oral rifampin plus bacitracin	0/7	0/7	–	–	0/7	–
	No treatment	2/8	2/8	–	–	2/8	–
Mupirocin Study Group, 1996 ^{55,56}	Mupirocin ointment	18/134 ^a	18/134 ^{a,b}	1 in 81.8 patient months	3/134 ^{a,b}	9/134	1 in 99.3 patient months
	Placebo ointment	24/133 ^a	24/133 ^{a,b}	1 in 53.8 patient months	5/133 ^{a,b}	20/133	1 in 28.1 patient months
Antibiotic versus antibiotic							
<i>During dialysis:</i>							
Perez-Fontan, 1992 ⁵⁷	Mupirocin nasal ointment	0/12 ^b	0/12 ^b	–	–	1/12 ^c	–
	Neomycin sulphate ointment	1/10 ^b	1/10 ^b	–	–	1/10 ^c	–
Antibiotic versus antibiotic versus no antibiotic							
<i>During dialysis:</i>							
Sesso, 1994 ⁵⁸	Sodium fusidate ointment	1/9	1/9	0.16	4/9	5/9	0.97
	Oral ofloxacin	4/9	4/9	0.83	3/9	2/9	0.33
	Placebo tablets	5/13	5/13	0.75	6/9	3/13	0.50

^a Denominators are unclear, therefore numbers randomised are reported.

^b Episodes.

^c Catheter infections.

TABLE 9 Response to treatment and time to recolonisation (months, M)

Study ID	Comparison	Eradication: no. (%)	+1M	+2M	+3M	+4M	+6M	+10M
Perez-Fontan, 1992 ⁵⁷	Mupirocin	12 (100)	12 (0)	12 (8)	12 (41)	11 (55)	11 (55)	3 (66)
	Neomycin	10 (40)	4 (0)	4 (25)	4 (75)	–	–	–




FIGURE 5 Treatment of *S. aureus* carriage with oral antibiotics: number of patients with peritonitis caused by *S. aureus*




FIGURE 6 Treatment of *S. aureus* carriage with oral antibiotics: number of patients with exit-site and/or tunnel infections caused by *S. aureus*




FIGURE 7 Treatment of *S. aureus* carriage with topical antibiotics: number of patients with peritonitis caused by *S. aureus*

antibiotics (Figure 5: 1/16 versus 7/21: RR 0.27, 95% CI 0.05 to 1.35; $p = 0.11$) and fewer cases of exit site and/or tunnel infections caused by *S. aureus* (Figure 6, 2/16 versus 5/21: RR 0.60, 95% CI 0.16 to 2.28; $p = 0.46$). However, these results were not statistically significant.

Topical antibiotics versus no antibiotics

Two trials compared topical antibiotics with no antibiotics. When considering all topical antibiotics

together, there were fewer cases of peritonitis caused by *S. aureus* in the groups which received antibiotics (Figure 7: 22/143 versus 29/146: RR 0.80, 95% CI 0.49 to 1.32; $p = 0.39$), fewer patients requiring catheter removal (Figure 8, 7/143 versus 11/142: RR 0.63, 95% CI 0.29 to 1.39; $p = 0.26$), and fewer cases of exit site and/or tunnel infections caused by *S. aureus* (Figure 9, 14/143 versus 23/146: RR 0.66, 95% CI 0.36 to 1.20; $p = 0.17$). However, these results were not statistically significant.




FIGURE 8 Treatment of *S. aureus* carriage with topical antibiotics: number of patients requiring catheter removal




FIGURE 9 Treatment of *S. aureus* carriage with topical antibiotics: number of patients with exit-site and/or tunnel infections caused by *S. aureus*

TABLE 10 Summary of the clinical effect size

Outcome	Prophylaxis amongst all		Treatment of <i>S. aureus</i> carriage	
	n/N	RR (95% CI)	n/N	RR (95% CI)
Oral antibiotic versus no antibiotic				
Peritonitis (no.)	6/283 vs 7/185	0.75 (0.29 to 1.93)	1/16 vs 7/21	0.27 (0.05 to 1.35)
ESI and/or TI (no.)	(5/70 vs 20/70)	0.27 (0.11 to 0.65)	2/16 vs 5/21	0.60 (0.16 to 2.28)
Topical antibiotic versus no antibiotic				
Peritonitis (no.)	ND	ND	22/143 vs 29/146	0.80 (0.49 to 1.32)
Catheter removal (no.)	ND	ND	7/143 vs 11/142	0.63 (0.29 to 1.39)
ESI and/or TI (no.)	ND	ND	14/143 vs 23/146	0.66 (0.36 to 1.20)
Antiseptic versus no antiseptic				
Peritonitis (no.)	16/231 vs 12/197	1.08 (0.54 to 2.16)	ND	ND
ESI and/or TI (no.)	26/281 vs 50/229	0.43 (0.28 to 0.66)	ND	ND
ND, no data.				

Clinical effect size

When considering trials comparing antibiotics with no antibiotics, a summary of the clinical effect size for all outcomes where data were available are given in *Table 10*.

When considering prophylaxis amongst all patients, there is a consistent finding that exit-site and/or tunnel infections are statistically

significantly reduced with the use of antibiotics (oral or topical) and antiseptics. However, these findings do not appear to translate into a reduction in peritonitis. To some extent this may reflect the greater frequency of exit-site and/or tunnel infections than peritonitis, and hence lower power for peritonitis, but it does raise the question of how carriage leads to peritonitis.

Chapter 4

Economic evaluation

Introduction

In this chapter, the approach taken to consider the relative cost-effectiveness of interventions to prevent and treat *S. aureus* carriage is presented. A review of previous economic evaluations has not been conducted but one economic evaluation conducted alongside an RCT was identified.⁵⁹ This economic evaluation compared prophylactic nasal mupirocin with placebo in patients either starting or established on continuous ambulatory PD. Although this study was generally well conducted and reported, it did not consider the full range of interventions for the prevention and treatment of *S. aureus* carriage. As reported in *Table 8*, the use of the antibiotics reduced the rate of a catheter infection caused by *S. aureus* from one every 28.1 months to one every 99.3 months. The incremental cost per *S. aureus*-related catheter infection prevented in 1994 prices was £187. The costs included the cost of screening and prophylaxis for 1 year and the cost savings arising from the reduced use of therapeutic antibiotics and hospitalisations avoided. Quality-adjusted life-years (QALYs) were not reported as part of this study. Nevertheless, the gain in QALYs required to provide an incremental cost per QALY that society might consider worthwhile (between £20,000 and £30,000 per QALY) would be between 0.0019 and 0.0029. This would be equivalent to between an additional 0.7–1.1 days in full health over 1 year (1 day in full health is equal to 0.00274 QALYs). From this particular study, a judgement would be required as to whether the gains in QALYs estimated could be realised in practice and, even if they can be realised, whether society would be willing to pay for these additional benefits.

The usefulness of the study by Davey and colleagues⁵⁹ is that the results indicate that it is not implausible that interventions to prevent or treat *S. aureus* carriage might be cost-effective. Ideally, an economic evaluation comparing all relevant interventions (including the use of a no treatment arm) and utilising the best available evidence would be performed.

The first part of this chapter outlines the framework provided by economic evaluation for informing decision-making. As described in this

section, there is insufficient evidence to determine the relative efficiency of the alternative interventions. In response to the limited evidence available, no economic evaluation was performed. However, a hypothetical model is outlined. If sufficient data were available from future research to populate this model, then it would provide an explicit framework to estimate cost-effectiveness.

The economic approach

Relationship between benefits and cost

The objective of economic evaluation is to provide information to assist decision-makers in the allocation of available scarce resources so that benefits can be maximised. The decision to use resources in one way means that the opportunity to use them in other desirable ways is given up. The cost of this decision is the benefits (health gains, etc.) that could have been obtained had the resources been used in another way. The 'opportunity cost' of a decision to use resources in one way is equivalent to the benefits forgone in the best alternative use of these resources. One of the goals of healthcare decision-making is to maximise benefits and minimise opportunity costs. To achieve this, information is required on both resource use (i.e. costs) and benefits (i.e. effectiveness) from alternative courses of action.

Data on effectiveness and costs can be brought together in a matrix format (*Figure 10*) to aid in the judgement about whether a new procedure is preferable to a comparator. In *Figure 10*, it can be seen that, relative to a comparator, the new procedure could achieve (1) greater effectiveness, (2) the same level of effectiveness or (3) less effectiveness. Of course, a fourth option is possible whereby there is not enough evidence to make a judgement on whether the new procedure is more or less effective. In terms of cost, a new procedure could (A) be less costly, (B) result in no difference in costs or (C) be more costly (again, there is the possibility of there being not enough evidence to judge, as represented by row D).

Figure 10 is adapted from that which appeared in early editions of the Cochrane Collaboration Handbook. For any procedure to prevent or treat




FIGURE 10 Matrix combining costs and effectiveness

S. aureus carriage or infection, the optimum position on the matrix is square A1, where an experimental treatment would both save costs and have greater effectiveness relative to current treatment. In squares A1, A2 and B1, the new procedure is more efficient and is assigned a ✓ response to the question of whether it is to be preferred to current practice. In squares B3, C2, and C3 the new procedure is less efficient and thus receives a X response. In squares A3 and C1, a judgement would be required as to whether the more costly procedure is worthwhile in terms of the additional effectiveness gained. Square B2 is neutral, as there is no difference in either costs or effectiveness and other reasons may be needed to justify the adoption of treatment. The areas marked with a ? response represent situations in which there is not enough evidence on effectiveness, costs or both to judge whether the new procedure is to be preferred.

Consideration of the available evidence

As reported in Chapter 3, the evidence available on relative effectiveness of the alternative methods of preventing or treating *S. aureus* carriage as a means of preventing peritonitis was limited. In terms of the matrix set out in *Figure 10* there is insufficient evidence to draw any conclusions about relative effectiveness (column 4 of the matrix), and hence about the relative cost-effectiveness of any of the interventions (square D4 of the matrix). Additional data collection is required to conduct a formal economic evaluation. The structure for a hypothetical economic model is presented in the next section.

Hypothetical economic model

The methods for a model and its use are illustrated below, and this helps to highlight the areas where additional data would be required before a robust evaluation could be conducted. A Markov model is used to display the temporal and logical sequence of prevention and treatment events. This approach adopted as a Markov model has the ability to represent repetitive events, and the time dependence of both probabilities and utilities which allows for more accurate representation of clinical settings that involve these issues.⁶⁰ The model would be designed to estimate costs from the UK NHS perspective and outcomes in terms of QALYs.

This study focuses on patients who receive PD as the initial modality of treatment. A patient who elects or receives PD could over time either die, receive a transplant or transfer to HD. The hypothetical model does not include transplantation and hence may be considered applicable to the majority of patients who, for whatever reason (usually lack of donor organs), do not receive a transplant. As part of the process of developing the model, the parameters needed to assess the cost-effectiveness of alternative interventions were identified. The systematic review of effectiveness reported in Chapter 3, secondary data sources and consultation with clinical experts would provide the parameter estimates. Where such data were likely to be deficient, this has been indicated in the text, to aid future research. The model structure was based on

detailed discussions with clinical members of the review team about the care pathways that patients might follow while on PD and further discussion about how these pathways (and transitions between different modalities of treatment and clinical events) would be influenced by the prevention or treatment of *S. aureus* carriage. The model was then presented to the clinicians and other members of the review team and any relevant changes made to the structure.

Description of the model

The model is made up of a set of health states between which a patient can move over specified periods of time (Figure 11). On entry into the model, all patients receive PD. The patient will spend 4 weeks in each state (the cycle length) before facing the possibility of making a transition to another state.

Within the model patients could move into any one of the following states:

1. *'Catheter insertion'*. In this initial state a patient has their peritoneal catheter inserted and begins PD. At the time of their peritoneal catheter insertion the patient may receive a prophylactic intervention or a treatment of *S. aureus* carriage. Following the first 4 weeks after insertion of the catheter, a patient may remain on PD with or without carriage of *S. aureus*. Patients in this state could potentially also develop an infection, transfer to HD or die.
2. *'On PD without SA carriage'*. In this state, the patient receives PD and may also receive routine checks for the development of *S. aureus* carriage. The risk of developing carriage and hence the probability of moving to 'On PD with SA carriage' may be affected by the use of some form of prophylactic preventive treatment either at the time of catheter insertion (the first initial state of the model) or while on dialysis. Patients in this state could potentially also develop an infection, transfer to HD or die.
3. *'On PD with SA carriage'*. Patients in this state are still on PD but are carriers of *S. aureus*. If *S. aureus* carriage were eradicated, the patient would move back to the state 'On PD without SA carriage'. The patient could suffer some form of infection although the risk of this happening may be affected by any of the methods of treating *S. aureus* carriage (antibiotic sprays, ointment or powders). Patients in this state could potentially also transfer to HD or die.
4. *'Infection'*. While on PD, a patient may suffer an exit-site infection, isolated tunnel infection or

peritonitis. The infections may occur either separately or sequentially: exit site infection leading to tunnel infection leading to peritonitis. While in this state, patients face the risk of losing their PD tube and moving into temporary or permanent HD. Factors that could make a person move from PD are clearance failure, technique failure or recurrent peritonitis. The types of infection and their effects are:

- (a) Exit-site infection, which is treated with using a local treatment, systemic treatment or catheter change.
- (b) Isolated tunnel infections, which are treated using systemic treatments and/or catheter removal.
- (c) Peritonitis infection, which is mainly due to contamination and is treated with 2 weeks of antibiotics administered peritoneally, intravenously or orally.

S. aureus infection can be cured without the patient moving from PD (i.e. move to 'On PD without SA carriage'). If *S. aureus* infection is not resolved, the catheter can be removed and the treatment modality switched to 'Temporary HD'. Non-resolution of *S. aureus* infection can be attributed to failure of antibiotics to clear the infection (relapsing peritonitis) or it may arise from an entirely new infection. Relapsing peritonitis can be defined as the recurrence of peritonitis caused by the same organism as the immediately preceding episode of peritonitis within 4 weeks of completion of antibiotic treatment. The model would allow a patient to have a maximum of between two and four infections (i.e. to stay in the state of infection for between two and four cycles) before the PD catheter is removed, in which case the patient would move to the state of 'Temporary HD'.

5. *'Temporary HD'*. As briefly described above, there are several factors that could make a person move from PD, such as clearance failure, technique failure or recurrent peritonitis. Once these factors are resolved some patients may elect to move back to PD. If they are not resolved, a patient may have to stay in HD until they die (and hence move to the state of 'Permanent HD').
6. *'Permanent HD'*. Once a patient enters this state, they do not leave it until they die.
7. *'Dead'* (included as all-cause mortality). This state can be entered from all preceding states.

While the model allows for variation in the parameters of the prevention and treatment of peritonitis across each intervention (either prophylactic prevention of *S. aureus* carriage or




FIGURE 11 Draft model structure for the estimation of the relative cost-effectiveness of alternative methods to prevent and treat *S. aureus* (SA) carriage

treatment of *S. aureus* carriage), it is necessary to assume that many parameters will be the same across the different branches. The following section identifies the data required to populate the model. To illustrate this description, the data available for the comparison of the prophylactic use of antibiotics at the time of catheter insertion compared with no treatment have been used.

Estimation of model parameters

A detailed description of the methods that might be used to derive parameters for this model are described in Appendix 7. In brief, this description covers the derivation of transition probabilities, costs and health state utilities.

Assessment of cost-effectiveness

The results of the base-case analysis would be based on the costs and outcomes faced by male and female patients who initially started on PD. If the National Institute for Health and Clinical Excellence (NICE) HTA guidelines were followed, discount rates of 3.5% per annum would be applied to both costs and health benefits.⁶¹ The central outcomes of the analysis and the systematic review would first be presented in terms of a balance sheet. In the balance sheet the incremental differences between the alternative interventions would be presented in their natural units, such as the number of patients with exit-site and/or tunnel infections caused by *S. aureus* and number of patients with peritonitis. The purpose of the balance sheet is to illustrate the trade-offs that would exist when choosing amongst interventions.

Within the economic model, the different outcomes would be combined into a single measure of relative efficiency measured in terms of the incremental cost per QALY. Data on the incremental cost per QALY would be presented in two ways. First, mean costs and QALYs for the alternative interventions could be presented and incremental cost per QALYs calculated where appropriate. The second way in which the cost-effectiveness of the alternative interventions might be presented would be by cost-effectiveness acceptability curves (CEACs). CEACs can be used to illustrate the uncertainty caused by the combined statistical variability in the model's parameter estimates. These curves illustrate the likelihood that a strategy is cost-effective at various threshold values for society's willingness to pay for an additional QALY. It should be noted that in order to be able to perform the probabilistic sensitivity analysis underpinning the estimation of CEACs, all the parameters required for the model should be described by an appropriate statistical

distribution that reflects the statistical imprecision surrounding the point estimates (which has not been attempted within this chapter).

Additional analyses

The results of any economic evaluation will be surrounded by uncertainty. In part, this will be reflected by the probabilistic analysis that is proposed above. However, other sensitivity analyses would be required to address the uncertainty around the available data or about the way in which it would be used in the model. In addition to the sensitivity analyses described above, another potential sensitivity analysis might focus on establishing at what point preventing or treating carriage ceases to be cost-effective. Examples of other potential sensitivity analyses are described below.

Risks of *S. aureus* carriage, risks of progression to infection and other transition probabilities

Data on the prevalence of *S. aureus* carriage are not available, yet it is likely that the cost-effectiveness will be dependent on the proportion of people starting PD who are carriers of *S. aureus* and the risks of developing carriage and the consequences of carriage in terms of the development of infections and transitions to other modalities of dialysis.

Costs

The costs of antibiotics identified varied greatly. The most expensive and least expensive costs could be used in the sensitivity analysis. These costs could be varied by increasing/reducing them to establish at what cost prevention or treatment of *S. aureus* carriage and infection ceased to be cost-effective. Similarly, the costs of dialysis would also be varied. This is because costs that would be used in the base-case analysis although coming from a very detailed costing exercise are derived from a small number of centres and so might not be generalisable to the rest of the NHS. The impact of using other relevant costs such as those reported in the NHS reference costs would be explored.

Utilities

The utility data used in the model were based on non-randomised data. These data were based on patient responses to the EQ-5D questionnaire weighted using UK population tariffs. Further analyses could be performed using the utility data from other sources.

Results

Although no formal attempt to conduct the proposed modelling exercise has been made, an

TABLE 11 Balance sheet of antibiotic versus no antibiotic at catheter insertion and during dialysis

Favours antibiotic	Favours no intervention	Trials contributing data
Trends towards fewer exit-site and/or tunnel infections (OR 0.15, 95% CI 0.06 to 0.3)	Lower costs	4
No statistically significant difference in number of patients with peritonitis (RR 0.73, 95% CI 0.31 to 1.72)		8
No information on: Numbers of <i>S. aureus</i> carriage Number of <i>S. aureus</i> cured Number with relapse Modality change rates		

OR, odds ratio; RR, relative risk.

illustration of the limitations of the evidence base is provided by presenting a balance sheet for the comparison of the use of antibiotic versus no antibiotic at catheter insertion (*Table 11*). As can be seen, the data available are very limited and due to the paucity of data no further analyses were carried out.

Summary

In this chapter, a hypothetical model for the comparison of alternative methods to prevent or treat *S. aureus* carriage has been presented. The purpose of this exercise was to consider what information would be required for an economic

evaluation and where the main information gaps are. There is insufficient information on the effectiveness and relative effectiveness of the interventions that might be considered. Better data are available for costs and utilities but further data collection would be helpful. In particular, evidence on the utility value for those experiencing any of the infections would be useful.

As the model is hypothetical, the structure outlined in this chapter may need to be adapted to reflect either new knowledge of the care pathways, restrictions imposed by the data available or the nature of the comparisons considered.

Chapter 5

Discussion

Volume of evidence

There is a good number of trials but, as discussed in Chapter 3, the quality of design, or at least of reporting, is not good by today's standards. The first priority is to determine whether treatments are effective, and this requires placebo controls. Many of the trials were of one antibiotic or antiseptic against another. *Table 12* shows those in which there was a placebo arm. The number falls to 13. Some of these were very small, for example those by Bennett-Jones and colleagues³⁵ with 26 patients, Blowey and colleagues⁵⁴ with 15 and Sesso and colleagues⁵⁸ with 31 amongst three arms.

A number of the trials show a reduction in exit-site infections but not in the incidence of peritonitis. This may just be a power problem (exit-site infections being much commoner than peritonitis, plus the relatively small numbers involved), but raises the question of the relationship between carriage, infection and peritonitis. It is likely that infection is introduced mainly at exchange via contamination of the tip of the catheter, rather than tracking along the tunnel. Better technique might reduce the risk.

In an observational study, the Scottish Renal Registry Group⁶² noted that peritonitis was 15% (95% CI 4 to 26%) less common in units using nasal mupirocin than those not, although this did not apply to *S. aureus* peritonitis (one episode every 106 months in user units versus one every 96 months in non-users; $p = 0.52$).

Other reviews

Our findings are similar to those of the Cochrane Review by Strippoli and colleagues,⁶³ who also concluded that nasal mupirocin reduces exit-site and tunnel infections, but not peritonitis.

Guideline 3I of the European Guidelines³⁰ states that, "Use of mupirocin or gentamicin cream at the exit site is recommended to reduce exit site infections", but cites no evidence that this reduces peritonitis. Like the other guidelines, they have to extrapolate from reduction in exit-site infections to reduction in peritonitis.

One issue of concern has been the emergence of resistance to mupirocin, especially in MRSA. Mupirocin became available in 1985⁶⁴ and some laboratories have reported increasing numbers of mupirocin-resistant *S. aureus*, especially MRSA.⁶⁴ Particularly high resistance rates have been reported from New Zealand, but that may be related to its availability over the counter without prescription.⁶⁵ In some European studies, high-level mupirocin resistance was seen in only 2–3% of *S. aureus* isolates,^{66,67} but there was variation amongst countries, from 0% in most up to 6% in Belgium and 5% in the UK. Much higher rates have been reported in units with high mupirocin use. In one neonatal intensive care unit, which applied mupirocin routinely to insertion sites of central venous catheters, resistance rates rose over 5 years to 42% of coagulase-negative staphylococci (no results for *S. aureus* were reported), falling again once the routine use was stopped.⁶⁸

TABLE 12 Summary list of trials of active agents against placebo

	I.v. antibiotics	Oral antibiotics	Topical antibiotics	Antiseptics
Prophylaxis				
At first insertion	Bennett-Jones, 1988 ³⁵ Lye, 1992 ³⁶ Gadallah, 2000 ⁴⁵			Waite, 1997 ⁴⁶
During later dialysis		Zimmerman, 1991 ³⁹ Sharma, 1971 ³⁷	Wong, 2003 ³⁸	Wong, 2002 ⁴⁹ Luzar, 1990 ³ Wilson, 1997 ⁴⁸
Eradication		Blowey, 1994 ⁵⁴ Sesso, 1994 ⁵⁸	Sesso, 1994 ⁵⁸	Mupirocin Study Group, 1996 ⁵⁵

Research needs

As the Cochrane Review said:⁶³

“Given the large number of patients on PD and the importance of peritonitis, the lack of adequately powered RCTs to inform decision-making about strategies to prevent peritonitis is striking.”

This is echoed in the UK guidelines:⁶⁹

“We recommend that a large double-blind placebo controlled study is now needed to confirm whether mupirocin remains useful in clearing carriage in patients or staff when low-level mupirocin resistance is present.”

One of their concerns was that eradication of carriage was lower in resistant strains, whether they had high or low level resistance.

The key questions include:

1. What is the natural history and biology of carriage? What are the links between carriage and exit-site infection, and between exit-site infection and peritonitis? How long does carriage last for without treatment? How often is it temporary rather than permanent? The natural history of MRSA carriage suggests that up to half of those colonised will clear spontaneously within 1 year.⁷⁰
2. How do we define carriage? Some centres take swabs from multiple sites. But there is evidence that eradication from the nose reduces carriage elsewhere. Other sites include throat, groin, gut, any wounds and the catheter. Site of carriage seems to be important.
3. Treatment of carriage. Is MSSA relatively harmless? MRSA carriage seems to be a much stronger predictor of infection than MSSA (about 50% by 18 months versus 2% with MSSA).⁷¹ Should the focus be on those with MRSA? Is decolonisation of proven effectiveness, or is recolonisation rapid? Typing of strains could separate relapse from reinfection. Most decolonisation efforts are directed to the nose, which is the most common site of carriage, and to the catheter insertion site, but topical application of antibiotic or antiseptic to these sites will not affect carriage elsewhere, unless carriage elsewhere requires repeated spread of the organism from its more favoured sites. Individual strain type may also be important.
4. What other options for reducing peritonitis might be tried? Would more training help?

5. What factors predict carriage – home contacts, smoking, recent antibiotic treatment, recent hospital admissions? The underlying disease, such as diabetes, may affect susceptibility to infection.

Eradication topics include:

- intermittent versus chronic
- antiseptics versus antibiotics
- the choice of drug
- is vaccination worth revisiting?

The design of any intervention trial should consider confounding factors such as type of catheter, training and automated PD versus ambulatory PD.

The choice of antibiotic(s) to be tested in trials should take into account susceptibility of individual strains, and these may vary amongst different dialysis centres. MRSA rates also vary, and its presence is likely to compromise the benefits of any β -lactam antibiotic. MRSA strains also vary in their susceptibility to other key antibiotics such as gentamicin, rifampicin, fucidin, neomycin and mupirocin, though probably not to antiseptics. Long-term studies would be needed to monitor the emergence of resistance – this is high risk for agents such as mupirocin and rifampicin. Some agents such as mupirocin, rifampicin and fucidin are active mainly against Gram-positive infections.

The widespread use of mupirocin, and the concerns about resistance, make it a high priority for research.

The key outcomes of research into prevention would be:

- Episodes of peritonitis – average number per patient per annum in population on PD in each unit.
- Patient-based data – number of patients having one or more episodes per annum, or over a longer period; time from first insertion of catheter to first episode of peritonitis. Even if the number of infections was the same, delaying infection would be a useful outcome.
- Numbers of temporary transfers to HD.
- Duration of successful treatment on PD. Repeated episodes of peritonitis will shorten the life of the peritoneal membrane as a dialysis membrane.

Chapter 6

Conclusions

The importance of peritonitis in PD is not in doubt, and it remains the main cause of transfer to HD. The evidence on prevention is disappointing: exit-site infections are reduced but not peritonitis, although this may be because the

studies were too small or too short, or because the incidence of peritonitis was low. There is also some concern about the development of resistance to mupirocin amongst MRSA strains. More research is required.



Acknowledgements

We thank our peer reviewers, Dr Chris Isles, Dumfries, Dr Conal Daly, Glasgow, and Dr Andrew Lloyd, London, for commenting on a near final draft, and Professor Peter Davey, Dundee, for commenting on an earlier one, but we absolve them from any deficiencies in the final document, responsibility for which rests with the Aberdeen HTA Group.

Contribution of authors

Kirsty McCormack (Research Fellow), Linda McIntyre (Systematic Reviewer), Sian Thomas (Systematic Reviewer) and Helen Rothnie (Systematic Reviewer) carried out the assessment of studies for inclusion and data extraction. Kirsty McCormack completed the review of effectiveness.

Mary Kilonzo (Research Fellow) conducted the economic evaluation under supervision by Luke Vale (Senior Research Fellow). Cynthia Fraser (Information Officer) developed and ran the search strategies, and was responsible for obtaining papers and for reference management. Kannaiyan Rabindranath (Specialist Registrar in Nephrology) drafted the protocol and the introduction and provided specialist renal advice. Nick Fluck (Consultant Nephrologist) and Ian Gould (Consultant Microbiologist) provided expert advice on renal and microbiological aspects, respectively. Norman Waugh (Professor of Public Health; methodology adviser) provided clinical and methodological advice and commented on drafts of the review.



References

1. Ansell D, Feest T, Ahmad A, Rao R. *UK Renal Registry: 7th Annual Report*. London: UK Renal Registry. URL: http://www.renalreg.com/Report%202004/Cover_Frame.htm. Accessed January 2006.
2. Zimakoff J, Pedersen FB, Bergen L, BaagoNielsen J, Daldorph B, Espersen F, *et al.* *Staphylococcus aureus* carriage and infections among patients in four haemo- and peritoneal-dialysis centres in Denmark. *J Hosp Infect* 1996;**33**:289–300.
3. Luzar MA, Brown CB, Balf D, Hill L, Issad B, Monnier B, *et al.* Exit-site care and exit-site infection in continuous ambulatory peritoneal dialysis (CAPD): results of a randomized multicenter trial. *Perit Dial Int* 1990;**10**:25–9.
4. Vychytil A, Lorenz M, Schneider B, Horl WH, Haag-Weber M. New strategies to prevent *Staphylococcus aureus* infections in peritoneal dialysis patients. *J Am Soc Nephrol* 1998;**9**:669–76.
5. Gokal R, Alexander S, Ash S, Chen TW, Danielson A, Holmes C, *et al.* Peritoneal catheters and exit-site practices toward optimum peritoneal access: 1998 update. *Perit Dial Int* 1998;**18**:11–33.
6. Piraino B, Bernardini J, Sorkin M. The influence of peritoneal catheter exit-site infections on peritonitis, tunnel infections, and catheter loss in patients on continuous ambulatory peritoneal dialysis. *Am J Kidney Dis* 1986;**8**:436–40.
7. Woodrow G, Turney JH, Brownjohn AM. Technique failure in peritoneal dialysis and its impact on patient survival. *Perit Dial Int* 1997;**17**:360–4.
8. Van Biesen W, Dequidt C, Vijt D, Vanholder R, Lameire N. Analysis of the reasons for transfers between hemodialysis and peritoneal dialysis and their effect on survivals. *Adv Perit Dial* 1998;**14**:90–4.
9. Fried L, Abidi S, Bernardini J, Johnston JR, Piraino B. Hospitalization in peritoneal dialysis patients. *Am J Kidney Dis* 1999;**3**:927–33.
10. Borg D, Shetty A, Williams D, Faber MD. Fivefold reduction in peritonitis using a multifaceted continuous quality initiative program. *Adv Perit Dial* 2003;**19**:202–5.
11. Scalomogna A, Castelnovo C, De Vecchi A, Ponticelli C. Exit-site and tunnel infections in continuous ambulatory peritoneal dialysis patients. *Am J Kidney Dis* 1991;**18**:674–7.
12. Holley JL, Bernardini J, Piraino B. Risk factors for tunnel infections in continuous peritoneal dialysis. *Am J Kidney Dis* 1991;**18**:344–8.
13. Zelenitsky S, Barns L, Findlay I, Alfa M, Ariano R, Fine A, *et al.* Analysis of microbiological trends in peritoneal dialysis-related peritonitis from 1991 to 1998. *Am J Kidney Dis* 2000;**36**:1009–13.
14. Van Biesen W, Vanholder R, Vogelaers D, Peleman R, Verschraegen G, Vijt D, *et al.* The need for a center-tailored treatment protocol for peritonitis. *Perit Dial Int* 1998;**18**:274–81.
15. Bloom BS, Fendrick AM, Chernew ME, Patel P. Clinical and economic effects of mupirocin calcium on preventing *Staphylococcus aureus* infection in hemodialysis patients: a decision analysis. *Am J Kidney Dis* 1996;**27**:687–94.
16. Lye WC, Leong SO, van der SJ, Lee EJ. *Staphylococcus aureus* CAPD-related infections are associated with nasal carriage. *Adv Perit Dial* 1994;**10**:163–5.
17. Oxtan LL, Zimmerman SW, Roecker EB, Wakeen M. Risk factors for peritoneal dialysis-related infections. *Perit Dial Int* 1994;**14**:137–44.
18. Sewell CM, Clarridge J, Lacke C, Weinman EJ, Young EJ. Staphylococcal nasal carriage and subsequent infection in peritoneal dialysis patients. *JAMA* 1982;**248**:1493–5.
19. Piraino B, Perlmutter JA, Holley JL, Bernardini J. *Staphylococcus aureus* peritonitis is associated with *Staphylococcus aureus* nasal carriage in peritoneal dialysis patients. *Perit Dial Int* 1993;**13**:S332–4.
20. Sesso R, Draibe S, Castelo A, Sato I, Leme I, Barbosa D, *et al.* *Staphylococcus aureus* skin carriage and development of peritonitis in patients on continuous ambulatory peritoneal dialysis. *Clin Nephrol* 1989;**31**:264–8.
21. Kim D, Tapson J, Wu G, Khanna R, Vas SI, Oreopoulos DG. *Staph aureus* peritonitis in patients on continuous ambulatory peritoneal dialysis. *Trans Am Soc Artif Intern Organs* 1984;**30**:494–7.
22. Digenis GE, Abraham G, Savin E, Blake P, Dombros N, Sombolos K, *et al.* Peritonitis-related deaths in continuous ambulatory peritoneal dialysis (CAPD) patients. *Perit Dial Int* 1990;**10**:45–7.
23. Fried LF, Bernardini J, Johnston JR, Piraino B. Peritonitis influences mortality in peritoneal dialysis patients. *J Am Soc Nephrol* 1996;**7**:2176–82.

24. Finkelstein ES, Jekel J, Troidle L, Gorban-Brennan N, Finkelstein FO, Bia FJ. Patterns of infection in patients maintained on long-term peritoneal dialysis therapy with multiple episodes of peritonitis. *Am J Kidney Dis* 2002;**39**:1278–86.
25. Davies SJ, Ogg CS, Cameron JS, Poston S, Noble WC. *Staphylococcus aureus* nasal carriage, exit-site infection and catheter loss in patients treated with continuous ambulatory peritoneal dialysis (CAPD). *Perit Dial Int* 1989;**9**:61–4.
26. Luzar MA, Coles GA, Faller B, Slingeneyer A, Dah GD, Briat C, *et al.* *Staphylococcus aureus* nasal carriage and infection in patients on continuous ambulatory peritoneal dialysis. *N Engl J Med* 1990; **322**:505–9.
27. Reagan DR, Doebbeling BN, Pfaller MA, Sheetz CT, Houston AK, Hollis RJ, *et al.* Elimination of coincident *Staphylococcus aureus* nasal and hand carriage with intranasal application of mupirocin calcium ointment. *Ann Intern Med* 1991;**114**:101–6.
28. Amato D, de Jesus Ventura M, Miranda G, Leanos B, Alcantara G, Hurtado ME, *et al.* Staphylococcal peritonitis in continuous ambulatory peritoneal dialysis: colonization with identical strains at exit site, nose, and hands. *Am J Kidney Dis* 2001;**37**:43–8.
29. Royal College of Physicians of London and the Renal Association. *Treatment of adults and children with renal failure: Standards and audit measures*. 3rd ed. London: Renal Association. URL: http://www.renal.org/Standards/RenalStandards_2002b.pdf. Accessed January 2006.
30. Krediet RT. European best practice guidelines on peritoneal dialysis. *Nephrol Dial Transplant* 2005; **20**(Suppl 9).
31. Piraino B. ISPD guidelines/recommendations. Peritoneal dialysis-related infections: recommendations 2005 update. *Perit Dial Int* 2005; **25**:107–31.
32. Caring for Australians with Renal Impairment (CARI). Evidence for peritonitis treatment and prophylaxis: prophylactic antibiotics for insertion of peritoneal dialysis catheter. *Nephrology* 2004;**9**:S72–5.
33. Caring for Australians with Renal Impairment (CARI). Evidence for peritonitis treatment and prophylaxis: prophylaxis for exit site/tunnel infections using mupirocin. *Nephrology* 2004; **9**:S86–90.
34. Caring for Australians with Renal Impairment (CARI). Evidence for peritonitis treatment and prophylaxis: peritoneal dialysis catheter-related infection: exit site and tunnel. *Nephrology* 2004; **9**:S82–5.
35. Bennett-Jones DN, Martin J, Barrett A, Duffy TJ, Naish PF, Aber GM. Prophylactic gentamicin in the prevention of early exit-site infections and peritonitis in CAPD. *Adv Perit Dial* 1988;**4**:147–50.
36. Lye WC, Lee EJ, Tan CC. Prophylactic antibiotics in the insertion of Tenckhoff catheters. *Scand J Urol Nephrol* 1992;**26**:177–80.
37. Sharma BK, Rodriguez H, Gandhi VC, Smith EC, Pillay VK, Dunea G. Trial of oral neomycin during peritoneal dialysis. *Am J Med Sci* 1971;**262**:175–8.
38. Wong SSH, Chu K-H, Cheuk A, Tsang WK, Fung SKS, Chan HWH, *et al.* Prophylaxis against Gram-positive organisms causing exit-site infection and peritonitis in continuous ambulatory peritoneal dialysis patients by applying mupirocin ointment at the catheter exit site. *Perit Dial Int* 2003; **23**(Suppl 2):S153–8.
39. Zimmerman SW, Ahrens E, Johnson CA, Craig W, Leggett J, O'Brien M, *et al.* Randomized controlled trial of prophylactic rifampin for peritoneal dialysis-related infections. *Am J Kidney Dis* 1991;**18**:225–31.
40. Bernardini J, Piraino B, Holley J, Johnston JR, Lutes R. A randomized trial of *Staphylococcus aureus* prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin. *Am J Kidney Dis* 1996;**27**:695–700.
41. Bernardini J, Bender F, Florio T, Sloan J, Palmmontalbano L, Fried L, *et al.* Randomized, double-blind trial of antibiotic exit site cream for prevention of exit site infection in peritoneal dialysis patients. *J Am Soc Nephrol* 2005;**16**:539–45.
42. Bernardini J, Fried L, Bender F, Sloan J, Palmmontalbano L, Florio T, *et al.* A randomized double-blind trial of PD infection comparing mupirocin to gentamicin sulfate cream. *Perit Dial Int* 2004;**24**(Suppl 2):S53.
43. Cavdar C, Zeybel M, Atay T, Sifil A, Sanlidag C, Gulay Z, *et al.* The effects of once- or thrice-weekly mupirocin application on mupirocin resistance in patients on continuous ambulatory peritoneal dialysis – first 6 months' experience. *Adv Perit Dial* 2004;**20**:62–6.
44. Gadallah MF, Ramdeen G, Torres C, Mignone J, Patel D, Mitchell L, *et al.* Preoperative vancomycin prophylaxis for newly placed peritoneal dialysis catheters prevents postoperative peritonitis. *Adv Perit Dial* 2000;**16**:199–203.
45. Gadallah MF, Ramdeen G, Mignone J, Patel D, Mitchell L, Tatro S. Role of preoperative antibiotic prophylaxis in preventing postoperative peritonitis in newly placed peritoneal dialysis catheters. *Am J Kidney Dis* 2000;**36**:1014–19.
46. Waite NM, Webster N, Laurel M, Johnson M, Fong IW. The efficacy of exit site povidone–iodine ointment in the prevention of early peritoneal dialysis-related infections. *Am J Kidney Dis* 1997; **29**:763–8.
47. Sesso R, Barbosa D, Sato I, Draibe S, Castelo A, Ajzen H. A randomized controlled trial to assess the

- effectiveness of daily baths with 4% chlorhexidine gluconate vs neutral soap in CAPD patients. *Perit Dial Int* 1988;**8**:288.
48. Wilson AP, Lewis C, O'Sullivan H, Shetty N, Neild GH, Mansell M. The use of povidone iodine in exit site care for patients undergoing continuous peritoneal dialysis (CAPD). *J Hosp Infect* 1997;**35**:287–93.
 49. Wong FSY, Chan W-K, Chow N-Y, Tsui Y-T, Yung JCU, Cheng Y-L. Comparison of exit-site infection with the use of pure liquid soap and chlorhexidine soap in daily exit-site care. *Hong Kong J Nephrol* 2002;**4**:54–9.
 50. Fuchs J, Gallagher ME, Jackson-Bey D, Krawtz D, Schreiber MJJ. A prospective randomized study of peritoneal catheter exit-site care. *Dial Transplant* 1990;**19**:81–4.
 51. Poole-Warren LA, Hallett MD, Hone PW, Burden SH, Farrell PC. Vaccination for prevention of CAPD associated staphylococcal infection: results of a prospective multicentre clinical trial. *Clin Nephrol* 1991;**35**:198–206.
 52. Turner K, Edgar D, Hair M, Uttley L, Sternland R, Hunt L, *et al.* Does catheter immobilization reduce exit-site infections in CAPD patients? *Adv Perit Dial* 1992;**8**:265–8.
 53. Warady BA, Ellis EN, Fivush BA, Lum GM, Alexander SR, Brewer ED, *et al.* "Flush before fill" in children receiving automated peritoneal dialysis. *Perit Dial Int* 2003;**23**:493–8.
 54. Blowey DL, Warady BA, McFarland KS. The treatment of *Staphylococcus aureus* nasal carriage in pediatric peritoneal dialysis patients. *Adv Perit Dial* 1994;**10**:297–9.
 55. Mupirocin Study Group. Nasal mupirocin prevents *Staphylococcus aureus* exit-site infection during peritoneal dialysis. Mupirocin Study Group. *J Am Soc Nephrol* 1996;**7**:2403–8.
 56. Davey P. Randomised clinical trial and cost analysis of mupirocin for prevention of exit site infections (ESI) in continuous ambulatory peritoneal dialysis (CAPD). *Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy* 1996;**36**:296.
 57. Perez-Fontan M, Rosales M, Rodriguez-Carmona A, Moncalian J, Fernandez-Rivera C, Cao M, *et al.* Treatment of *Staphylococcus aureus* nasal carriers in CAPD with mupirocin. *Adv Perit Dial* 1992;**8**:242–5.
 58. Sesso R, Parisio K, Dalboni A, Rabelo T, Barbosa D, Cendoroglo M, *et al.* Effect of sodium fusidate and ofloxacin on *Staphylococcus aureus* colonization and infection in patients on continuous ambulatory peritoneal dialysis. *Clin Nephrol* 1994;**41**:370–6.
 59. Davey P, Craig AM, Hau C, Malek M. Cost-effectiveness of prophylactic nasal mupirocin in patients undergoing peritoneal dialysis based on a randomized, placebo-controlled trial. *J Antimicrob Chemother* 1999;**43**:105–12.
 60. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. *Med Decis Making* 1993;**13**:322–38.
 61. NICE. *Guide to the methods of technology appraisal*. London: National Institute for Health and Clinical Excellence. URL: <http://www.nice.org.uk/page.aspx?o=201974>. Accessed September 2005.
 62. Kavanagh D, Prescott GJ, Mactier RA on behalf of the Scottish Renal Registry. Peritoneal dialysis-associated peritonitis in Scotland (1999–2002). *Nephrol Dial Transplant* 2004;**19**:2584–91.
 63. Strippoli GF, Tong A, Johnson D, Schena FP, Craig JC. Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients. *Cochrane Database Syst Rev* 2004;(4):CD004679.
 64. Cookson BD. The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice. *J Antimicrob Chemother* 1998;**41**:11–18.
 65. Upton A, Lang S, Heffernan H. Mupirocin and *Staphylococcus aureus*: a recent paradigm of emerging antibiotic resistance. *J Antimicrob Chemother* 2003;**51**:613–17.
 66. Kresken M, Hafner D, Schmitz FJ, Wichelhaus TA, Paul Ehrlich Society for Chemotherapy. Prevalence of mupirocin resistance in clinical isolates of *Staphylococcus aureus* and *Staphylococcus epidermidis*: results of the Antimicrobial Resistance Surveillance Study of the Paul Ehrlich Society for Chemotherapy, 2001. *Int J Antimicrob Agents* 2004;**23**:577–81.
 67. Schmitz FJ, Lindenlauf E, Hofmann B, Fluit AC, Verhoef J, Heinz HP, *et al.* The prevalence of low- and high-level mupirocin resistance in staphylococci from 19 European hospitals. *J Antimicrob Chemother* 1998;**42**:489–95.
 68. Zakrzewska-Bode A, Muijtens HL, Liem KD, Hoogkamp-Korstanje JA. Mupirocin resistance in coagulase-negative staphylococci, after topical prophylaxis for the reduction of colonization of central venous catheters. *J Hosp Infect* 1995;**31**:189–93.
 69. Gemmell CG, Edwards DI, Fraise AP, Gould FK, Ridgway GL, Warren RE. Guidelines for the prophylaxis and treatment of methicillin-resistant *Staphylococcus aureus* (MRSA) infections in the UK. *J Antimicrob Chemother* 2006;**57**:589–608.
 70. Scanvic A, Denic L, Gaillon S, Giry P, Andreumont A, Lucet J-C. Duration of colonization by methicillin-resistant *Staphylococcus aureus* after hospital discharge and risk factors for prolonged carriage. *Clin Infect Dis* 2001;**32**:1393–8.

71. Gould IM. The clinical significance of methicillin-resistant *Staphylococcus aureus*. *J Hosp Infect* 2005; **61**:277–82.
72. Curtis L, Netten A. *Unit costs of health and social care 2005*. Canterbury: Personal Social Services Research Unit. URL: <http://www.pssru.ac.uk/uc/uc2005contents.htm>. Accessed January 2006.
73. Kirby L, Vale L. Dialysis for end-stage renal disease. Determining a cost-effective approach. *Int J Technol Assess Health Care* 2001; **17**:181–9.
74. de Wit GA, Ramsteijn PG, de Charro FT. Economic evaluation of end stage renal disease treatment. *Health Policy* 1998; **44**:215–32.
75. Wordsworth S, Ludbrook A, Caskey F, Macleod A. Collecting unit cost data in multicentre studies. Creating comparable methods. *Eur J Health Econ* 2005; **6**:38–44.
76. Gonzalez-Perez JG, Vale L, Stearns SC, Wordsworth S. Hemodialysis for end-stage renal disease: a cost-effectiveness analysis of treatment-options. *Int J Technol Assess Health Care* 2005; **21**:32–9.
77. The EuroQol Group. *EQ-5D user guide: a measure of health related quality of life*. Rotterdam: Rotterdam Centre for Health Policy and Law, Erasmus University; 1996.
78. Plum J, Artik S, Busch T, Sahin K, Grabensee B. Oral versus intraperitoneal application of clindamycin in tunnel infections: a prospective, randomized study in CAPD patients. *Perit Dial Int* 1997; **17**:486–92.
79. Bennett-Jones DN, Russell GI, Barrett A. A comparison between oral ciprofloxacin and intraperitoneal vancomycin and gentamicin in the treatment of CAPD peritonitis. *J Antimicrob Chemother* 1990; **26**:73–6.
80. Cheng IKP, Chan CY, Wong WT. A randomized prospective comparison of oral ofloxacin and intraperitoneal vancomycin plus aztreonam in the treatment of bacterial peritonitis complicating continuous ambulatory peritoneal-dialysis (Capd). *Perit Dial Int* 1991; **11**:27–30.
81. Flanigan MJ, Lim VS. Initial treatment of dialysis associated peritonitis – a controlled trial of vancomycin versus cefazolin. *Perit Dial Int* 1991; **11**:31–7.
82. Gucek A, Bren AF, Lindic J, Hergouth V, Mlinsek D. Is monotherapy with cefazolin or ofloxacin an adequate treatment for peritonitis in CAPD patients? *Adv Perit Dial* 1994; **10**:144–6.
83. Gucek A, Bren AF, Hergouth V, Lindic J. Cefazolin and netilmicin versus vancomycin and ceftazidime in the treatment of CAPD peritonitis. *Adv Perit Dial* 1997; **13**:218–20.
84. Leung C-B, Szeto C-C, Chow K-M, Kwan BCH, Wang AYM, Lui S-F, *et al*. Cefazolin plus ceftazidime versus imipenem/cilastatin monotherapy for treatment of CAPD peritonitis – a randomized controlled trial. *Perit Dial Int* 2004; **24**:440–6.
85. Merchant MR, Anwar N, Were A, Uttley L, Tooth JA, Gokal R. Imipenem versus netilmicin and vancomycin in the treatment of CAPD peritonitis. *Adv Perit Dial* 1992; **8**:234–7.
86. Tong MKH, Leung KT, Siu Y-P, Lee KF, Lee HK, Yung CY, *et al*. Use of intraperitoneal urokinase for resistant bacterial peritonitis in continuous ambulatory peritoneal dialysis. *J Nephrol* 2005; **18**:204–8.

Appendix I

Search strategies

The following search strategies were used to identify reports of RCTs and systematic reviews evaluating the effectiveness of preventing and treating *Staphylococcus aureus* carriage on peritoneal catheter-related infections.

MEDLINE (1996–November Week 3 2005), EMBASE (1980–Week 1 2006) (MEDLINE Extra 6 January 2006)

Ovid Multifile Search. URL:
<http://gateway.ovid.com/athens>

- 1 exp peritoneal dialysis/
- 2 continuous ambulatory peritoneal dialysis/ use emez
- 3 peritoneal dialysis.tw.
- 4 (capd or ccpd or apd).tw.
- 5 or/1-4
- 6 staphylococcal infections/pc
- 7 peritonitis/pc
- 8 bacterial peritonitis/pc use emez
- 9 catheterization/ae use mesz
- 10 catheterization/ use emez
- 11 catheters, indwelling/ae use mesz
- 12 indwelling catheter/ use emez
- 13 surgical wound infection/ use mesz
- 14 surgical infection/ use emez
- 15 catheter exit\$.tw.
- 16 exit site\$.tw.
- 17 (catheter adj3 infect\$.tw.
- 18 (catheter adj3 infect\$.tw.
- 19 (tunnel adj3 infect\$.tw.
- 20 or/13-19
- 21 (prevent\$ or prophyla\$ or reduc\$ or limit\$.tw.
- 22 20 and 21
- 23 or/6-12,22
- 24 5 and 23
- 25 staphylococcus aureus/
- 26 bacterium carrier/ use emez
- 27 bacterial colonization/ use emez
- 28 methicillin resistance/ use mesz
- 29 vancomycin resistance/ use mesz
- 30 methicillin resistant staphylococcus aureus/ use emez
- 31 aureus.tw.
- 32 (msra or mssa or visa or vrsa).tw.
- 33 (carriage or carrier\$ or host\$.tw.
- 34 (colony or coloni?ation).tw.
- 35 33 or 34
- 36 or/25,28-32

- 37 35 and 36
- 38 or/26-27,37
- 39 5 and 38
- 40 antibiotic prophylaxis/
- 41 exp anti-infective agents/
- 42 or/40-41
- 43 5 and (25 or 31) and 42
- 44 24 or 39 or 43
- 45 animal/ not human/ use mesz
- 46 (animal/ or nonhuman/) not human/ use emez
- 47 44 not (45 or 46)
- 48 clinical trial.pt. use mesz
- 49 exp controlled clinical trials/ use mesz
- 50 randomised controlled trial/ use emez
- 51 clinical trial/ use emez
- 52 random allocation/ use mesz
- 53 randomization/ use emez
- 54 placebo effect/ use mesz
- 55 placebo/ use emez
- 56 random\$.tw.
- 57 placebo\$.tw.
- 58 or/48-57
- 59 meta analysis.tw.
- 60 meta analysis.pt. use mesz
- 61 meta analysis/ use emez
- 62 review.ab.
- 63 review.pt. use mesz
- 64 systematic review/ use emez
- 65 or/60-65
- 66 47 and (59 or 66)
- 67 67 and eng.la.
- 68 remove duplicates from 68

CINAHL (1982–December Week 2 2005)

Ovid Multifile Search. URL:
<http://gateway.ovid.com/athens>

- 1 exp peritoneal dialysis/
- 2 peritoneal dialysis.tw.
- 3 (capd or ccpd or apd).tw.
- 4 or/1-3
- 5 staphylococcal infections/pc
- 6 peritonitis/pc
- 7 catheterization/ae
- 8 catheters, dialysis/ae
- 9 catheter-related infections/
- 10 catheter exit\$.tw.
- 11 exit site\$.tw.
- 12 (catheter adj3 infect\$.tw.
- 13 (tunnel adj3 infect\$.tw.

- 14 or/9-13
 15 prevent\$ or prophyla\$ or reduc\$ or limit\$).tw.
 16 14 and 15
 17 or/5-8,16
 18 4 and 17
 19 Staphylococcus Aureus/
 20 methicillin resistance/
 21 vancomycin resistance/
 22 aureus.tw.
 23 (msra or mssa or visa or vrsa).tw.
 24 bacterial colonization/
 25 carrier state/
 26 (carriage or carrier\$ or host\$).tw.
 27 (colony or coloni?ation).tw.
 28 or/25-27
 29 or/19-23
 30 28 and 29
 31 24 or 30
 32 4 and 31
 33 antibiotic prophylaxis/
 34 exp antiinfective agents/
 35 or/33-34
 36 4 and (19 or 22) and 35
 37 18 or 32 or 36
 38 37 and eng.lg.

Science Citation Index (1985–7 January 2006)
SCI Proceedings (1990–6 January 2006)

Web of Knowledge URL: <http://wok.mimas.ac.uk/>

- #1 TS=(capd OR ccpd OR apd)
 #2 TS=(peritoneal SAME dialysis)
 #3 #1 OR #2
 #4 TS=(coloni* SAME (aureus OR msra OR mssa OR visa OR vrsa))
 #5 TS=(colony SAME (aureus OR msra OR mssa OR visa OR vrsa))
 #6 TS=(host* SAME (aureus OR msra OR mssa OR visa OR vrsa))
 #7 TS=(carrier* SAME (aureus OR msra OR mssa OR visa OR vrsa))
 #8 TS=(carriage SAME (aureus OR msra OR mssa OR visa OR vrsa))
 #9 TS=((methicillin OR vancomycin) SAME resist*)
 #10 #4 OR #5 OR #6 OR #7 OR #8 OR #9
 #11 #3 AND #10
 #12 TS=((prevent* OR prophyla* OR reduc* OR limit*) SAME staphylococcal)
 #13 TS=((prevent* OR prophyla* OR reduc* OR limit*) SAME aureus)
 #14 TS=((prevent* OR prophyla* OR reduc* OR limit*) SAME peritonitis)
 #15 TS=(catheter* SAME infect*)
 #16 TS=(tunnel SAME infect*)
 #17 TS=(exit* SAME (catheter* OR site*))

- #18 #12 OR #13 OR #14 OR #15 OR #16 OR #17
 #19 #3 AND #18
 #20 #11 OR #19
 #21 TS=randomized
 #22 TS=randomised
 #23 TS=random
 #24 TS=randomly
 #25 TS=random* assign*
 #26 TS=random* alloc*
 #27 TS=(control* SAME trial*)
 #28 TS=meta analysis
 #29 TS=systematic review*
 #30 #20 AND (#21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29)

DocType=All document types; Language=All languages

BIOSIS (1985–3 January 2006)

Edina URL: <http://edina.ac.uk/biosis/>

(((((al: (meta analysis) or al: (systemtic review*))) and ()) or ((al: (random or randomly) or al: (control* n3 trial*)) and ())) or ((al: (randomized or randomised) or al: (random* alloc*) or al: (random* assign*)) and ()))) and (((((((al: (exit* n3 catheter*) or al: (exit* n3 site*)) and ())) or ((al: (catheter* n3 infect*) or al: (tunnel n3 infect*)) and ())) or ((al: (prevent* or prophyla* or reduc* or limit*) and al: (staphylococcal or aureus or peritonitis)) and ()))) and (((al: (peritoneal n3 dialysis)) and ())) or ((al: (capd) or al: (ccpd) or al: (apd)) and ()))))) or (((((((al: (methicillin n3 resist*) or al: (vancomycin n3 resist*)) and ())) or (al: (aureus or msra or mssa or visa or vrsa) and al: (carriage or carrier* or host* or colony or coloni*)))))) and (((al: (peritoneal n3 dialysis)) and ())) or ((al: (capd) or al: (ccpd) or al: (apd)) and ())))))

Clinical Trials (December 2005)

URL: <http://clinicaltrials.gov/ct/gui/c/r>

Current Controlled Trials (December 2005)

URL: <http://www.controlled-trials.com/>

Aureus AND (peritoneal OR CAPD)

Cochrane Library Issue 4, 2005

URL: <http://www3.interscience.wiley.com/cgi-bin/mrwhome/106568753/HOME>

National Research Register (Issue 4, 2005)

URL: <http://www.update-software.com/National/>

- #1 MeSH descriptor Peritoneal Dialysis explode all trees in MeSH products
 #2 peritoneal dialysis in All Fields in all products

- #3 capd in All Fields or ccpd in All Fields or apd in All Fields in all products
 #4 (#1 OR #2 OR #3)
 #5 MeSH descriptor Staphylococcal Infections explode all trees with qualifier: PC in MeSH products
 #6 MeSH descriptor Peritonitis explode all trees with qualifier: PC in MeSH products
 #7 MeSH descriptor Catheterization explode all trees with qualifier: AE in MeSH products
 #8 MeSH descriptor Catheters, Indwelling explode all trees with qualifier: AE in MeSH products
 #9 MeSH descriptor Surgical Wound Infection explode all trees in MeSH products
 #10 exit site* in All Fields or catheter NEAR/3 infect* in All Fields or tunnel NEAR/3 infect* in All Fields or catheter exit* in All Fields in all products
 #11 (#9 OR #10)
 #12 prevent* in All Fields or prophyla* in All Fields or reduc* in All Fields or limit* in All Fields in all products
 #13 (#11 AND #12)
 #14 (#5 OR #6 OR #7 OR #8 OR #13)
 #15 (#4 AND #14)
 #16 MeSH descriptor Staphylococcus aureus explode all trees in MeSH products
 #17 aureus in All Fields in all products
 #18 mrsa in All Fields or mssa in All Fields or visa in All Fields or vrsa in All Fields in all products
 #19 MeSH descriptor Methicillin Resistance explode all trees in MeSH products
 #20 MeSH descriptor Vancomycin Resistance explode all trees in MeSH products
 #21 carriage in All Fields or carrier* in All Fields or host* in All Fields in all products

- #22 colony in All Fields or colonization in All Fields or colonisation in All Fields in all products
 #23 (#16 OR #17 OR #18 OR #19 OR #20)
 #24 (#21 OR #22)
 #25 (#23 AND #24)
 #26 (#4 AND #25)
 #27 MeSH descriptor Antibiotic Prophylaxis explode all trees in MeSH products
 #28 MeSH descriptor Anti-Infective Agents explode all trees in MeSH products
 #29 (#27 OR #28)
 #30 (#16 OR #17)
 #31 (#4 AND #29 AND #30)
 #32 (#15 OR #26 OR #31)

DARE and HTA Databases (December 2005)
NHS Centre for Reviews and Dissemination
 URL: <http://nhscrd.york.ac.uk/welcome.htm>

Peritoneal-dialysis (exploded) or capd and aureus

Conference proceedings abstracts screened

1st Asian Chapter Meeting ISPD, Hong Kong, December 2002, *Perit Dial Int* 2003;**23**(Suppl 2).
 2nd Asian Chapter Meeting, Hyderabad, India, January 2005, *Perit Dial Int* 2005;**25**(Suppl 2).
 1st Joint ISPD/EUROPD Congress, Amsterdam, August 2004, *Perit Dial Int* 2004;**24**(Suppl 2).

Journals full text screened

Peritoneal Dialysis International (1981–2005)
Advances in Peritoneal Dialysis (1985–2004)

Appendix 2

Study eligibility form

Effectiveness of preventing and treating *Staphylococcus aureus* carriage on peritoneal catheter-related infections

Study ID: _____ Refman ID: _____

Type of study

Q1. Is the study a randomised controlled trial or a quasi-randomised controlled trial?

Yes	Unclear	No
↓	↓	↓
Go to Next question		Exclude

Participants in the study

Q2. Were the participants in the study adult or paediatric patients undergoing peritoneal dialysis or about to undergo a peritoneal catheter placement procedure?

Yes	Unclear	No
↓	↓	↓
Go to Next question		Exclude

Interventions in the study

Q3. Did one group receive antimicrobial treatment, antiseptic medication or other intervention to prevent or treat *S. aureus* carriage?

Yes	Unclear	No
↓	↓	↓
Go to Next question		Exclude

Q4. Did another group receive a different intervention or no treatment to prevent or treat *S. aureus* carriage?

Yes	Unclear	No
↓	↓	↓
Go to Next question		Exclude

Outcomes in the study

Q5. Did the study report any of the pre-specified outcomes (refer to data abstraction and quality assessment form)

Yes	Unclear	No
↓	↓	↓
Include, subject to clarification of 'unclear' points		Exclude

Final decision:

Include trial Background information Economic data Systematic review
 Unclear Exclude

Appendix 3

Data abstraction and quality assessment form

Effectiveness of preventing and treating *Staphylococcus aureus* carriage on peritoneal catheter-related infections

Reviewer ID: _____

Study Details			
Study ID:	Abstract <input type="checkbox"/>	Full text <input type="checkbox"/>	Unpublished <input type="checkbox"/>
Authors:	_____		

Title:	_____		

Publication year or date of interim data collection:	_____		

Study Design			
	RCT <input type="checkbox"/>		Quasi RCT <input type="checkbox"/>
	Prevention trial <input type="checkbox"/>		Treatment trial <input type="checkbox"/>
Randomisation details	_____		

Quality assessment			
Allocation concealment:	Adequate <input type="checkbox"/>	Inadequate <input type="checkbox"/>	Unclear <input type="checkbox"/>
Blinding:			
Blinding of investigators:	Yes <input type="checkbox"/>	No <input type="checkbox"/>	Unclear <input type="checkbox"/>
Blinding of participants:	Yes <input type="checkbox"/>	No <input type="checkbox"/>	Unclear <input type="checkbox"/>
Blinding of outcome assessor:	Yes <input type="checkbox"/>	No <input type="checkbox"/>	Unclear <input type="checkbox"/>
Blinding of data analysis:	Yes <input type="checkbox"/>	No <input type="checkbox"/>	Unclear <input type="checkbox"/>
Intention to treat analysis:			
	Stated & confirmed ITT <input type="checkbox"/>		Not stated but confirmed ITT <input type="checkbox"/>
	Not stated but confirmed <u>not</u> ITT <input type="checkbox"/>		Stated but not confirmed <u>not</u> ITT <input type="checkbox"/>
			Not stated <input type="checkbox"/>
Participants lost to follow-up	Yes <input type="checkbox"/>	No <input type="checkbox"/>	Unclear <input type="checkbox"/>
Percent of participants excluded or lost to follow-up:	_____		

Participants	
Number of participants randomised or included in trial: _____	
Proportion of numbers in clinic included in trial: _____	
Criteria for inclusion:	Criteria for exclusion:

Setting and Timing	
Setting of study:	_____
Recruitment period:	_____
Follow-up period:	_____

Screening and treatment of nasal <i>S. aureus</i>	
Screening:	_____

Treatment	_____

Interventions		
	Treatment/Prevention	No of patients
Intervention 1 _____	_____	_____
Intervention 2 _____	_____	_____
Intervention 3 _____	_____	_____

Patient Characteristics			
	Intervention 1	Intervention 2	Intervention 3
Age (years) _____	_____	_____	_____
Sex (M/F) _____	_____	_____	_____
Adults (No) _____	_____	_____	_____
Paediatrics (No) _____	_____	_____	_____
Diabetic Nephropathy (No) _____	_____	_____	_____
Hypertension and Renovascular Disease (No) _____	_____	_____	_____
Glomerulonephritis (No) _____	_____	_____	_____
Adult Polycystic Kidney Disease (No) _____	_____	_____	_____
Reflux Nephropathy (No) _____	_____	_____	_____
E coli 0157 (No) _____	_____	_____	_____
Other aetiology (No & specify) _____	_____	_____	_____
Time on PD before treatment _____	_____	_____	_____
Indications of infirmity (specify) _____	_____	_____	_____
Hygiene measures taken (specify) _____	_____	_____	_____

Outcomes			
	Intervention 1	Intervention 2	Intervention 3
No of patients with <i>S. aureus</i> carriage			
Time to <i>S. aureus</i> carriage			
No of patients with peritonitis			
Peritonitis rate (no of episodes over total pt months on PD)			
Time to first peritonitis episode			
Peritonitis relapse (No & specify time to)			
No of patients requiring catheter removal			
No of patients switching to haemodialysis			
No of patients requiring catheter replacement			
No of patients with exit-site and tunnel infections			
Exit-site and tunnel infection rate			
Side effects of antibiotics			
Death due to peritonitis			
Hospitalisation rates			
Quality of life			
Development of antibiotic resistance			

Appendix 4

List of included studies

Bennett-Jones, 1988

Bennett-Jones DN, Martin J, Barrett A, Duffy TJ, Naish PF, Aber GM. Prophylactic gentamicin in the prevention of early exit-site infections and peritonitis in CAPD. *Adv Perit Dial* 1988;**4**:147–50.

Bernardini, 1996

Bernardini J, Piraino B, Holley J, Johnston JR, Lutes R. A randomized trial of *Staphylococcus aureus* prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin. *Am J Kidney Dis* 1996;**27**:695–700.

Bernardini, 2005

Primary reference

Bernardini J, Bender F, Florio T, Sloand J, Palmmontalbano L, Fried L, *et al.* Randomized, double-blind trial of antibiotic exit site cream for prevention of exit site infection in peritoneal dialysis patients. *J Am Soc Nephrol* 2005;**16**:539–45.

Secondary reference

Bernardini J, Fried L, Bender F, Sloand J, Palmmontalbano L, Florio T, *et al.* A randomized double-blind trial of PD infection comparing mupirocin to gentamicin sulfate cream. *Perit Dial Int* 2004;**24**(Suppl 2):S53.

Blowey, 1994

Blowey DL, Warady BA, McFarland KS. The treatment of *Staphylococcus aureus* nasal carriage in pediatric peritoneal dialysis patients. *Adv Perit Dial* 1994;**10**:297–9.

Cavdar, 2004

Cavdar C, Zeybel M, Atay T, Sifil A, Sanlidag C, Gulay Z, *et al.* The effects of once- or thrice-weekly mupirocin application on mupirocin resistance in patients on continuous ambulatory peritoneal dialysis – first 6 months' experience. *Adv Perit Dial* 2004;**20**:62–6.

Fuchs, 1990

Fuchs J, Gallagher ME, Jackson-Bey D, Krawtz D, Schreiber MJJ. A prospective randomized study of peritoneal catheter exit-site care. *Dial Transplant* 1990;**19**:81–4.

Gadallah, 2000

Primary reference

Gadallah MF, Ramdeen G, Torres C, Mignone J, Patel D, Mitchell L, *et al.* Preoperative vancomycin prophylaxis for newly placed peritoneal dialysis catheters prevents postoperative peritonitis. *Adv Perit Dial* 2000;**16**:199–203.

Secondary reference

Gadallah MF, Ramdeen G, Mignone J, Patel D, Mitchell L, Tatro S. Role of preoperative antibiotic prophylaxis in preventing postoperative peritonitis in

newly placed peritoneal dialysis catheters. *Am J Kidney Dis* 2000;**36**:1014–19.

Luzar, 1990

Luzar MA, Brown CB, Balf D, Hill L, Issad B, Monnier B, *et al.* Exit-site care and exit-site infection in continuous ambulatory peritoneal dialysis (CAPD): results of a randomized multicenter trial. *Perit Dial Int* 1990;**10**:25–9.

Lye, 1992

Lye WC, Lee EJ, Tan CC. Prophylactic antibiotics in the insertion of Tenckhoff catheters. *Scand J Urol Nephrol* 1992;**26**:177–80.

Mupirocin Study Group, 1996

Primary reference

Mupirocin Study Group. Nasal mupirocin prevents *Staphylococcus aureus* exit-site infection during peritoneal dialysis. Mupirocin Study Group. *J Am Soc Nephrol* 1996;**7**:2403–8.

Secondary reference

Davey P. Randomised clinical trial and cost analysis of mupirocin for prevention of exit site infections (ESI) in continuous ambulatory peritoneal dialysis (CAPD). *Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy* 1996;**36**:296.

Perez-Fontan, 1992

Perez-Fontan M, Rosales M, Rodriguez-Carmona A, Moncalian J, Fernandez-Rivera C, Cao M, *et al.* Treatment of *Staphylococcus aureus* nasal carriers in CAPD with mupirocin. *Adv Perit Dial* 1992;**8**:242–5.

Poole-Warren, 1991

Poole-Warren LA, Hallett MD, Hone PW, Burden SH, Farrell PC. Vaccination for prevention of CAPD associated staphylococcal infection: results of a prospective multicentre clinical trial. *Clin Nephrol* 1991;**35**:198–206.

Sesso, 1988

Sesso R, Barbosa D, Sato I, Draibe S, Castelo A, Ajzen H. A randomized controlled trial to assess the effectiveness of daily baths with 4% chlorhexidine gluconate vs neutral soap in CAPD patients. *Perit Dial Int* 1988;**8**:288.

Sesso, 1994

Sesso R, Parisio K, Dalboni A, Rabelo T, Barbosa D, Cendoroglo M, *et al.* Effect of sodium fusidate and ofloxacin on *Staphylococcus aureus* colonization and infection in patients on continuous ambulatory peritoneal dialysis. *Clin Nephrol* 1994;**41**:370–6.

Sharma, 1971

Sharma BK, Rodriguez H, Gandhi VC, Smith EC, Pillay VK, Dunea G. Trial of oral neomycin during peritoneal dialysis. *Am J Med Sci* 1971;**262**:175–8.

Turner, 1992

Turner K, Edgar D, Hair M, Uttley L, Sternland R, Hunt L, *et al.* Does catheter immobilization reduce exit-site infections in CAPD patients? *Adv Perit Dial* 1992;**8**:265–8.

Waite, 1997

Waite NM, Webster N, Laurel M, Johnson M, Fong IW. The efficacy of exit site povidone-iodine ointment in the prevention of early peritoneal dialysis-related infections. *Am J Kidney Dis* 1997;**29**:763–8.

Warady, 2003

Warady BA, Ellis EN, Fivush BA, Lum GM, Alexander SR, Brewer ED, *et al.* “Flush before fill” in children receiving automated peritoneal dialysis. *Perit Dial Int* 2003;**23**:493–8.

Wilson, 1997

Wilson AP, Lewis C, O’Sullivan H, Shetty N, Neild GH, Mansell M. The use of povidone iodine in exit site care for patients undergoing continuous peritoneal dialysis (CAPD). *J Hosp Infect* 1997;**35**:287–93.

Wong, 2002

Wong FSY, Chan W-K, Chow N-Y, Tsui Y-T, Yung JCU, Cheng Y-L. Comparison of exit-site infection with the use of pure liquid soap and chlorhexidine soap in daily exit-site care. *Hong Kong J Nephrol* 2002;**4**:54–9.

Wong, 2003

Wong SSH, Chu K-H, Cheuk A, Tsang WK, Fung SKS, Chan HWH, *et al.* Prophylaxis against Gram-positive organisms causing exit-site infection and peritonitis in continuous ambulatory peritoneal dialysis patients by applying mupirocin ointment at the catheter exit site. *Perit Dial Int* 2003;**23**(Suppl 2):S153–8.

Zimmerman, 1991

Zimmerman SW, Ahrens E, Johnson CA, Craig W, Leggett J, O’Brien M, *et al.* Randomized controlled trial of prophylactic rifampin for peritoneal dialysis-related infections. *Am J Kidney Dis* 1991;**18**:225–31.

Appendix 5

Detailed quality assessment results for included trials

Study ID	Allocation concealment	Blinding of investigators	Blinding of participants	Blinding of assessor	Blinding of data analysis	ITT	Lost to follow-up
Bennett-Jones, 1988 ³⁵	Inadequate	Unclear	Unclear	Unclear	Unclear	Not stated	Yes
Bernardini, 1996 ⁴⁰	Unclear	Unclear	Unclear	Unclear	Unclear	Stated	Unclear
Bernardini, 2005 ^{41,42}	Adequate	Yes	Yes	Unclear	Unclear	Stated	Unclear
Blowey, 1994 ⁵⁴	Unclear	Unclear	Unclear	Unclear	Unclear	Not stated	Unclear
Cavdar, 2004 ⁴³	Unclear	Unclear	Unclear	Unclear	Unclear	Not stated	Unclear
Fuchs, 1990 ⁵⁰	Unclear	Unclear	Unclear	Unclear	Unclear	Not stated	Yes
Gadallah, 2000 ^{44,45}	Inadequate	Unclear	Unclear	Unclear	Unclear	Not stated	Unclear
Luzar, 1990 ³	Unclear	Unclear	Unclear	Unclear	Unclear	Not stated	Yes
Lye, 1992 ³⁶	Inadequate	Unclear	Unclear	Unclear	Unclear	Not stated	Unclear
Mupirocin Study Group, 1996 ^{55,56}	Unclear	Unclear	Unclear	Unclear	Unclear	Stated	Unclear
Perez-Fontan, 1992 ⁵⁷	Unclear	Unclear	Unclear	Unclear	Unclear	Not stated	Yes
Poole-Warren, 1991 ⁵¹	Unclear	Unclear	Yes	Unclear	Unclear	Not stated	Unclear
Sesso, 1988 ⁴⁷	Unclear	Unclear	Unclear	Unclear	Unclear	Not stated	Yes
Sesso, 1994 ⁵⁸	Unclear	Unclear	Unclear	Unclear	Unclear	Not stated	Yes
Sharma, 1971 ³⁷	Unclear	Unclear	Unclear	Unclear	Unclear	Not stated	Yes
Turner, 1992 ⁵²	Unclear	No	No	No	Unclear	Not stated	Unclear
Waite, 1997 ⁴⁶	Unclear	Unclear	Unclear	Yes	Unclear	Not stated	Yes
Warady, 2003 ⁵³	Unclear	No	No	Unclear	Unclear	Not stated	Yes
Wilson, 1997 ⁴⁸	Unclear	Unclear	Unclear	Unclear	Unclear	Not stated	Yes
Wong, 2002 ⁴⁹	Inadequate	Unclear	Unclear	Unclear	Unclear	Not stated	Yes
Wong, 2003 ³⁸	Unclear	No	No	Unclear	Unclear	Not stated	Yes
Zimmerman, 1991 ³⁹	Unclear	No	No	No	No	Not stated	Unclear

Appendix 6

Detailed description of included studies

Study	Study details	Intervention/comparator	Intervention 1 population characteristics	Intervention 2 population characteristics	Intervention 3 population characteristics
Bennett-Jones, 1988 ³⁵	Single-centre RCT 27 participants Follow-up = 28 days Full text	Gentamicin 1.5 mg/kg body weight given i.v. by anaesthetist at time of induction of anaesthesia in anaesthetic room ($n = 13$) versus no treatment ($n = 13$; 1 withdrawn)	Age mean \pm SD 52.7 \pm 18.6 years 8 male/5 female	Age mean \pm SD 53.1 \pm 13.0 years 9 male/4 female	
Bernardini, 1996 ⁴⁰	Single-centre RCT 82 participants Follow-up = mean 1 year Full text	Mupirocin calcium ointment 2%, applied daily to catheter exit site ($n = 41$) versus 300 mg oral rifampin twice per day for 5 days once every 3 months ($n = 41$)	49% male/51% female 41/41 adult Time on PD mean (range) 1.3 \pm 1.8 (0–57) years 44% <i>S. aureus</i> carriage	59% male/41% female 41/41 adult Time on PD mean (range) 1.1 \pm 1.7 (0–9.1) years 44% <i>S. aureus</i> carriage	
Bernardini, 2005 ^{41,42}	Multicentre RCT 133 participants Follow-up = median (range) 8 (0.13–28.2) months Full text	Mupirocin 2% cream daily to catheter exit site ($n = 66$) versus gentamicin cream 0.1% daily to exit site ($n = 67$)	Age mean \pm SD 51 \pm 15 years 38 male/28 female 66/66 adult 9/66 <i>S. aureus</i> carriage	Age mean \pm SD 54 \pm 15 years 34 male/33 female 67/67 adult 9/67 <i>S. aureus</i> carriage	
Blowey, 1994 ⁵⁴	Single-centre RCT 15 participants Follow-up = 1 month Full text	Oral rifampin (20 mg/kg/day in 2 doses for 5 days) and bacitracin (topical to anterior nares 2 times per day for 7 days) ($n = 7$) versus no treatment ($n = 8$)	7/7 <i>S. aureus</i> carriage	8/8 <i>S. aureus</i> carriage	
Cavdar, 2004 ⁴³	Single-centre RCT 36 participants Follow-up = 6 months Full text	Mupirocin to exit site once weekly ($n = 18$) versus mupirocin to exit site 3 times weekly ($n = 18$)	Age mean 55.3 \pm 1.8 years 10 male/8 female 3/18 <i>S. aureus</i> carriage	Age mean 55.0 \pm 2.3 years 11 male/7 female 0/18 <i>S. aureus</i> carriage	

continued

Study	Study details	Intervention/comparator	Intervention 1 population characteristics	Intervention 2 population characteristics	Intervention 3 population characteristics
Fuchs, 1990 ⁵⁰	RCT 51 participants Follow-up = mean (range) 6.63 (1–12) months Full text	Washing exit site with chlorhexidine, then rinsing well, no dressing applied (n = 18), versus cleaning the exit site once daily with 0.005% sodium hypochlorite no dressing applied (n = 13), versus daily cleansing of exit site with 10% povidone-iodine swabsticks, followed by application of povidone ointment and a dry sterile dressing (n = 20)	Age mean 46 years 7 male/11 female 66/66 adult Time on PD mean \pm SD 14.3 \pm 12.9 months	Age mean 47 years 7 male/6 female 67/67 adult Time on PD mean \pm SD 21.2 \pm 28.6 months	Age mean 55 years 13 male/7 female 67/67 adult Time on PD mean \pm SD 23.6 \pm 19.0 months
Gadallah, 2000 ^{44,45}	Quasi-RCT 265 participants (305 catheters) Follow-up = 14 days Full text	i.v. vancomycin 1000 mg ~12 hours before PD catheter placement (n = 90; 103 catheters) versus i.v. cefazolin 1000 mg ~3 hours before PD catheter placement (n = 88, 102 catheters) versus no antibiotics for at least 1 week before procedure (n = 87, 100 catheters)	Age 46 (15–72) years 38 male/52 female 90/90 adult 32/90 diabetic nephropathy 42/90 hypertension and renovascular disease 4/90 glomerulonephritis 3/90 APKD 4/90 lupus nephritis 5/90 HIV nephropathy	Age 47 (20–81) years 43 male/45 female 88/88 adult 30/88 diabetic nephropathy 38/88 hypertension and renovascular disease 5/88 glomerulonephritis 4/88 APKD 4/88 lupus nephritis 7/88 HIV nephropathy	Age 45 (19–76) years 38 male/49 female 87/87 adult 28/87 diabetic nephropathy 41/87 hypertension and renovascular disease 6/87 glomerulonephritis 2/87 APKD 5/87 lupus nephritis 5/87 HIV nephropathy
Luzar, 1990 ³	Multicentre RCT 127 participants Follow-up = mean 9.03 months Full text	Povidone-iodine (concentration 20 g/l) applied to exit site with sterile gauze (n = 74) versus cleaning of exit site daily with non-disinfectant soap on sterile gauze (simple soap in UK or savon de Marseilles in France) (n = 53)	63% male/37% female 74/74 adult 17% diabetic glomerulonephritis	59% male/41% female 53/53 adult 11% diabetic glomerulonephritis	

continued

Study	Study details	Intervention/comparator	Intervention 1 population characteristics	Intervention 2 population characteristics	Intervention 3 population characteristics
Lye, 1992 ³⁶	Single-centre quasi-RCT 50 participants Follow-up = 3 months Full text	Preoperative antibiotics: cefazolin (500 mg) and gentamicin (80 mg) as rapid i.v. infusion no more than 60 minutes before surgery (n = 25) versus no treatment (n = 25)	Age mean \pm SD 56.0 \pm 14.3 years 8 male/17 female 17/25 diabetic nephropathy 4/25 glomerulonephritis 1/25 urolithiasis 3/25 other 3/25 <i>S. aureus</i> carriage 6/25 MRSA	Age mean \pm SD 52.3 \pm 14.0 years 15 male/10 female 13/25 diabetic nephropathy 7/25 glomerulonephritis 1/25 urolithiasis 4/25 other 6/25 <i>S. aureus</i> carriage 4/25 MRSA	
Mupirocin Study Group, 1996 ^{55,56}	Multicentre RCT 267 participants Follow-up = max. 18 months Full text	Calcium mupirocin 2%, 2 \times daily for 5 consecutive days every 4 weeks (n = 134) versus placebo ointment (n = 133)	Age mean 60.3 years 60.4% male/39.6% female 16.4% hypertension and renovascular disease 26.1% glomerulonephritis 10.4% polycystic disease 5.2% pyelonephritis 24.6% other 134/134 <i>S. aureus</i> carriage	Age mean 60.3 years 60.2% male/39.8% female 8.3% hypertension and renovascular disease 19.5% glomerulonephritis 5.3% polycystic disease 7.5% pyelonephritis 36.8% other 133/133 <i>S. aureus</i> carriage	
Perez-Fontan, 1992 ⁵⁷	Single-centre RCT 22 participants Follow-up = mean (range) 9.5 (3–15) months Full text	2% mupirocin nasal ointment t.d.s. for 7 days (n = 12) versus 0.1% neomycin sulphate ointment t.d.s. for 7 days (n = 10)	Age mean \pm SD 51 \pm 15 years 5 male/7 female Time on PD 32 \pm 16 months 12/12 <i>S. aureus</i> carriage	Age mean \pm SD 48 \pm 21 years 5 male/5 female Time on PD 32 \pm 15 months 10/10 <i>S. aureus</i> carriage	
Poole-Warren, 1991 ⁵¹	Multicentre RCT 124 participants Follow-up = 1 year Full text	Vaccinated with combined staphylococcus toxoid/whole killed staphylococci formulation (SB). Given i.m. Six injections given in increasing concentrations (1, 5, 10, 20, 50% and undiluted) over 6 weeks. Four booster injections (each 1 ml of undiluted SB) given every 12 weeks (weeks 17, 29, 41 and 53) (n = 65), versus placebo (normal saline injections given i.m. on same schedule) (n = 59)	Age mean \pm SD 54 \pm 11 years 1.5 [ratio] 12/65 diabetic nephropathy 11/65 hypertension and renovascular disease 16/65 glomerulonephritis 5/65 reflux nephropathy 7/65 analgesic nephropathy 8/65 other Time on PD mean \pm SD 1.5 \pm 1.3 years 13/40 <i>S. aureus</i> carriage	Age mean \pm SD 52 \pm 14 years 0.7 [ratio] 9/59 diabetic nephropathy 5/59 hypertension and renovascular disease 18/59 glomerulonephritis 2/59 reflux nephropathy 9/59 analgesic nephropathy 6/59 other Time on PD mean \pm SD 1.7 \pm 1.9 years 11/36 <i>S. aureus</i> carriage	

continued

Study	Study details	Intervention/comparator	Intervention 1 population characteristics	Intervention 2 population characteristics	Intervention 3 population characteristics
Sesso, 1988 ⁴⁷	RCT 39 participants Follow-up = Group A 150 patient months; Group B 133 patient months Correspondence	4% chlorhexidine gluconate (n = 20) versus neutral soap (n = 19)	Age mean \pm SE 46.1 \pm 3.8 (33–69) years 6 male/3 female 9/9 adult 1/9 diabetic nephropathy 0/9 glomerulonephritis 8/9 other Time on PD mean \pm SE 9.9 \pm 4.0 months <i>S. aureus</i> carriage: all = 9/9; nares = 2/9; exit site = 2/9; nares + exit site = 5/9	Age mean \pm SE 36.6 \pm 4.6 (22–61) years 6 male/3 female 9/9 adult 3/9 diabetic nephropathy 1/9 glomerulonephritis 5/9 other Time on PD mean \pm SE 16.1 \pm 6.2 months <i>S. aureus</i> carriage: all = 9/9; nares = 0/9; exit site = 4/9; nares + exit site = 5/9	Age mean \pm SE 42.1 \pm 4.6 (17–68) years 9 male/4 female 13/13 adult 1/13 diabetic nephropathy 3/13 glomerulonephritis 6/13 other Time on PD mean \pm SE 15.0 \pm 4.5 months <i>S. aureus</i> carriage: all = 13/13; nares = 4/9; exit site = 4/13; nares + exit site = 5/13
Sesso, 1994 ⁵⁸	Single-centre RCT 31 participants Follow-up = mean \pm SE 7.8 \pm 0.6 months Full text	2% sodium fusidate (ointment as applied to anterior nares and catheter exit site \times 2 daily for 5 days) (n = 9) versus 200 mg ofloxacin orally every 48 hours for 5 days (n = 9) versus placebo tablets (n = 13)	Age mean \pm SE 46.1 \pm 3.8 (33–69) years 6 male/3 female 9/9 adult 1/9 diabetic nephropathy 0/9 glomerulonephritis 8/9 other Time on PD mean \pm SE 9.9 \pm 4.0 months <i>S. aureus</i> carriage: all = 9/9; nares = 2/9; exit site = 2/9; nares + exit site = 5/9	Age mean \pm SE 36.6 \pm 4.6 (22–61) years 6 male/3 female 9/9 adult 3/9 diabetic nephropathy 1/9 glomerulonephritis 5/9 other Time on PD mean \pm SE 16.1 \pm 6.2 months <i>S. aureus</i> carriage: all = 9/9; nares = 0/9; exit site = 4/9; nares + exit site = 5/9	Age mean \pm SE 42.1 \pm 4.6 (17–68) years 9 male/4 female 13/13 adult 1/13 diabetic nephropathy 3/13 glomerulonephritis 6/13 other Time on PD mean \pm SE 15.0 \pm 4.5 months <i>S. aureus</i> carriage: all = 13/13; nares = 4/9; exit site = 4/13; nares + exit site = 5/13
Sharma, 1971 ³⁷	RCT 41 participants (95 dialysates) Follow-up = at least 48 hours Full text	Neomycin (0.5 g by mouth or nasogastric tube every 6 hours) (n = 48 dialysates) versus placebo (n = 41 dialysates)	Age mean \pm SE 46.1 \pm 3.8 (33–69) years 6 male/3 female 9/9 adult 1/9 diabetic nephropathy 0/9 glomerulonephritis 8/9 other Time on PD mean \pm SE 9.9 \pm 4.0 months <i>S. aureus</i> carriage: all = 9/9; nares = 2/9; exit site = 2/9; nares + exit site = 5/9	Age mean \pm SE 36.6 \pm 4.6 (22–61) years 6 male/3 female 9/9 adult 3/9 diabetic nephropathy 1/9 glomerulonephritis 5/9 other Time on PD mean \pm SE 16.1 \pm 6.2 months <i>S. aureus</i> carriage: all = 9/9; nares = 0/9; exit site = 4/9; nares + exit site = 5/9	Age mean \pm SE 42.1 \pm 4.6 (17–68) years 9 male/4 female 13/13 adult 1/13 diabetic nephropathy 3/13 glomerulonephritis 6/13 other Time on PD mean \pm SE 15.0 \pm 4.5 months <i>S. aureus</i> carriage: all = 13/13; nares = 4/9; exit site = 4/13; nares + exit site = 5/13
Turner, 1992 ⁵²	Single-centre RCT 66 participants Follow-up = mean (range) 20 \pm 17 (2–49) versus 21 \pm 17 (2–54) versus 23 \pm 20 (1–60) weeks Full text	Immobiliser (n = 22) versus tape (n = 23) versus non- immobilised (n = 21)	Age mean \pm SE 46.1 \pm 3.8 (33–69) years 6 male/3 female 9/9 adult 1/9 diabetic nephropathy 0/9 glomerulonephritis 8/9 other Time on PD mean \pm SE 9.9 \pm 4.0 months <i>S. aureus</i> carriage: all = 9/9; nares = 2/9; exit site = 2/9; nares + exit site = 5/9	Age mean \pm SE 36.6 \pm 4.6 (22–61) years 6 male/3 female 9/9 adult 3/9 diabetic nephropathy 1/9 glomerulonephritis 5/9 other Time on PD mean \pm SE 16.1 \pm 6.2 months <i>S. aureus</i> carriage: all = 9/9; nares = 0/9; exit site = 4/9; nares + exit site = 5/9	Age mean \pm SE 42.1 \pm 4.6 (17–68) years 9 male/4 female 13/13 adult 1/13 diabetic nephropathy 3/13 glomerulonephritis 6/13 other Time on PD mean \pm SE 15.0 \pm 4.5 months <i>S. aureus</i> carriage: all = 13/13; nares = 4/9; exit site = 4/13; nares + exit site = 5/13

continued

Study	Study details	Intervention/comparator	Intervention 1 population characteristics	Intervention 2 population characteristics	Intervention 3 population characteristics
Waite, 1997 ⁴⁶	Single-centre RCT 120 participants (117 analysed) Follow-up = mean 14.6 vs 13.2 months Full text	3.5 g 10% povidone-iodine ointment (n = 61) versus no intervention (n = 56)	Age mean \pm SD 54.4 \pm 15.1 years 33 male/28 female 22/61 <i>S. aureus</i> carriage	Age mean \pm SD 53.2 \pm 14.5 years 30 male/26 female 14/56 <i>S. aureus</i> carriage	
Warady, 2003 ⁵³	Multicentre RCT 121 participants Follow-up = mean 305.3 \pm 22.2 vs 313.0 \pm 26.5 days Abstract	'Flush before fill' flushing of 100 ml of sterile dialysate from each bag of dialysate through the cyclor tubing and into the drain bag following drainage of effluent from the patient and before the infusion of sterile dialysate into the patient (n = 62) versus 15 ml of sterile dialysate flushed through the tubing originating only from the heater bag into the drain bag prior to infusion (n = 59)	Age mean 11.4 \pm 5.6 years 54.8% male/45.2% female 62/62 paediatrics 3.2% reflux nephropathy 41.9% other Time on PD 24.6(3.8) months	Age mean 11.2 \pm 6.0 year 59.3% male/40.7% female 59/59 paediatrics 1.7% reflux nephropathy 50.8% other Time on PD 18.9 (2.9) months	
Wilson, 1997 ⁴⁸	RCT 130 participants (149 catheters) Follow-up = 1 year or until a significant difference was present Full text	Sterile povidone iodine (2.5%) dry powder spray to exit site every time dressing changed (every other day) (n = 77 catheters) versus no intervention (n = 72 catheters)	Age mean (range) 53 (18–82) years 55 male/22 female 77/77 adults 3.2% reflux nephropathy 41.9% other Time on PD median (range) 422 (52–1280) days	Age mean (range) 51 (21–76) years 43 male/29 female 72 adults 1.7% reflux nephropathy 50.8% other Time on PD median (range) 512 (42–1572) days	
Wong, 2002 ⁴⁹	Single-centre quasi-RCT 124 participants (117 analysed) Follow-up = 6 months Full text	4% chlorhexidine liquid soap used in cleansing of exit site (n = 69) versus pure liquid soap used in cleansing of exit site (n = 48)	Age mean 59.0 \pm 11.50 years 34 male/35 female	Age mean 56.3 \pm 11.7 years 23 male/25 female	

continued

Study	Study details	Intervention/comparator	Intervention 1 population characteristics	Intervention 2 population characteristics	Intervention 3 population characteristics
Wong, 2003 ³⁸	Single-centre RCT 166 participants (154 analysed) Follow-up = 5 months Full text	Mupirocin applied using cotton-tipped applicator to apply ointment round skin around catheter exit site daily ($n = 78$, 73 analysed) versus no intervention ($n = 88$, 81 analysed)	Age mean 60 ± 12 years 32 male/41 female Time on PD 41 ± 37 months 16/73 <i>S. aureus</i> carriage	Age mean 59 ± 13 years 47 male/34 female Time on PD 39 ± 25 months 14/81 <i>S. aureus</i> carriage	
Zimmerman, 1991 ³⁹	Single-centre RCT 64 participants Follow-up = mean \pm SEM 10.2 ± 1.2 vs 12.0 ± 1.3 months Full text	Rifampin 300 mg 2 times daily for 5 days at the start of each 12-week interval ($n = 32$) versus no treatment ($n = 32$)	Age mean \pm SEM 53 ± 3 years 17 male/15 female 32/32 adults Time on PD 41 ± 37 months 9/32 <i>S. aureus</i> carriage	Age mean \pm SEM 55 ± 4 years 24 male/8 female 32/32 adults Time on PD 39 ± 25 months 8/32 <i>S. aureus</i> carriage	
APKD, adult polycystic kidney disease; SD, standard deviation; SE, standard error; SEM, standard error of the mean.					

Appendix 7

Proposed methods for parameterising the economic model

Probabilities

As mentioned before, the main source of effectiveness data that would be used to populate the model is the review of effectiveness (Chapter 3). However, as described below, other sources such as existing datasets and population cohort studies may be required. The outcomes of the systematic review of effectiveness were primarily presented in terms of relative effect sizes (RRs) for the comparison of prophylactic antibiotic with no treatments. By identifying the relevant transition probabilities for the 'no treatment' intervention and combining with relevant relative effect sizes for the prophylactic antibiotic intervention, the transition probabilities for this intervention can be derived.

Estimation of baselines comparator transition probabilities

One source of data on the relevant transition probabilities for this is the control arms of studies that compared an active treatment with no treatment. *Table 13* describes the parameters used to determine transitions between the states of the model. The data that might be used for these parameters are described below.

Transition probabilities from 'Catheter insertion'

Following the initial insertion of the PD catheter a person would receive PD, although they may have a risk of being a carrier of *S. aureus*. Ideally, the risk of *S. aureus* carriage would come from a large population based survey of patients pre-dialysis. Some data on the risk of *S. aureus* carriage at the time of catheter insertion could be obtained from systematic review of effectiveness^{36,46} (see *Table 6*). These sources provide rates of *S. aureus* carriage of between 18.0 and 30.8% and a crude mean of 27.0% (46 cases out of 167 trial participants). In the model, it would be assumed that 27% of those who do not die less those who experience an infection (see below) would transfer into the state of 'On PD with SA carriage'.

The risk of infections caused by *S. aureus* following catheter insertion could also be provided by review

TABLE 13 Baseline parameter values required for the model

State	Parameter
'Catheter insertion'	On PD without SA carriage On PD with SA carriage On PD with an infection
'On PD without SA'	Remain on PD without SA carriage On PD with SA carriage On PD with an infection Transfer to HD Die
'On PD with SA'	Go back to PD without SA carriage Remain on PD with SA carriage On PD with an infection Transfer to HD Die
'Infection' ^a	Infection cured, return to PD without SA carriage Relapsing infection Temporary HD HD Die
'Temporary HD'	Infection cured, return to PD without SA carriage HD Die
'Permanent HD'	Remain on HD Die

^a In the hypothetical model, 'infection' is defined as a single state. In a full model, the different types of infection might be defined as individual states that would allow them to occur either singularly or in sequence.

of effectiveness data. The systematic review of effectiveness sought to identify the number of patients with peritonitis, peritonitis rates, peritonitis relapses, exit-site and tunnel infection rates. Although the aim was to identify exit-site, tunnel and peritonitis infections separately, most of the studies reported exit-site/tunnel infections together (Chapter 3). *Table 6* provides details on the number of patients without *S. aureus* carriage who develop peritonitis and also the mean number of episodes per patient year. The data from the no treatment arms of these studies can

be used to provide some information of the risks of infection (and types of infection) per year. However, very few data are available.³⁹ A crude estimate of the risk of peritonitis per patient per month would be 1.3%. A similar estimate for the risk of exit-site or tunnel infections would be 5.4%. Such data come from a small study and hence are imprecise and unreliable.³⁹ Ideally, such data would be replaced by data from a larger study. Data are also required on the risk of infections for those with *S. aureus* carriage. Data from the no treatment arms for comparisons of alternative methods to treat *S. aureus* carriage provided by the systematic review are one source of data⁵⁵ (Table 8). However, such data are not comparable to the risks of infections for those without *S. aureus* carriage. For example, from the data available, the risk of peritonitis per patient per month can be calculated as 1.9% and the risk of exit-site and tunnel infections as 3.6%. It might be expected that the infections caused by *S. aureus* would be greater in the group that were known carriers of *S. aureus*. Ideally, the information on infection rates amongst those who are and are not carriers of *S. aureus* would come from a single study of sufficient size to provide reasonably precise and reliable data for a UK setting.

Survival rates or death rates for patients on PD would also be needed. The Renal Registry has published survival rates derived from data on 3-year survival rates using Kaplan–Meier survival analysis.¹ To use such data would require that the proportion of people dying from *S. aureus* infection while on PD is only a small proportion of the total risk of death on PD.

Transition probabilities from ‘On PD without SA carriage’

Patients who are *S. aureus* free can remain on PD until they die either free of *S. aureus* carriage or become carriers of *S. aureus*. There is insufficient information on the risk that a patient might develop *S. aureus* carriage from the review of effectiveness, but one study reported how the risk of *S. aureus* nasal carriage changes over time.⁵¹ This study is small and even though such data could be used in the model, they are likely to be both imprecise and unreliable. Ideally, such data should come from the control arm of a large RCT or from a large cohort study relevant to a UK setting.

As indicated in Table 10, a patient on PD but free of *S. aureus* also faces the probability of developing an infection or dying. The data required to derive the relevant transition probabilities could be

derived using similar methods to those outlined for the transitions from ‘Catheter insertion’.

The remaining transition probability required from the state ‘On PD without SA carriage’ is the transition to HD. The review of effectiveness sought to establish the number of patients requiring catheter replacement/removal (and hence requiring temporary HD, a clinically possible transition but not one allowed for this state in this hypothetical model) and the number of patients permanently switching to HD (unclear whether this included both permanent and temporary transfers). Although some data were reported on catheter removal for those with *S. aureus* carriage (see Table 6), no data were identified on the number of patients switching modality. A search of the Renal Registry indicated that the sequential annual risk of switching from PD to HD permanently was 11% at the end of the first year, 18% at the end of the second year and 23% at the end of the third year (based on data for patients established on PD in 1998–9, the most recent years for which data are available).¹ From such data, monthly transition probabilities might be estimated.

Transition probabilities from ‘On PD with SA carriage’

Similar methods and data sources would be required to estimate the transition probabilities from this state as those described for transitions from ‘Catheter insertion’ and ‘On PD without SA carriage’.

Transition probabilities from ‘Infection’

Ideally, the likelihood that an infection is cured would be derived by consideration of the data on the effectiveness of interventions to treat *S. aureus* infections. The most appropriate source of such data would not be the review of effectiveness reported in Chapter 3 but a new review of studies looking at alternative treatments of infections (the data from such a review are presented in Appendix 8). From such a review, data would be extracted on the likelihood of infections that do not resolve and the risk of death or transferring modality. Following consultation with the clinical co-reviewers, it has been assumed in the model that should a patient suffer three consecutive months (cycles) of infection that they would automatically transfer to the state of temporary HD.

Transition probabilities from ‘Temporary HD’

Patients who enter this state will remain in it for only one cycle; at the end of that cycle, they may

either transfer to the state 'On PD without SA carriage', transfer to the state of 'Permanent HD' or die. The risk of death is not likely to be greatly different to the rates used for earlier states. However, there is no evidence available on the likelihood of returning to PD or moving to permanent HD. Data from the Renal Registry suggest that patients rarely switch from HD to PD (approximately 3% per annum), but these numbers may not be applicable for the group of patients who switch to HD only until their symptoms resolve. Ideally, data from a well-designed study would be useful but, as this is only a transitory state, sensitivity analysis could be conducted over a range of plausible values.

Transitions from 'Permanent HD'

In the model, it is assumed that once patients are transferred to HD they will stay in this state until they die. The Renal Registry has published survival rates using Kaplan–Meier survival analysis and these data could be used to establish the relevant transition probabilities.

Estimation of relative effect sizes

Data on relative effect sizes for an active treatment compared with no treatment (e.g. antibiotics versus no antibiotics for the prevention of carriage) can, when combined with the transition probabilities for no treatment, be used to estimate the transition probabilities for the an active treatment, e.g. prophylactic antibiotics. The various relative effect sizes estimated as part of the review of effectiveness are presented in *Figures 1–7*. Although such relative effect sizes could be used in a model, they are limited as they are based on sparse data, and a full evaluation comparing all relevant interventions would rely on indirect comparisons. Details of the data available for comparison of antibiotics provided at the time of catheter insertion compared with no treatment are provided below.

S. aureus carriage cure rates

This relative effect size is needed to estimate the probability of entering 'PD without SA carriage' and 'PD with SA carriage' states following prophylactic use of antibiotics at the time of catheter insertion. From the review of effectiveness, no data were available on the ability of prophylactic antibiotics at the time of catheter insertion to prevent infection with *S. aureus*. Some estimate could be obtained by considering the effectiveness of antibiotics at curing those with known *S. aureus* carriage. *Table 8* reports the

results on the number of people treated for *S. aureus* carriage during dialysis. The number of patients cured (those who did not have *S. aureus* at the end of the treatment) could therefore be derived from these data.

S. aureus infection rates

These relative effect sizes would be used to estimate the likelihood of developing an infection. Data are not available split by whether the infections occurred in those who were *S. aureus* carriers and those who were not. Although consideration of data provided in *Figures 1, 2, 5* and *6* might provide some information with which plausible estimates could be derived. Nevertheless, ideally such data would be more usefully derived from the participant-level data from a large controlled study.

Exit site/tunnel and peritonitis cure rates

Once an infection has occurred, the assumption would be made that the probability of cure would be independent of the intervention used to prevent or treat *S. aureus* carriage. Thus, the transition probabilities from the state of 'Infection' following the use of prophylactic antibiotics would be the same as those following no treatment. What would vary between the two interventions would be the probability of an infection.

Modality changes

Few studies provided any data on the number of patients switching modality from PD or the number of patients requiring catheter removal (and at least a move to temporary HD). The studies identified in Chapter 3 were not designed to provide such data and provided, at best, only proxy indicators. Such data as are available are presented in *Tables 6* and *8* but are both imprecise and potentially unreliable due to the small size of the studies. Furthermore, such data would ideally be split by those who were *S. aureus* carriers and those who were not carriers. Ideally, such data would be more usefully derived from the participant-level data from a large controlled study.

Relative effect sizes for the risk of modality changes from the states of 'Infection', 'Temporary HD' and 'Permanent HD' would not be required as these transition probabilities are assumed to be independent of the method used to prevent or treat *S. aureus* carriage.

Death or survival rates

Exactly the same situation arises for relative effect sizes associated with the risk of death as those

noted above for changes in modality. Again, data from a large controlled study would be useful. Such a study would need to have sufficiently long enough follow-up to capture differences in survival (and other relevant effects).

Cost data

The perspective of the assessment of costs would be that of the NHS and Personal Social Services. Resource use data would be identified from published studies, healthcare service utilisation data and advice from experts in this field. Cost data used to illustrate this part of the hypothetical model were mainly extracted from the literature published in 1999 and were inflated to 2005 using the Hospital and Community Health Services (HCHS) pay and price inflation indices⁷² and the currency used is pounds sterling (£). The main cost components were the costs of the interventions themselves and the costs of treating an infection or the consequences of an infection (e.g. a change in modality or the replacement of a catheter). Details of the cost values used are reported in *Table 14* and the methods used to derive these values are described below.

Estimation of the cost of catheter insertion

The cost of inserting a peritoneal catheter was derived from Kirby and Vale.⁷³ These costs were calculated by identifying items of resource use from studies and by consulting the renal administrator at NHS Grampian. Local prices were then attached to each item and drug costs obtained from nationally available sources. The cost of access was estimated at £1955 in 1999 (£2235 in 2004 prices). The same cost would be used for patients who required a replacement of a PD catheter (following a period on temporary HD).

Estimation of the cost of interventions to prevent or treat *S. aureus* carriage

Data on patients who received antibiotics were derived from a published study.⁵⁹ The cost data reported were based on the consideration of the unit dose, route of administration, doses per day and duration of therapy. The total cost of 1 year's treatment per identified carrier of *S. aureus* was £157 (at 1994 prices) and this comprised costs of £64 for screening and £93 for antibiotics. These costs were based on one antibiotic (mupirocin). The inflated annual cost per identified carrier of *S. aureus* is £179 (£73 for screening and £106 for antibiotic).

Estimation of the costs of treating infections

Data on patients who received antibiotics were derived from a published study⁵⁹ and the costs of treatment were comprised of unit dose, route of administration, doses per day and duration. The study indicated that the mean costs of treating infections were highly skewed. The mean costs of treating all infections (exit-site infections and other infections) was £178 for the prophylaxis group and £379 for the placebo group at 1994 prices. The difference between the means was not statistically significant –£201 (–£493 to £90). The cost data inflated to 2005 prices were £203 for the prophylaxis group and £433 for the placebo group.

Estimation of the costs of providing dialysis

The cost data for these interventions included consumables such as catheters and prophylactic treatments, staff costs, capital costs of providing HD, overheads and transport where necessary. These data were based on data provided by the EURODICE study (Wordsworth S, Health Economist, Oxford: personal communication, 2005). This study was an observational study investigating the costs, effects and cost-effectiveness of PD and HD in 10 European centres, two of which were in the UK. Costs in each centre were detailed data on the use of resources required for the different dialysis modalities in use. These were collected between 1999 and 2001 during site visits, detailed examination of records and the completion of questionnaires by manager, healthcare professionals and patients. In this review, data from the two UK centres (Aberdeen and Dundee) would be used as they are most likely to be applicable to the UK. The five main categories included in the estimation of costs were consumables, staff, capital, overheads and patient transport. The consumables were composed mainly of disposable items such as dialysers, line and recombinant human erythropoietin (EPO). Staff costs were based on weekly work rosters from the units which detailed the time devoted to the provision of HD and PD. The capital costs for HD were composed of building costs, dialysis machine, repairs, water treatment and computers. Although PD typically takes place outwith the hospital, some hospital costs would normally be incurred. The capital costs of PD were based on building costs, weighing scales, bag warmers, drip stand and blood pressure monitor. Staff costs were derived by identifying the salary grades of those who spent time with the patients (both medical and nursing)

and the amount of time they spent with the patients. Overhead costs included floor space allocation that was composed of cleaning, building, engineering, local government authority taxation on buildings (rates), water, energy and occupied bed days allocation that were composed of medical records, linen and catering. The total cost of HD for 1 month was £2458 and for PD £1603 at 2005 prices.

Estimation of costs of change in modality

One of the main effects of infections is the need to remove and replace the catheter and the cost of change in modality of treatment. The cost of loss of catheter/catheter replacement is based on the cost of a catheter, which is £2235 as reported above. The cost of switch in modality is the cost of HD, including creation of the access fistula. These data were also derived from Kirby and Vale and were estimated using the same methods as described for the cost of catheter insertion.⁷³ The cost was £1959 (1999 prices), which was inflated to £2240 (2005 prices).

Estimation of quality of life

The main measure of effectiveness that would be used within the economic evaluation is QALYs. QALYs would be estimated by multiplying the length of time spent in each health state by a quality of life weight (a utility value) for that state. A search for studies on quality of life identified one study.⁷⁴ The data came from 165 dialysis patients and were elicited using the EQ-5D instrument. Their results indicated that patients undergoing hospital HD had a utility score of 0.66, satellite HD patients had a value of 0.81, continuous ambulatory PD patients had a value of 0.71 and continuous cycling PD patients had a value of 0.81. As these do not come from an RCT, these utility scores are influenced by the choice of

modality for each patient (i.e. there may be a selection bias). Although the utility scores for patients with end-stage renal disease were identified, there were no data on utilities of people on dialysis with infections.

Another further source of utility values was the data collected by the European Dialysis and Cost Effectiveness (EURODICE) study. This study prospectively identified cohorts of patients starting on HD and PD and collected EQ-5D data from patients on 1 July 1998 and 31 October 1999 every 6 months for a period of 2–3 years. Health state utilities were collected from all study participants including those from two UK centres (Aberdeen and Dundee). These data had not been previously reported but were obtained from the study researchers (Caskey F, Consultant Nephrologist, Bristol: personal communication, 2005)^{75,76} and the utilities were derived using the UK population tariffs.⁷⁷

The modality of first treatment was assumed to be the method the patient was receiving at 90 days and not the initial dialysis method, as many patients, especially those being referred late to renal units, undergo a brief period of HD before being established on PD. Utility scores for this and three other time points (collected every 6 months) were estimated from the data provided. Secondary analysis was also carried out on the scores of patients who transferred from PD to HD. However, the numbers of patients changing treatment modality from PD to HD were very low, so the estimates were not reliable. Although there is not much detail on what type of HD and PD was being administered by the 12th month, EQ-5D values are similar to these reported by de Wit and colleagues.⁷⁴ The utility value for patients receiving PD was 0.84 and for those receiving HD it was 0.69. These scores could therefore be used as the utility scores associated with 'PD without SA carriage', 'PD with SA carriage', 'Temporary HD',

TABLE 14 Cost parameters available for use in the hypothetical model

Cost element	Value (£)	Unit
Peritoneal dialysis	1603	Cost per month
Permanent and temporary haemodialysis	2458	Cost per month
Prophylaxis for <i>S. aureus</i> carriage	15	Cost
Treatment for <i>S. aureus</i> carriage	15	Cost per course
Treatment of exit-site infection	192	Cost per treatment
Treatment of tunnel infection	1035	Cost per treatment complication; may require removal of catheter
Catheter replacement	2235	Cost per procedure
Cost of creating access for haemodialysis	2240	Cost per access
Treatment of peritonitis	203	Cost per treatment

and 'Permanent HD' in the model, as they are more representative of the UK population than those available from de Wit and colleagues.⁷⁴ These data, however, should be treated with great caution as they are associated with considerable imprecision (which, although reported here, would need to be incorporated into the economic evaluation) derived from a non-randomised study and, like the data from de Wit and colleagues,⁷⁴ will suffer from patient selection bias.

The EURODICE data provided no information with which to inform estimates of the utility

associated with infections. Ideally, primary data collection would be performed to inform this. In the absence of such data, one approach would be to perform a sensitivity analysis using a range of values to explore the impact of this uncertainty on the results. A second approach would be to explore the use of other data sets such as the Health Outcomes Data Repository (eHODAR) (<http://www.crc-limited.co.uk>), although it is unlikely that such sources will contain sufficient information on the utilities relevant to this study.

Appendix 8

Treatment of clinical infections

Eight trials evaluated different antibiotic regimes for the treatment of PD-related infections and one trial compared intraperitoneal urokinase with a placebo.

Table 15 provides details, where reported, of the results for the following outcomes: number of patients with peritonitis caused by *S. aureus*; number of patients to have a primary response or successful treatment; number of patients for whom the treatment has failed; peritonitis relapse (number and specify time to) caused by *S. aureus*; and number of patients requiring catheter removal.

Number of patients with exit-site and/or tunnel infections caused by *S. aureus*

Plum and colleagues⁷⁸ reported the number of exit sites with *S. aureus* carriage as 6/8 versus 4/8; tunnel erythema before treatment 2/6 versus 1/4 and after treatment 0/6 versus 0/4; and tunnel

drainage before treatment 6/6 versus 4/4 and after treatment 2/6 versus 1/4.

Side-effects

One trial⁷⁹ reported one pseudo-obstruction and one hypotension as a result of antibiotic use in the intraperitoneal vancomycin plus gentamicin group and three nausea and one abdominal swelling in the oral ciproflaxin group.

Death due to peritonitis caused by *S. aureus*

Tong and colleagues⁸⁶ reported that one death in the placebo group was due to peritonitis.

No data were reported for the following outcomes: number of patients requiring catheter replacement caused by *S. aureus*; number of patients switching to HD; hospitalisation rates; quality of life; and development of antibiotic resistance.

TABLE 15 Outcome results for studies assessing treatment of clinical infections

Study	Comparison	S. aureus peritonitis (no.)	Primary response/treatment success (no.)	Treatment failure (no.)	Peritonitis relapse (no.)	Catheter removal (no.)
Antibiotic vs antibiotic Bennett-Jones, 1990 ⁷⁹	I.p. vancomycin + gentamicin	5/26	2/5	3/5	1/5 (14 days)	—
	Oral ciprofloxacin	5/22	4/5	1/5	1/5 (14 days)	—
Cheng, 1991 ⁸⁰	Oral ofloxacin	3/23 ^a	3/3	0/3	0/3	—
	I.p. vancomycin/aztreonam	5/25 ^a	5/5	0/5	1/5	—
Flanigan, 1991 ⁸¹	I.p. vancomycin	—	—	—	—	4/30
	I.p. cefazolin	—	—	—	—	5/15
Gucek, 1994 ⁸²	I.p. cefazolin	15%	1/3	2/3	—	—
	Oral ofloxacin	0%	—	—	—	—
Gucek, 1997 ⁸³	Cefazolin/netilmycin	3/26 ^a	2/3	1/3	—	—
	Vancomycin/ceftazidime	2/26 ^a	2/2	0/2	—	—
Leung, 2004 ⁸⁴	I.p. imipenem/cilastatin	2/51	0/2	—	—	—
	I.p. cefazolin/ceftazidime	13/51	4/13	—	—	—
Merchant, 1992 ⁸⁵	I.p. imipenem/cilastatin	2/21	1/2	1/2	—	1/2
	I.p. netilmicin/vancomycin	1/20	1/1	0/1	—	0/1
Plum, 1997 ⁸	Oral clindamycin	—	—	—	—	—
	I.p. clindamycin	—	—	—	—	—
Other Tong, 2005 ⁸⁶	I.p. urokinase	7/44 (3 MRSA)	3/4	—	—	—
	Placebo	11/44 (4 MRSA)	3/7	—	—	—

^a Episodes.



Health Technology Assessment reports published to date

Volume 1, 1997

No. 1

Home parenteral nutrition: a systematic review.

By Richards DM, Deeks JJ, Sheldon TA, Shaffer JL.

No. 2

Diagnosis, management and screening of early localised prostate cancer.

A review by Selley S, Donovan J, Faulkner A, Coast J, Gillatt D.

No. 3

The diagnosis, management, treatment and costs of prostate cancer in England and Wales.

A review by Chamberlain J, Melia J, Moss S, Brown J.

No. 4

Screening for fragile X syndrome.

A review by Murray J, Cuckle H, Taylor G, Hewison J.

No. 5

A review of near patient testing in primary care.

By Hobbs FDR, Delaney BC, Fitzmaurice DA, Wilson S, Hyde CJ, Thorpe GH, *et al.*

No. 6

Systematic review of outpatient services for chronic pain control.

By McQuay HJ, Moore RA, Eccleston C, Morley S, de C Williams AC.

No. 7

Neonatal screening for inborn errors of metabolism: cost, yield and outcome.

A review by Pollitt RJ, Green A, McCabe CJ, Booth A, Cooper NJ, Leonard JV, *et al.*

No. 8

Preschool vision screening.

A review by Snowdon SK, Stewart-Brown SL.

No. 9

Implications of socio-cultural contexts for the ethics of clinical trials.

A review by Ashcroft RE, Chadwick DW, Clark SRL, Edwards RHT, Frith L, Hutton JL.

No. 10

A critical review of the role of neonatal hearing screening in the detection of congenital hearing impairment.

By Davis A, Bamford J, Wilson I, Ramkalawan T, Forshaw M, Wright S.

No. 11

Newborn screening for inborn errors of metabolism: a systematic review.

By Seymour CA, Thomason MJ, Chalmers RA, Addison GM, Bain MD, Cockburn F, *et al.*

No. 12

Routine preoperative testing: a systematic review of the evidence.

By Munro J, Booth A, Nicholl J.

No. 13

Systematic review of the effectiveness of laxatives in the elderly.

By Petticrew M, Watt I, Sheldon T.

No. 14

When and how to assess fast-changing technologies: a comparative study of medical applications of four generic technologies.

A review by Mowatt G, Bower DJ, Brebner JA, Cairns JA, Grant AM, McKee L.

Volume 2, 1998

No. 1

Antenatal screening for Down's syndrome.

A review by Wald NJ, Kennard A, Hackshaw A, McGuire A.

No. 2

Screening for ovarian cancer: a systematic review.

By Bell R, Petticrew M, Luengo S, Sheldon TA.

No. 3

Consensus development methods, and their use in clinical guideline development.

A review by Murphy MK, Black NA, Lamping DL, McKee CM, Sanderson CFB, Askham J, *et al.*

No. 4

A cost-utility analysis of interferon beta for multiple sclerosis.

By Parkin D, McNamee P, Jacoby A, Miller P, Thomas S, Bates D.

No. 5

Effectiveness and efficiency of methods of dialysis therapy for end-stage renal disease: systematic reviews.

By MacLeod A, Grant A, Donaldson C, Khan I, Campbell M, Daly C, *et al.*

No. 6

Effectiveness of hip prostheses in primary total hip replacement: a critical review of evidence and an economic model.

By Faulkner A, Kennedy LG, Baxter K, Donovan J, Wilkinson M, Bevan G.

No. 7

Antimicrobial prophylaxis in colorectal surgery: a systematic review of randomised controlled trials.

By Song F, Glenny AM.

No. 8

Bone marrow and peripheral blood stem cell transplantation for malignancy.

A review by Johnson PWM, Simnett SJ, Sweetenham JW, Morgan GJ, Stewart LA.

No. 9

Screening for speech and language delay: a systematic review of the literature.

By Law J, Boyle J, Harris F, Harkness A, Nye C.

No. 10

Resource allocation for chronic stable angina: a systematic review of effectiveness, costs and cost-effectiveness of alternative interventions.

By Sculpher MJ, Petticrew M, Kelland JL, Elliott RA, Holdright DR, Buxton MJ.

No. 11

Detection, adherence and control of hypertension for the prevention of stroke: a systematic review.

By Ebrahim S.

No. 12

Postoperative analgesia and vomiting, with special reference to day-case surgery: a systematic review.

By McQuay HJ, Moore RA.

No. 13

Choosing between randomised and nonrandomised studies: a systematic review.

By Britton A, McKee M, Black N, McPherson K, Sanderson C, Bain C.

No. 14

Evaluating patient-based outcome measures for use in clinical trials.

A review by Fitzpatrick R, Davey C, Buxton MJ, Jones DR.

No. 15

Ethical issues in the design and conduct of randomised controlled trials.

A review by Edwards SJL, Lilford RJ, Braunholtz DA, Jackson JC, Hewison J, Thornton J.

No. 16

Qualitative research methods in health technology assessment: a review of the literature.

By Murphy E, Dingwall R, Greatbatch D, Parker S, Watson P.

No. 17

The costs and benefits of paramedic skills in pre-hospital trauma care.

By Nicholl J, Hughes S, Dixon S, Turner J, Yates D.

No. 18

Systematic review of endoscopic ultrasound in gastro-oesophageal cancer.

By Harris KM, Kelly S, Berry E, Hutton J, Roderick P, Cullingworth J, *et al.*

No. 19

Systematic reviews of trials and other studies.

By Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F.

No. 20

Primary total hip replacement surgery: a systematic review of outcomes and modelling of cost-effectiveness associated with different prostheses.

A review by Fitzpatrick R, Shortall E, Sculpher M, Murray D, Morris R, Lodge M, *et al.*

Volume 3, 1999

No. 1

Informed decision making: an annotated bibliography and systematic review.

By Bekker H, Thornton JG, Airey CM, Connelly JB, Hewison J, Robinson MB, *et al.*

No. 2

Handling uncertainty when performing economic evaluation of healthcare interventions.

A review by Briggs AH, Gray AM.

No. 3

The role of expectancies in the placebo effect and their use in the delivery of health care: a systematic review.

By Crow R, Gage H, Hampson S, Hart J, Kimber A, Thomas H.

No. 4

A randomised controlled trial of different approaches to universal antenatal HIV testing: uptake and acceptability. Annex: Antenatal HIV testing – assessment of a routine voluntary approach.

By Simpson WM, Johnstone FD, Boyd FM, Goldberg DJ, Hart GJ, Gormley SM, *et al.*

No. 5

Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review.

By Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ.

No. 6

Assessing the costs of healthcare technologies in clinical trials.

A review by Johnston K, Buxton MJ, Jones DR, Fitzpatrick R.

No. 7

Cooperatives and their primary care emergency centres: organisation and impact.

By Hallam L, Henthorne K.

No. 8

Screening for cystic fibrosis.

A review by Murray J, Cuckle H, Taylor G, Littlewood J, Hewison J.

No. 9

A review of the use of health status measures in economic evaluation.

By Brazier J, Deverill M, Green C, Harper R, Booth A.

No. 10

Methods for the analysis of quality-of-life and survival data in health technology assessment.

A review by Billingham LJ, Abrams KR, Jones DR.

No. 11

Antenatal and neonatal haemoglobinopathy screening in the UK: review and economic analysis.

By Zeuner D, Ades AE, Karnon J, Brown J, Dezateux C, Anionwu EN.

No. 12

Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses.

A review by Moher D, Cook DJ, Jadad AR, Tugwell P, Moher M, Jones A, *et al.*

No. 13

'Early warning systems' for identifying new healthcare technologies.

By Robert G, Stevens A, Gabbay J.

No. 14

A systematic review of the role of human papillomavirus testing within a cervical screening programme.

By Cuzick J, Sasieni P, Davies P, Adams J, Normand C, Frater A, *et al.*

No. 15

Near patient testing in diabetes clinics: appraising the costs and outcomes.

By Grieve R, Beech R, Vincent J, Mazurkiewicz J.

No. 16

Positron emission tomography: establishing priorities for health technology assessment.

A review by Robert G, Milne R.

No. 17 (Pt 1)

The debridement of chronic wounds: a systematic review.

By Bradley M, Cullum N, Sheldon T.

No. 17 (Pt 2)

Systematic reviews of wound care management: (2) Dressings and topical agents used in the healing of chronic wounds.

By Bradley M, Cullum N, Nelson EA, Petticrew M, Sheldon T, Torgerson D.

No. 18

A systematic literature review of spiral and electron beam computed tomography: with particular reference to clinical applications in hepatic lesions, pulmonary embolus and coronary artery disease.

By Berry E, Kelly S, Hutton J, Harris KM, Roderick P, Boyce JC, *et al.*

No. 19

What role for statins? A review and economic model.

By Ebrahim S, Davey Smith G, McCabe C, Payne N, Pickin M, Sheldon TA, *et al.*

No. 20

Factors that limit the quality, number and progress of randomised controlled trials.

A review by Prescott RJ, Counsell CE, Gillespie WJ, Grant AM, Russell IT, Kiauka S, *et al.*

No. 21

Antimicrobial prophylaxis in total hip replacement: a systematic review.

By Glenny AM, Song F.

No. 22

Health promoting schools and health promotion in schools: two systematic reviews.

By Lister-Sharp D, Chapman S, Stewart-Brown S, Sowden A.

No. 23

Economic evaluation of a primary care-based education programme for patients with osteoarthritis of the knee.

A review by Lord J, Victor C, Littlejohns P, Ross FM, Axford JS.

Volume 4, 2000

No. 1

The estimation of marginal time preference in a UK-wide sample (TEMPUS) project.

A review by Cairns JA, van der Pol MM.

No. 2

Geriatric rehabilitation following fractures in older people: a systematic review.

By Cameron I, Crotty M, Currie C, Finnegan T, Gillespie L, Gillespie W, *et al.*

No. 3

Screening for sickle cell disease and thalassaemia: a systematic review with supplementary research.

By Davies SC, Cronin E, Gill M, Greengross P, Hickman M, Normand C.

No. 4

Community provision of hearing aids and related audiology services.

A review by Reeves DJ, Alborz A, Hickson FS, Bamford JM.

No. 5

False-negative results in screening programmes: systematic review of impact and implications.

By Petticrew MP, Sowden AJ, Lister-Sharp D, Wright K.

No. 6

Costs and benefits of community postnatal support workers: a randomised controlled trial.

By Morrell CJ, Spiby H, Stewart P, Walters S, Morgan A.

No. 7

Implantable contraceptives (subdermal implants and hormonally impregnated intrauterine systems) versus other forms of reversible contraceptives: two systematic reviews to assess relative effectiveness, acceptability, tolerability and cost-effectiveness.

By French RS, Cowan FM, Mansour DJA, Morris S, Procter T, Hughes D, *et al.*

No. 8

An introduction to statistical methods for health technology assessment.

A review by White SJ, Ashby D, Brown PJ.

No. 9

Disease-modifying drugs for multiple sclerosis: a rapid and systematic review.

By Clegg A, Bryant J, Milne R.

No. 10

Publication and related biases.

A review by Song F, Eastwood AJ, Gilbody S, Duley L, Sutton AJ.

No. 11

Cost and outcome implications of the organisation of vascular services.

By Michaels J, Brazier J, Palfreyman S, Shackley P, Slack R.

No. 12

Monitoring blood glucose control in diabetes mellitus: a systematic review.

By Coster S, Gulliford MC, Seed PT, Powrie JK, Swaminathan R.

No. 13

The effectiveness of domiciliary health visiting: a systematic review of international studies and a selective review of the British literature.

By Elkan R, Kendrick D, Hewitt M, Robinson JJA, Tolley K, Blair M, *et al.*

No. 14

The determinants of screening uptake and interventions for increasing uptake: a systematic review.

By Jepson R, Clegg A, Forbes C, Lewis R, Sowden A, Kleijnen J.

No. 15

The effectiveness and cost-effectiveness of prophylactic removal of wisdom teeth.

A rapid review by Song F, O'Meara S, Wilson P, Golder S, Kleijnen J.

No. 16

Ultrasound screening in pregnancy: a systematic review of the clinical effectiveness, cost-effectiveness and women's views.

By Bricker L, Garcia J, Henderson J, Mugford M, Neilson J, Roberts T, *et al.*

No. 17

A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer.

By Lister-Sharp D, McDonagh MS, Khan KS, Kleijnen J.

No. 18

Liquid-based cytology in cervical screening: a rapid and systematic review.

By Payne N, Chilcott J, McGoogan E.

No. 19

Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy and usual general practitioner care in the management of depression as well as mixed anxiety and depression in primary care.

By King M, Sibbald B, Ward E, Bower P, Lloyd M, Gabbay M, *et al.*

No. 20

Routine referral for radiography of patients presenting with low back pain: is patients' outcome influenced by GPs' referral for plain radiography?

By Kerry S, Hilton S, Patel S, Dundas D, Rink E, Lord J.

No. 21

Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration.

By O'Meara S, Cullum N, Majid M, Sheldon T.

No. 22

Using routine data to complement and enhance the results of randomised controlled trials.

By Lewsey JD, Leyland AH, Murray GD, Boddy FA.

No. 23

Coronary artery stents in the treatment of ischaemic heart disease: a rapid and systematic review.

By Meads C, Cummins C, Jolly K, Stevens A, Burls A, Hyde C.

No. 24

Outcome measures for adult critical care: a systematic review.

By Hayes JA, Black NA, Jenkinson C, Young JD, Rowan KM, Daly K, *et al.*

No. 25

A systematic review to evaluate the effectiveness of interventions to promote the initiation of breastfeeding.

By Fairbank L, O'Meara S, Renfrew MJ, Woolridge M, Sowden AJ, Lister-Sharp D.

No. 26

Implantable cardioverter defibrillators: arrhythmias. A rapid and systematic review.

By Parkes J, Bryant J, Milne R.

No. 27

Treatments for fatigue in multiple sclerosis: a rapid and systematic review.

By Brañas P, Jordan R, Fry-Smith A, Burls A, Hyde C.

No. 28

Early asthma prophylaxis, natural history, skeletal development and economy (EASE): a pilot randomised controlled trial.

By Baxter-Jones ADG, Helms PJ, Russell G, Grant A, Ross S, Cairns JA, *et al.*

No. 29

Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.

By Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HAW.

No. 30

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists in the medical management of unstable angina.

By McDonagh MS, Bachmann LM, Golder S, Kleijnen J, ter Riet G.

No. 31

A randomised controlled trial of prehospital intravenous fluid replacement therapy in serious trauma.

By Turner J, Nicholl J, Webber L, Cox H, Dixon S, Yates D.

No. 32

Intrathecal pumps for giving opioids in chronic pain: a systematic review.

By Williams JE, Louw G, Towler G.

No. 33

Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review.

By Shepherd J, Waugh N, Hewitson P.

No. 34

A systematic review of comparisons of effect sizes derived from randomised and non-randomised studies.

By MacLehose RR, Reeves BC, Harvey IM, Sheldon TA, Russell IT, Black AMS.

No. 35

Intravascular ultrasound-guided interventions in coronary artery disease: a systematic literature review, with decision-analytic modelling, of outcomes and cost-effectiveness.

By Berry E, Kelly S, Hutton J, Lindsay HSJ, Blaxill JM, Evans JA, *et al.*

No. 36

A randomised controlled trial to evaluate the effectiveness and cost-effectiveness of counselling patients with chronic depression.

By Simpson S, Corney R, Fitzgerald P, Beecham J.

No. 37

Systematic review of treatments for atopic eczema.

By Hoare C, Li Wan Po A, Williams H.

No. 38

Bayesian methods in health technology assessment: a review.

By Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR.

No. 39

The management of dyspepsia: a systematic review.

By Delaney B, Moayyedi P, Deeks J, Innes M, Soo S, Barton P, *et al.*

No. 40

A systematic review of treatments for severe psoriasis.

By Griffiths CEM, Clark CM, Chalmers RJG, Li Wan Po A, Williams HC.

Volume 5, 2001

No. 1

Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.

By Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, *et al.*

No. 2

The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease: a rapid and systematic review.

By Stewart A, Sandercock J, Bryan S, Hyde C, Barton PM, Fry-Smith A, *et al.*

No. 3

Equity and the economic evaluation of healthcare.

By Sassi F, Archard L, Le Grand J.

No. 4

Quality-of-life measures in chronic diseases of childhood.

By Eiser C, Morse R.

No. 5

Eliciting public preferences for healthcare: a systematic review of techniques.

By Ryan M, Scott DA, Reeves C, Bate A, van Teijlingen ER, Russell EM, *et al.*

No. 6

General health status measures for people with cognitive impairment: learning disability and acquired brain injury.

By Riemsma RP, Forbes CA, Glanville JM, Eastwood AJ, Kleijnen J.

No. 7

An assessment of screening strategies for fragile X syndrome in the UK.

By Pembrey ME, Barnicoat AJ, Carmichael B, Bobrow M, Turner G.

No. 8

Issues in methodological research: perspectives from researchers and commissioners.

By Lilford RJ, Richardson A, Stevens A, Fitzpatrick R, Edwards S, Rock F, *et al.*

No. 9

Systematic reviews of wound care management: (5) beds; (6) compression; (7) laser therapy, therapeutic ultrasound, electrotherapy and electromagnetic therapy.

By Cullum N, Nelson EA, Flemming K, Sheldon T.

No. 10

Effects of educational and psychosocial interventions for adolescents with diabetes mellitus: a systematic review.

By Hampson SE, Skinner TC, Hart J, Storey L, Gage H, Foxcroft D, *et al.*

No. 11

Effectiveness of autologous chondrocyte transplantation for hyaline cartilage defects in knees: a rapid and systematic review.

By Jobanputra P, Parry D, Fry-Smith A, Burls A.

No. 12

Statistical assessment of the learning curves of health technologies.

By Ramsay CR, Grant AM, Wallace SA, Garthwaite PH, Monk AF, Russell IT.

No. 13

The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review.

By Dinnes J, Cave C, Huang S, Major K, Milne R.

No. 14

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of debriding agents in treating surgical wounds healing by secondary intention.

By Lewis R, Whiting P, ter Riet G, O'Meara S, Glanville J.

No. 15

Home treatment for mental health problems: a systematic review.

By Burns T, Knapp M, Catty J, Healey A, Henderson J, Watt H, *et al.*

No. 16

How to develop cost-conscious guidelines.

By Eccles M, Mason J.

No. 17

The role of specialist nurses in multiple sclerosis: a rapid and systematic review.

By De Broe S, Christopher F, Waugh N.

No. 18

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity.

By O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G.

No. 19

The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review.

By Chilcott J, Wight J, Lloyd Jones M, Tappenden P.

No. 20

Extended scope of nursing practice: a multicentre randomised controlled trial of appropriately trained nurses and preregistration house officers in pre-operative assessment in elective general surgery.

By Kinley H, Czoski-Murray C, George S, McCabe C, Primrose J, Reilly C, *et al.*

No. 21

Systematic reviews of the effectiveness of day care for people with severe mental disorders: (1) Acute day hospital versus admission; (2) Vocational rehabilitation; (3) Day hospital versus outpatient care.

By Marshall M, Crowther R, Almaraz-Serrano A, Creed F, Sledge W, Kluiters H, *et al.*

No. 22

The measurement and monitoring of surgical adverse events.

By Bruce J, Russell EM, Mollison J, Krukowski ZH.

No. 23

Action research: a systematic review and guidance for assessment.

By Waterman H, Tillen D, Dickson R, de Koning K.

No. 24

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer.

By Ward S, Morris E, Bansback N, Calvert N, Crellin A, Forman D, *et al.*

No. 25

A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer.

By Lloyd Jones M, Hummel S, Bansback N, Orr B, Seymour M.

No. 26

Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.

By Brocklebank D, Ram F, Wright J, Barry P, Cates C, Davies L, *et al.*

No. 27

The cost-effectiveness of magnetic resonance imaging for investigation of the knee joint.

By Bryan S, Weatherburn G, Bungay H, Hatrick C, Salas C, Parry D, *et al.*

No. 28

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.

By Forbes C, Shirran L, Bagnall A-M, Duffy S, ter Riet G.

No. 29

Superseded by a report published in a later volume.

No. 30

The role of radiography in primary care patients with low back pain of at least 6 weeks duration: a randomised (unblinded) controlled trial.

By Kendrick D, Fielding K, Bentley E, Miller P, Kerslake R, Pringle M.

No. 31

Design and use of questionnaires: a review of best practice applicable to surveys of health service staff and patients.

By McColl E, Jacoby A, Thomas L, Soutter J, Bamford C, Steen N, *et al.*

No. 32

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.

By Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N.

No. 33

Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives.

By Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey Smith G.

No. 34

Depot antipsychotic medication in the treatment of patients with schizophrenia: (1) Meta-review; (2) Patient and nurse attitudes.

By David AS, Adams C.

No. 35

A systematic review of controlled trials of the effectiveness and cost-effectiveness of brief psychological treatments for depression.

By Churchill R, Hunot V, Corney R, Knapp M, McGuire H, Tylee A, *et al.*

No. 36

Cost analysis of child health surveillance.

By Sanderson D, Wright D, Acton C, Duree D.

Volume 6, 2002**No. 1**

A study of the methods used to select review criteria for clinical audit.

By Hearnshaw H, Harker R, Cheater F, Baker R, Grimshaw G.

No. 2

Fludarabine as second-line therapy for B cell chronic lymphocytic leukaemia: a technology assessment.

By Hyde C, Wake B, Bryan S, Barton P, Fry-Smith A, Davenport C, *et al.*

No. 3

Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation.

By Wake B, Hyde C, Bryan S, Barton P, Song F, Fry-Smith A, *et al.*

No. 4

A systematic review of discharge arrangements for older people.

By Parker SG, Peet SM, McPherson A, Cannaby AM, Baker R, Wilson A, *et al.*

No. 5

The clinical effectiveness and cost-effectiveness of inhaler devices used in the routine management of chronic asthma in older children: a systematic review and economic evaluation.

By Peters J, Stevenson M, Beverley C, Lim J, Smith S.

No. 6

The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment.

By O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G.

No. 7

The cost-effectiveness of magnetic resonance angiography for carotid artery stenosis and peripheral vascular disease: a systematic review.

By Berry E, Kelly S, Westwood ME, Davies LM, Gough MJ, Bamford JM, *et al.*

No. 8

Promoting physical activity in South Asian Muslim women through 'exercise on prescription'.

By Carroll B, Ali N, Azam N.

No. 9

Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation.

By Burls A, Clark W, Stewart T, Preston C, Bryan S, Jefferson T, *et al.*

No. 10

A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models.

By Richards RG, Sampson FC, Beard SM, Tappenden P.

No. 11

Screening for gestational diabetes: a systematic review and economic evaluation.

By Scott DA, Loveman E, McIntyre L, Waugh N.

No. 12

The clinical effectiveness and cost-effectiveness of surgery for people with morbid obesity: a systematic review and economic evaluation.

By Clegg AJ, Colquitt J, Sidhu MK, Royle P, Loveman E, Walker A.

No. 13

The clinical effectiveness of trastuzumab for breast cancer: a systematic review.

By Lewis R, Bagnall A-M, Forbes C, Shirran E, Duffy S, Kleijnen J, *et al.*

No. 14

The clinical effectiveness and cost-effectiveness of vinorelbine for breast cancer: a systematic review and economic evaluation.

By Lewis R, Bagnall A-M, King S, Woolcott N, Forbes C, Shirran L, *et al.*

No. 15

A systematic review of the effectiveness and cost-effectiveness of metal-on-metal hip resurfacing arthroplasty for treatment of hip disease.

By Vale L, Wyness L, McCormack K, McKenzie L, Brazzelli M, Stearns SC.

No. 16

The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation.

By Woolcott NF, Jones L, Forbes CA, Mather LC, Sowden AJ, Song FJ, *et al.*

No. 17

A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept.

By Cummins C, Connock M, Fry-Smith A, Burls A.

No. 18

Clinical effectiveness and cost-effectiveness of growth hormone in children: a systematic review and economic evaluation.

By Bryant J, Cave C, Mihaylova B, Chase D, McIntyre L, Gerard K, *et al.*

No. 19

Clinical effectiveness and cost-effectiveness of growth hormone in adults in relation to impact on quality of life: a systematic review and economic evaluation.

By Bryant J, Loveman E, Chase D, Mihaylova B, Cave C, Gerard K, *et al.*

No. 20

Clinical medication review by a pharmacist of patients on repeat prescriptions in general practice: a randomised controlled trial.

By Zermansky AG, Petty DR, Raynor DK, Lowe CJ, Frementle N, Vail A.

No. 21

The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation.

By Jobanputra P, Barton P, Bryan S, Burls A.

No. 22

A systematic review and economic evaluation of computerised cognitive behaviour therapy for depression and anxiety.

By Kaltenthaler E, Shackley P, Stevens K, Beverley C, Parry G, Chilcott J.

No. 23

A systematic review and economic evaluation of pegylated liposomal doxorubicin hydrochloride for ovarian cancer.

By Forbes C, Wilby J, Richardson G, Sculpher M, Mather L, Reimsma R.

No. 24

A systematic review of the effectiveness of interventions based on a stages-of-change approach to promote individual behaviour change.

By Riemsma RP, Pattenden J, Bridle C, Sowden AJ, Mather L, Watt IS, *et al.*

No. 25

A systematic review update of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists.

By Robinson M, Ginnelly L, Sculpher M, Jones L, Riemsma R, Palmer S, *et al.*

No. 26

A systematic review of the effectiveness, cost-effectiveness and barriers to implementation of thrombolytic and neuroprotective therapy for acute ischaemic stroke in the NHS.

By Sandercock P, Berge E, Dennis M, Forbes J, Hand P, Kwan J, *et al.*

No. 27

A randomised controlled crossover trial of nurse practitioner versus doctor-led outpatient care in a bronchiectasis clinic.

By Caine N, Sharples LD, Hollingworth W, French J, Keogan M, Exley A, *et al.*

No. 28

Clinical effectiveness and cost – consequences of selective serotonin reuptake inhibitors in the treatment of sex offenders.

By Adi Y, Ashcroft D, Browne K, Beech A, Fry-Smith A, Hyde C.

No. 29

Treatment of established osteoporosis: a systematic review and cost-utility analysis.

By Kanis JA, Brazier JE, Stevenson M, Calvert NW, Lloyd Jones M.

No. 30

Which anaesthetic agents are cost-effective in day surgery? Literature review, national survey of practice and randomised controlled trial.

By Elliott RA Payne K, Moore JK, Davies LM, Harper NJN, St Leger AS, *et al.*

No. 31

Screening for hepatitis C among injecting drug users and in genitourinary medicine clinics: systematic reviews of effectiveness, modelling study and national survey of current practice.

By Stein K, Dalziel K, Walker A, McIntyre L, Jenkins B, Horne J, *et al.*

No. 32

The measurement of satisfaction with healthcare: implications for practice from a systematic review of the literature.

By Crow R, Gage H, Hampson S, Hart J, Kimber A, Storey L, *et al.*

No. 33

The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review.

By Garside R, Round A, Dalziel K, Stein K, Royle R.

No. 34

A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis.

By Suri R, Wallis C, Bush A, Thompson S, Normand C, Flather M, *et al.*

No. 35

A systematic review of the costs and effectiveness of different models of paediatric home care.

By Parker G, Bhakta P, Lovett CA, Paisley S, Olsen R, Turner D, *et al.*

Volume 7, 2003

No. 1

How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study.

By Egger M, Jüni P, Bartlett C, Holenstein F, Sterne J.

No. 2

Systematic review of the effectiveness and cost-effectiveness, and economic evaluation, of home versus hospital or satellite unit haemodialysis for people with end-stage renal failure.

By Mowatt G, Vale L, Perez J, Wyness L, Fraser C, MacLeod A, *et al.*

No. 3

Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease.

By Clark W, Raftery J, Barton P, Song F, Fry-Smith A, Burls A.

No. 4

A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are rhesus negative.

By Chilcott J, Lloyd Jones M, Wight J, Forman K, Wray J, Beverley C, *et al.*

No. 5

Systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing's sarcoma and neuroblastoma.

By Riley RD, Burchill SA, Abrams KR, Heny D, Lambert PC, Jones DR, *et al.*

No. 6

The cost-effectiveness of screening for *Helicobacter pylori* to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete-event simulation model.

By Roderick P, Davies R, Raftery J, Crabbe D, Pearce R, Bhandari P, *et al.*

No. 7

The clinical effectiveness and cost-effectiveness of routine dental checks: a systematic review and economic evaluation.

By Davenport C, Elley K, Salas C, Taylor-Weetman CL, Fry-Smith A, Bryan S, *et al.*

No. 8

A multicentre randomised controlled trial assessing the costs and benefits of using structured information and analysis of women's preferences in the management of menorrhagia.

By Kennedy ADM, Sculpher MJ, Coulter A, Dwyer N, Rees M, Horsley S, *et al.*

No. 9

Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation.

By Meads C, Salas C, Roberts T, Moore D, Fry-Smith A, Hyde C.

No. 10

Evaluation of molecular tests for prenatal diagnosis of chromosome abnormalities.

By Grimshaw GM, Szczepura A, Hultén M, MacDonald F, Nevin NC, Sutton F, *et al.*

No. 11

First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS).

By Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM.

No. 12

The effectiveness and cost-effectiveness of ultrasound locating devices for central venous access: a systematic review and economic evaluation.

By Calvert N, Hind D, McWilliams RG, Thomas SM, Beverley C, Davidson A.

No. 13

A systematic review of atypical antipsychotics in schizophrenia.

By Bagnall A-M, Jones L, Lewis R, Ginnelly L, Glanville J, Torgerson D, *et al.*

No. 14

Prostate Testing for Cancer and Treatment (ProtecT) feasibility study.

By Donovan J, Hamdy F, Neal D, Peters T, Oliver S, Brindle L, *et al.*

No. 15

Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation.

By Boland A, Dundar Y, Bagust A, Haycox A, Hill R, Mujica Mota R, *et al.*

No. 16

Screening for fragile X syndrome: a literature review and modelling.

By Song FJ, Barton P, Sleightholme V, Yao GL, Fry-Smith A.

No. 17

Systematic review of endoscopic sinus surgery for nasal polyps.

By Dalziel K, Stein K, Round A, Garside R, Royle P.

No. 18

Towards efficient guidelines: how to monitor guideline use in primary care.

By Hutchinson A, McIntosh A, Cox S, Gilbert C.

No. 19

Effectiveness and cost-effectiveness of acute hospital-based spinal cord injuries services: systematic review.

By Bagnall A-M, Jones L, Richardson G, Duffy S, Riemsma R.

No. 20

Prioritisation of health technology assessment. The PATHS model: methods and case studies.

By Townsend J, Buxton M, Harper G.

No. 21

Systematic review of the clinical effectiveness and cost-effectiveness of tension-free vaginal tape for treatment of urinary stress incontinence.

By Cody J, Wyness L, Wallace S, Glazener C, Kilonzo M, Stearns S, *et al.*

No. 22

The clinical and cost-effectiveness of patient education models for diabetes: a systematic review and economic evaluation.

By Loveman E, Cave C, Green C, Royle P, Dunn N, Waugh N.

No. 23

The role of modelling in prioritising and planning clinical trials.

By Chilcott J, Brennan A, Booth A, Karnon J, Tappenden P.

No. 24

Cost-benefit evaluation of routine influenza immunisation in people 65-74 years of age.

By Allsup S, Gosney M, Haycox A, Regan M.

No. 25

The clinical and cost-effectiveness of pulsatile machine perfusion versus cold storage of kidneys for transplantation retrieved from heart-beating and non-heart-beating donors.

By Wight J, Chilcott J, Holmes M, Brewer N.

No. 26

Can randomised trials rely on existing electronic data? A feasibility study to explore the value of routine data in health technology assessment.

By Williams JG, Cheung WY, Cohen DR, Hutchings HA, Longo MF, Russell IT.

No. 27

Evaluating non-randomised intervention studies.

By Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovich C, Song F, *et al.*

No. 28

A randomised controlled trial to assess the impact of a package comprising a patient-orientated, evidence-based self-help guidebook and patient-centred consultations on disease management and satisfaction in inflammatory bowel disease.

By Kennedy A, Nelson E, Reeves D, Richardson G, Roberts C, Robinson A, *et al.*

No. 29

The effectiveness of diagnostic tests for the assessment of shoulder pain due to soft tissue disorders: a systematic review.

By Dinnes J, Loveman E, McIntyre L, Waugh N.

No. 30

The value of digital imaging in diabetic retinopathy.

By Sharp PE, Olson J, Strachan F, Hipwell J, Ludbrook A, O'Donnell M, *et al.*

No. 31

Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy.

By Law M, Wald N, Morris J.

No. 32

Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation.

By Ward S, Kaltenthaler E, Cowan J, Brewer N.

No. 33

Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review.

By Hummel S, Paisley S, Morgan A, Currie E, Brewer N.

No. 34

Literature searching for clinical and cost-effectiveness studies used in health technology assessment reports carried out for the National Institute for Clinical Excellence appraisal system.

By Royle P, Waugh N.

No. 35

Systematic review and economic decision modelling for the prevention and treatment of influenza A and B.

By Turner D, Wailoo A, Nicholson K, Cooper N, Sutton A, Abrams K.

No. 36

A randomised controlled trial to evaluate the clinical and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses.

By Boland A, Haycox A, Bagust A, Fitzsimmons L.

No. 37

Redesigning postnatal care: a randomised controlled trial of protocol-based midwifery-led care focused on individual women's physical and psychological health needs.

By MacArthur C, Winter HR, Bick DE, Lilford RJ, Lancashire RJ, Knowles H, *et al.*

No. 38

Estimating implied rates of discount in healthcare decision-making.

By West RR, McNabb R, Thompson AGH, Sheldon TA, Grimley Evans J.

No. 39

Systematic review of isolation policies in the hospital management of methicillin-resistant *Staphylococcus aureus*: a review of the literature with epidemiological and economic modelling.

By Cooper BS, Stone SP, Kibbler CC, Cookson BD, Roberts JA, Medley GF, *et al.*

No. 40

Treatments for spasticity and pain in multiple sclerosis: a systematic review.

By Beard S, Hunn A, Wight J.

No. 41

The inclusion of reports of randomised trials published in languages other than English in systematic reviews.

By Moher D, Pham B, Lawson ML, Klassen TP.

No. 42

The impact of screening on future health-promoting behaviours and health beliefs: a systematic review.

By Bankhead CR, Brett J, Bukach C, Webster P, Stewart-Brown S, Munafa M, *et al.*

Volume 8, 2004

No. 1

What is the best imaging strategy for acute stroke?

By Wardlaw JM, Keir SL, Seymour J, Lewis S, Sandercock PAG, Dennis MS, *et al.*

No. 2

Systematic review and modelling of the investigation of acute and chronic chest pain presenting in primary care.

By Mant J, McManus RJ, Oakes RAL, Delaney BC, Barton PM, Deeks JJ, *et al.*

No. 3

The effectiveness and cost-effectiveness of microwave and thermal balloon endometrial ablation for heavy menstrual bleeding: a systematic review and economic modelling.

By Garside R, Stein K, Wyatt K, Round A, Price A.

No. 4

A systematic review of the role of bisphosphonates in metastatic disease.

By Ross JR, Saunders Y, Edmonds PM, Patel S, Wonderling D, Normand C, *et al.*

No. 5

Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda®) for locally advanced and/or metastatic breast cancer.

By Jones L, Hawkins N, Westwood M, Wright K, Richardson G, Riemsma R.

No. 6

Effectiveness and efficiency of guideline dissemination and implementation strategies.

By Grimshaw JM, Thomas RE, MacLennan G, Fraser C, Ramsay CR, Vale L, *et al.*

No. 7

Clinical effectiveness and costs of the Sugarbaker procedure for the treatment of pseudomyxoma peritonei.

By Bryant J, Clegg AJ, Sidhu MK, Brodin H, Royle P, Davidson P.

No. 8

Psychological treatment for insomnia in the regulation of long-term hypnotic drug use.

By Morgan K, Dixon S, Mathers N, Thompson J, Tomeny M.

No. 9

Improving the evaluation of therapeutic interventions in multiple sclerosis: development of a patient-based measure of outcome.

By Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ.

No. 10

A systematic review and economic evaluation of magnetic resonance cholangiopancreatography compared with diagnostic endoscopic retrograde cholangiopancreatography.

By Kaltenthaler E, Bravo Vergel Y, Chilcott J, Thomas S, Blakeborough T, Walters SJ, *et al.*

No. 11

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis.

By Barton P, Jobanputra P, Wilson J, Bryan S, Burls A.

No. 12

Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review.

By Pandor A, Eastham J, Beverley C, Chilcott J, Paisley S.

No. 13

Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation.

By Czoski-Murray C, Warren E, Chilcott J, Beverley C, Psyllaki MA, Cowan J.

No. 14

Routine examination of the newborn: the EMREN study. Evaluation of an extension of the midwife role including a randomised controlled trial of appropriately trained midwives and paediatric senior house officers.

By Townsend J, Wolke D, Hayes J, Davé S, Rogers C, Bloomfield L, *et al.*

No. 15

Involving consumers in research and development agenda setting for the NHS: developing an evidence-based approach.

By Oliver S, Clarke-Jones L, Rees R, Milne R, Buchanan P, Gabbay J, *et al.*

No. 16

A multi-centre randomised controlled trial of minimally invasive direct coronary bypass grafting versus percutaneous transluminal coronary angioplasty with stenting for proximal stenosis of the left anterior descending coronary artery.

By Reeves BC, Angelini GD, Bryan AJ, Taylor FC, Cripps T, Spyt TJ, *et al.*

No. 17

Does early magnetic resonance imaging influence management or improve outcome in patients referred to secondary care with low back pain? A pragmatic randomised controlled trial.

By Gilbert FJ, Grant AM, Gillan MGC, Vale L, Scott NW, Campbell MK, *et al.*

No. 18

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.

By Clark W, Jobanputra P, Barton P, Burls A.

No. 19

A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder.

By Bridle C, Palmer S, Bagnall A-M, Darba J, Duffy S, Sculpher M, *et al.*

No. 20

Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis.

By Karnon J, Peters J, Platt J, Chilcott J, McGoogan E, Brewer N.

No. 21

Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.

By Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC, *et al.*

No. 22

Autoantibody testing in children with newly diagnosed type 1 diabetes mellitus.

By Dretzke J, Cummins C, Sandercock J, Fry-Smith A, Barrett T, Burls A.

No. 23

Clinical effectiveness and cost-effectiveness of prehospital intravenous fluids in trauma patients.

By Dretzke J, Sandercock J, Bayliss S, Burls A.

No. 24

Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation.

By Dündar Y, Boland A, Strobl J, Dodd S, Haycox A, Bagust A, *et al.*

No. 25

Development and validation of methods for assessing the quality of diagnostic accuracy studies.

By Whiting P, Rutjes AWS, Dinnes J, Reitsma JB, Bossuyt PMM, Kleijnen J.

No. 26

EVALUATE hysterectomy trial: a multicentre randomised trial comparing abdominal, vaginal and laparoscopic methods of hysterectomy.

By Garry R, Fountain J, Brown J, Manca A, Mason S, Sculpher M, *et al.*

No. 27

Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon- β and glatiramer acetate for multiple sclerosis.

By Tappenden P, Chilcott JB, Eggington S, Oakley J, McCabe C.

No. 28

Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis.

By Dalziel K, Round A, Stein K, Garside R, Price A.

No. 29

VenUS I: a randomised controlled trial of two types of bandage for treating venous leg ulcers.

By Iglesias C, Nelson EA, Cullum NA, Torgerson DJ on behalf of the VenUS Team.

No. 30

Systematic review of the effectiveness and cost-effectiveness, and economic evaluation, of myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction.

By Mowatt G, Vale L, Brazzelli M, Hernandez R, Murray A, Scott N, *et al.*

No. 31

A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme.

By Claxton K, Ginnelly L, Sculpher M, Philips Z, Palmer S.

No. 32

The Social Support and Family Health Study: a randomised controlled trial and economic evaluation of two alternative forms of postnatal support for mothers living in disadvantaged inner-city areas.

By Wiggins M, Oakley A, Roberts I, Turner H, Rajan L, Austerberry H, *et al.*

No. 33

Psychosocial aspects of genetic screening of pregnant women and newborns: a systematic review.

By Green JM, Hewison J, Bekker HL, Bryant, Cuckle HS.

No. 34

Evaluation of abnormal uterine bleeding: comparison of three outpatient procedures within cohorts defined by age and menopausal status.

By Critchley HOD, Warner P, Lee AJ, Brechin S, Guise J, Graham B.

No. 35

Coronary artery stents: a rapid systematic review and economic evaluation.

By Hill R, Bagust A, Bakhai A, Dickson R, Dündar Y, Haycox A, *et al.*

No. 36

Review of guidelines for good practice in decision-analytic modelling in health technology assessment.

By Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, *et al.*

No. 37

Rituximab (MabThera[®]) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.

By Knight C, Hind D, Brewer N, Abbott V.

No. 38

Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.

By Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, *et al.*

No. 39

Pegylated interferon α -2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

By Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

No. 40

Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation.

By Main C, Palmer S, Griffin S, Jones L, Orton V, Sculpher M, *et al.*

No. 41

Provision, uptake and cost of cardiac rehabilitation programmes: improving services to under-represented groups.

By Beswick AD, Rees K, Griebisch I, Taylor FC, Burke M, West RR, *et al.*

No. 42

Involving South Asian patients in clinical trials.

By Hussain-Gambles M, Leese B, Atkin K, Brown J, Mason S, Tovey P.

No. 43

Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes.

By Colquitt JL, Green C, Sidhu MK, Hartwell D, Waugh N.

No. 44

Identification and assessment of ongoing trials in health technology assessment reviews.

By Song FJ, Fry-Smith A, Davenport C, Bayliss S, Adi Y, Wilson JS, *et al.*

No. 45

Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine

By Warren E, Weatherley-Jones E, Chilcott J, Beverley C.

No. 46

Supplementation of a home-based exercise programme with a class-based programme for people with osteoarthritis of the knees: a randomised controlled trial and health economic analysis.

By McCarthy CJ, Mills PM, Pullen R, Richardson G, Hawkins N, Roberts CR, *et al.*

No. 47

Clinical and cost-effectiveness of once-daily versus more frequent use of same potency topical corticosteroids for atopic eczema: a systematic review and economic evaluation.

By Green C, Colquitt JL, Kirby J, Davidson P, Payne E.

No. 48

Acupuncture of chronic headache disorders in primary care: randomised controlled trial and economic analysis.

By Vickers AJ, Rees RW, Zollman CE, McCarney R, Smith CM, Ellis N, *et al.*

No. 49

Generalisability in economic evaluation studies in healthcare: a review and case studies.

By Sculpher MJ, Pang FS, Manca A, Drummond MF, Golder S, Urdahl H, *et al.*

No. 50

Virtual outreach: a randomised controlled trial and economic evaluation of joint teleconferenced medical consultations.

By Wallace P, Barber J, Clayton W, Currell R, Fleming K, Garner P, *et al.*

Volume 9, 2005

No. 1

Randomised controlled multiple treatment comparison to provide a cost-effectiveness rationale for the selection of antimicrobial therapy in acne.

By Ozolins M, Eady EA, Avery A, Cunliffe WJ, O'Neill C, Simpson NB, *et al.*

No. 2

Do the findings of case series studies vary significantly according to methodological characteristics?

By Dalziel K, Round A, Stein K, Garside R, Castelnovo E, Payne L.

No. 3

Improving the referral process for familial breast cancer genetic counselling: findings of three randomised controlled trials of two interventions.

By Wilson BJ, Torrance N, Mollison J, Wordsworth S, Gray JR, Haites NE, *et al.*

No. 4

Randomised evaluation of alternative electrosurgical modalities to treat bladder outflow obstruction in men with benign prostatic hyperplasia.

By Fowler C, McAllister W, Plail R, Karim O, Yang Q.

No. 5

A pragmatic randomised controlled trial of the cost-effectiveness of palliative therapies for patients with inoperable oesophageal cancer.

By Shenfine J, McNamee P, Steen N, Bond J, Griffin SM.

No. 6

Impact of computer-aided detection prompts on the sensitivity and specificity of screening mammography.

By Taylor P, Champness J, Given-Wilson R, Johnston K, Potts H.

No. 7

Issues in data monitoring and interim analysis of trials.

By Grant AM, Altman DG, Babiker AB, Campbell MK, Clemens FJ, Darbyshire JH, *et al.*

No. 8

Lay public's understanding of equipoise and randomisation in randomised controlled trials.

By Robinson EJ, Kerr CEP, Stevens AJ, Lilford RJ, Brauholtz DA, Edwards SJ, *et al.*

No. 9

Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies.

By Greenhalgh J, Knight C, Hind D, Beverley C, Walters S.

No. 10

Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology.

By Smith SC, Lamping DL, Banerjee S, Harwood R, Foley B, Smith P, *et al.*

No. 11

Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris®) for the treatment of severe sepsis in adults: a systematic review and economic evaluation.

By Green C, Dinnes J, Takeda A, Shepherd J, Hartwell D, Cave C, *et al.*

No. 12

A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy.

By Dinnes J, Deeks J, Kirby J, Roderick P.

No. 13

Cervical screening programmes: can automation help? Evidence from systematic reviews, an economic analysis and a simulation modelling exercise applied to the UK.

By Willis BH, Barton P, Pearmain P, Bryan S, Hyde C.

No. 14

Laparoscopic surgery for inguinal hernia repair: systematic review of effectiveness and economic evaluation.

By McCormack K, Wake B, Perez J, Fraser C, Cook J, McIntosh E, *et al.*

No. 15

Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation.

By Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, *et al.*

No. 16

A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine.

By Peveler R, Kendrick T, Buxton M, Longworth L, Baldwin D, Moore M, *et al.*

No. 17

Clinical effectiveness and cost-effectiveness of immediate angioplasty for acute myocardial infarction: systematic review and economic evaluation.

By Hartwell D, Colquitt J, Loveman E, Clegg AJ, Brodin H, Waugh N, *et al.*

No. 18

A randomised controlled comparison of alternative strategies in stroke care.

By Kalra L, Evans A, Perez I, Knapp M, Swift C, Donaldson N.

No. 19

The investigation and analysis of critical incidents and adverse events in healthcare.

By Woloshnowych M, Rogers S, Taylor-Adams S, Vincent C.

No. 20

Potential use of routine databases in health technology assessment.

By Raftery J, Roderick P, Stevens A.

No. 21

Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.

By Woodroffe R, Yao GL, Meads C, Bayliss S, Ready A, Raftery J, *et al.*

No. 22

A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.

By Stevenson M, Lloyd Jones M, De Nigris E, Brewer N, Davis S, Oakley J.

No. 23

A systematic review to examine the impact of psycho-educational interventions on health outcomes and costs in adults and children with difficult asthma.

By Smith JR, Mugford M, Holland R, Candy B, Noble MJ, Harrison BDW, *et al.*

No. 24

An evaluation of the costs, effectiveness and quality of renal replacement therapy provision in renal satellite units in England and Wales.

By Roderick P, Nicholson T, Armitage A, Mehta R, Mullee M, Gerard K, *et al.*

No. 25

Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.

By Wilson J, Connock M, Song F, Yao G, Fry-Smith A, Raftery J, *et al.*

No. 26

Indirect comparisons of competing interventions.

By Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D'Amico R, *et al.*

No. 27

Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling.

By Robinson M, Palmer S, Sculpher M, Philips Z, Ginnelly L, Bowens A, *et al.*

No. 28

Outcomes of electrically stimulated gracilis neosphincter surgery.

By Tillin T, Chambers M, Feldman R.

No. 29

The effectiveness and cost-effectiveness of pimecrolimus and tacrolimus for atopic eczema: a systematic review and economic evaluation.

By Garside R, Stein K, Castelnovo E, Pitt M, Ashcroft D, Dimmock P, *et al.*

No. 30

Systematic review on urine albumin testing for early detection of diabetic complications.

By Newman DJ, Mattock MB, Dawney ABS, Kerry S, McGuire A, Yaqoob M, *et al.*

No. 31

Randomised controlled trial of the cost-effectiveness of water-based therapy for lower limb osteoarthritis.

By Cochrane T, Davey RC, Matthes Edwards SM.

No. 32

Longer term clinical and economic benefits of offering acupuncture care to patients with chronic low back pain.

By Thomas KJ, MacPherson H, Ratcliffe J, Thorpe L, Brazier J, Campbell M, *et al.*

No. 33

Cost-effectiveness and safety of epidural steroids in the management of sciatica.

By Price C, Arden N, Cogan L, Rogers P.

No. 34

The British Rheumatoid Outcome Study Group (BROSG) randomised controlled trial to compare the effectiveness and cost-effectiveness of aggressive versus symptomatic therapy in established rheumatoid arthritis.

By Symmons D, Tricker K, Roberts C, Davies L, Dawes P, Scott DL.

No. 35

Conceptual framework and systematic review of the effects of participants' and professionals' preferences in randomised controlled trials.

By King M, Nazareth I, Lampe F, Bower P, Chandler M, Morou M, *et al.*

No. 36

The clinical and cost-effectiveness of implantable cardioverter defibrillators: a systematic review.

By Bryant J, Brodin H, Loveman E, Payne E, Clegg A.

No. 37

A trial of problem-solving by community mental health nurses for anxiety, depression and life difficulties among general practice patients. The CPN-GP study.

By Kendrick T, Simons L, Mynors-Wallis L, Gray A, Lathlean J, Pickering R, *et al.*

No. 38

The causes and effects of socio-demographic exclusions from clinical trials.

By Bartlett C, Doyal L, Ebrahim S, Davey P, Bachmann M, Egger M, *et al.*

No. 39

Is hydrotherapy cost-effective? A randomised controlled trial of combined hydrotherapy programmes compared with physiotherapy land techniques in children with juvenile idiopathic arthritis.

By Epps H, Ginnelly L, Utley M, Southwood T, Gallivan S, Sculpher M, *et al.*

No. 40

A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study.

By Hobbs FDR, Fitzmaurice DA, Mant J, Murray E, Jowett S, Bryan S, *et al.*

No. 41

Displaced intracapsular hip fractures in fit, older people: a randomised comparison of reduction and fixation, bipolar hemiarthroplasty and total hip arthroplasty.

By Keating JF, Grant A, Masson M, Scott NW, Forbes JF.

No. 42

Long-term outcome of cognitive behaviour therapy clinical trials in central Scotland.

By Durham RC, Chambers JA, Power KG, Sharp DM, Macdonald RR, Major KA, *et al.*

No. 43

The effectiveness and cost-effectiveness of dual-chamber pacemakers compared with single-chamber pacemakers for bradycardia due to atrioventricular block or sick sinus syndrome: systematic review and economic evaluation.

By Castelnovo E, Stein K, Pitt M, Garside R, Payne E.

No. 44

Newborn screening for congenital heart defects: a systematic review and cost-effectiveness analysis.

By Knowles R, Griesch I, Dezateux C, Brown J, Bull C, Wren C.

No. 45

The clinical and cost-effectiveness of left ventricular assist devices for end-stage heart failure: a systematic review and economic evaluation.

By Clegg AJ, Scott DA, Loveman E, Colquitt J, Hutchinson J, Royle P, *et al.*

No. 46

The effectiveness of the Heidelberg Retina Tomograph and laser diagnostic glaucoma scanning system (GDx) in detecting and monitoring glaucoma.

By Kwartz AJ, Henson DB, Harper RA, Spencer AF, McLeod D.

No. 47

Clinical and cost-effectiveness of autologous chondrocyte implantation for cartilage defects in knee joints: systematic review and economic evaluation.

By Clar C, Cummins E, McIntyre L, Thomas S, Lamb J, Bain L, *et al.*

No. 48

Systematic review of effectiveness of different treatments for childhood retinoblastoma.

By McDaid C, Hartley S, Bagnall A-M, Ritchie G, Light K, Riemsma R.

No. 49

Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis.

By Roderick P, Ferris G, Wilson K, Halls H, Jackson D, Collins R, *et al.*

No. 50

The effectiveness and cost-effectiveness of parent training/education programmes for the treatment of conduct disorder, including oppositional defiant disorder, in children.

By Dretzke J, Frew E, Davenport C, Barlow J, Stewart-Brown S, Sandercock J, *et al.*

Volume 10, 2006**No. 1**

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.

By Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, *et al.*

No. 2

FOOD: a multicentre randomised trial evaluating feeding policies in patients admitted to hospital with a recent stroke.

By Dennis M, Lewis S, Cranswick G, Forbes J.

No. 3

The clinical effectiveness and cost-effectiveness of computed tomography screening for lung cancer: systematic reviews.

By Black C, Bagust A, Boland A, Walker S, McLeod C, De Verteuil R, *et al.*

No. 4

A systematic review of the effectiveness and cost-effectiveness of neuroimaging assessments used to visualise the seizure focus in people with refractory epilepsy being considered for surgery.

By Whiting P, Gupta R, Burch J, Mujica Mota RE, Wright K, Marson A, *et al.*

No. 5

Comparison of conference abstracts and presentations with full-text articles in the health technology assessments of rapidly evolving technologies.

By Dundar Y, Dodd S, Dickson R, Walley T, Haycox A, Williamson PR.

No. 6

Systematic review and evaluation of methods of assessing urinary incontinence.

By Martin JL, Williams KS, Abrams KR, Turner DA, Sutton AJ, Chapple C, *et al.*

No. 7

The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy. A systematic review.

By Connock M, Frew E, Evans B-W, Bryan S, Cummins C, Fry-Smith A, *et al.*

No. 8

Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.

By Garside R, Pitt M, Somerville M, Stein K, Price A, Gilbert N.

No. 9

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

By Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, *et al.*

No. 10

Evaluation of molecular techniques in prediction and diagnosis of cytomegalovirus disease in immunocompromised patients.

By Szczepura A, Westmoreland D, Vinogradova Y, Fox J, Clark M.

No. 11

Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study.

By Wu O, Robertson L, Twaddle S, Lowe GDO, Clark P, Greaves M, *et al.*

No. 12

A series of systematic reviews to inform a decision analysis for sampling and treating infected diabetic foot ulcers.

By Nelson EA, O'Meara S, Craig D, Iglesias C, Golder S, Dalton J, *et al.*

No. 13

Randomised clinical trial, observational study and assessment of cost-effectiveness of the treatment of varicose veins (REACTIV trial).

By Michaels JA, Campbell WB, Brazier JE, MacIntyre JB, Palfreyman SJ, Ratcliffe J, *et al.*

No. 14

The cost-effectiveness of screening for oral cancer in primary care.

By Speight PM, Palmer S, Moles DR, Downer MC, Smith DH, Henriksson M *et al.*

No. 15

Measurement of the clinical and cost-effectiveness of non-invasive diagnostic testing strategies for deep vein thrombosis.

By Goodacre S, Sampson F, Stevenson M, Wailoo A, Sutton A, Thomas S, *et al.*

No. 16

Systematic review of the effectiveness and cost-effectiveness of HealOzone[®] for the treatment of occlusal pit/fissure caries and root caries.

By Brazzelli M, McKenzie L, Fielding S, Fraser C, Clarkson J, Kilonzo M, *et al.*

No. 17

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

By Lewis SW, Davies L, Jones PB, Barnes TRE, Murray RM, Kerwin R, *et al.*

No. 18

Diagnostic tests and algorithms used in the investigation of haematuria: systematic reviews and economic evaluation.

By Rodgers M, Nixon J, Hempel S, Aho T, Kelly J, Neal D, *et al.*

No. 19

Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: randomised controlled trial.

By Kennedy TM, Chalder T, McCrone P, Darnley S, Knapp M, Jones RH, *et al.*

No. 20

A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1.

By Connock M, Juarez-Garcia A, Frew E, Mans A, Dretzke J, Fry-Smith A, *et al.*

No. 21

Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation.

By Wright M, Grieve R, Roberts J, Main J, Thomas HC on behalf of the UK Mild Hepatitis C Trial Investigators.

No. 22

Pressure relieving support surfaces: a randomised evaluation.

By Nixon J, Nelson EA, Cranny G, Iglesias CP, Hawkins K, Cullum NA, *et al.*

No. 23

A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.

By King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, *et al.*

No. 24

The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.

By Connock M, Burls A, Frew E, Fry-Smith A, Juarez-Garcia A, McCabe C, *et al.*

No. 25

Effectiveness and cost-effectiveness of salicylic acid and cryotherapy for cutaneous warts. An economic decision model.

By Thomas KS, Keogh-Brown MR, Chalmers JR, Fordham RJ, Holland RC, Armstrong SJ, *et al.*

No. 26

A systematic literature review of the effectiveness of non-pharmacological interventions to prevent wandering in dementia and evaluation of the ethical implications and acceptability of their use.

By Robinson L, Hutchings D, Corner L, Beyer F, Dickinson H, Vanoli A, *et al.*

No. 27

A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.

By Buxton M, Caine N, Chase D, Connelly D, Grace A, Jackson C, *et al.*

No. 28

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

By Shepherd J, Jones J, Takeda A, Davidson P, Price A.

No. 29

An evaluation of the clinical and cost-effectiveness of pulmonary artery catheters in patient management in intensive care: a systematic review and a randomised controlled trial.

By Harvey S, Stevens K, Harrison D, Young D, Brampton W, McCabe C, *et al.*

No. 30

Accurate, practical and cost-effective assessment of carotid stenosis in the UK.

By Wardlaw JM, Chappell FM, Stevenson M, De Nigris E, Thomas S, Gillard J, *et al.*

No. 31

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

By Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, *et al.*

No. 32

The cost-effectiveness of testing for hepatitis C in former injecting drug users.

By Castelnuovo E, Thompson-Coon J, Pitt M, Cramp M, Siebert U, Price A, *et al.*

No. 33

Computerised cognitive behaviour therapy for depression and anxiety update: a systematic review and economic evaluation.

By Kaltenthaler E, Brazier J, De Nigris E, Tumor I, Ferriter M, Beverley C, *et al.*

No. 34

Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.

By Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, *et al.*

No. 35

Psychological therapies including dialectical behaviour therapy for borderline personality disorder: a systematic review and preliminary economic evaluation.

By Brazier J, Tumor I, Holmes M, Ferriter M, Parry G, Dent-Brown K, *et al.*

No. 36

Clinical effectiveness and cost-effectiveness of tests for the diagnosis and investigation of urinary tract infection in children: a systematic review and economic model.

By Whiting P, Westwood M, Bojke L, Palmer S, Richardson G, Cooper J, *et al.*

No. 37

Cognitive behavioural therapy in chronic fatigue syndrome: a randomised controlled trial of an outpatient group programme.

By O'Dowd H, Gladwell P, Rogers CA, Hollinghurst S, Gregory A.

No. 38

A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling.

By Brown TJ, Hooper L, Elliott RA, Payne K, Webb R, Roberts C, *et al.*

No. 39

The effectiveness and cost-effectiveness of computed tomography screening for coronary artery disease: systematic review.

By Waugh N, Black C, Walker S, McIntyre L, Cummins E, Hillis G.

No. 40

What are the clinical outcome and cost-effectiveness of endoscopy undertaken by nurses when compared with doctors? A Multi-Institution Nurse Endoscopy Trial (MINuET).

By Williams J, Russell I, Durai D, Cheung WY, Farrin A, Bloor K, *et al.*

No. 41

The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.

By Pandor A, Eggington S, Paisley S, Tappenden P, Sutcliffe P.

No. 42

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

By Chen Y-F, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, *et al.*

No. 43

Telemedicine in dermatology: a randomised controlled trial.

By Bowns IR, Collins K, Walters SJ, McDonagh AJG.

No. 44

Cost-effectiveness of cell salvage and alternative methods of minimising perioperative allogeneic blood transfusion: a systematic review and economic model.

By Davies L, Brown TJ, Haynes S, Payne K, Elliott RA, McCollum C.

No. 45

Clinical effectiveness and cost-effectiveness of laparoscopic surgery for colorectal cancer: systematic reviews and economic evaluation.

By Murray A, Lourenco T, de Verteuil R, Hernandez R, Fraser C, McKinley A, *et al.*

No. 46

Etanercept and efalizumab for the treatment of psoriasis: a systematic review.

By Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Bravo Vergel Y, *et al.*

No. 47

Systematic reviews of clinical decision tools for acute abdominal pain.

By Liu JLY, Wyatt JC, Deeks JJ, Clamp S, Keen J, Verde P, *et al.*

No. 48

Evaluation of the ventricular assist device programme in the UK.

By Sharples L, Buxton M, Caine N, Cafferty F, Demiris N, Dyer M, *et al.*

No. 49

A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children.

By Yao G, Albon E, Adi Y, Milford D, Bayliss S, Ready A, *et al.*

No. 50

Amniocentesis results: investigation of anxiety. The ARIA trial.

By Hewison J, Nixon J, Fountain J, Cocks K, Jones C, Mason G, *et al.*

Volume 11, 2007**No. 1**

Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation.

By Dundar Y, Bagust A, Dickson R, Dodd S, Green J, Haycox A, *et al.*

No. 2

A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer.

By Collins R, Fenwick E, Trowman R, Perard R, Norman G, Light K, *et al.*

No. 3

A systematic review of rapid diagnostic tests for the detection of tuberculosis infection.

By Dinnes J, Deeks J, Kunst H, Gibson A, Cummins E, Waugh N, *et al.*

No. 4

The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women.

By Stevenson M, Davis S, Lloyd-Jones M, Beverley C.

No. 5

A systematic review of quantitative and qualitative research on the role and effectiveness of written information available to patients about individual medicines.

By Raynor DK, Blenkinsopp A, Knapp P, Grime J, Nicolson DJ, Pollock K, *et al.*

No. 6

Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation.

By Adi Y, Juarez-Garcia A, Wang D, Jowett S, Frew E, Day E, *et al.*

No. 7

Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis.

By Kanis JA, Stevenson M, McCloskey EV, Davis S, Lloyd-Jones M.

No. 8

Epidemiological, social, diagnostic and economic evaluation of population screening for genital chlamydial infection.

By Low N, McCarthy A, Macleod J, Salisbury C, Campbell R, Roberts TE, *et al.*

No. 9

Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation.

By Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, *et al.*

No. 10

Exercise Evaluation Randomised Trial (EXERT): a randomised trial comparing GP referral for leisure centre-based exercise, community-based walking and advice only.

By Isaacs AJ, Critchley JA, See Tai S, Buckingham K, Westley D, Harridge SDR, *et al.*

No. 11

Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation.

By Shepherd J, Jones J, Hartwell D, Davidson P, Price A, Waugh N.

No. 12

Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.

By Tappenden P, Jones R, Paisley S, Carroll C.

No. 13

A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment.

By Wilson J, Yao GL, Raftery J, Bohlius J, Brunskill S, Sandercock J, *et al.*

No. 14

A systematic review and economic evaluation of statins for the prevention of coronary events.

By Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, *et al.*

No. 15

A systematic review of the effectiveness and cost-effectiveness of different models of community-based respite care for frail older people and their carers.

By Mason A, Weatherly H, Spilsbury K, Arksey H, Golder S, Adamson J, *et al.*

No. 16

Additional therapy for young children with spastic cerebral palsy: a randomised controlled trial.

By Weindling AM, Cunningham CC, Glenn SM, Edwards RT, Reeves DJ.

No. 17

Screening for type 2 diabetes: literature review and economic modelling.

By Waugh N, Scotland G, McNamee P, Gillett M, Brennan A, Goyder E, *et al.*

No. 18

The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation.

By Garside R, Pitt M, Anderson R, Mealing S, Roome C, Snaith A, *et al.*

No. 19

The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation.

By Takeda AL, Jones J, Loveman E, Tan SC, Clegg AJ.

No. 20

A systematic review of duplex ultrasound, magnetic resonance angiography and computed tomography angiography for the diagnosis and assessment of symptomatic, lower limb peripheral arterial disease.

By Collins R, Cranny G, Burch J, Aguiar-Ibáñez R, Craig D, Wright K, *et al.*

No. 21

The clinical effectiveness and cost-effectiveness of treatments for children with idiopathic steroid-resistant nephrotic syndrome: a systematic review.

By Colquitt JL, Kirby J, Green C, Cooper K, Trompeter RS.

No. 22

A systematic review of the routine monitoring of growth in children of primary school age to identify growth-related conditions.

By Fayer D, Nixon J, Hartley S, Rithalia A, Butler G, Rudolf M, *et al.*

No. 23

Systematic review of the effectiveness of preventing and treating *Staphylococcus aureus* carriage in reducing peritoneal catheter-related infections.

By McCormack K, Rabindranath K, Kilonzo M, Vale L, Fraser C, McIntyre L, *et al.*



Health Technology Assessment Programme

Director,
Professor Tom Walley,
 Director, NHS HTA Programme,
 Department of Pharmacology &
 Therapeutics,
 University of Liverpool

Deputy Director,
Professor Jon Nicholl,
 Director, Medical Care Research
 Unit, University of Sheffield,
 School of Health and Related
 Research

Prioritisation Strategy Group

Members

Chair,
Professor Tom Walley,
 Director, NHS HTA Programme,
 Department of Pharmacology &
 Therapeutics,
 University of Liverpool

Professor Bruce Campbell,
 Consultant Vascular & General
 Surgeon, Royal Devon & Exeter
 Hospital

Professor Robin E Ferner,
 Consultant Physician and
 Director, West Midlands Centre
 for Adverse Drug Reactions,
 City Hospital NHS Trust,
 Birmingham

Dr Edmund Jessop, Medical
 Adviser, National Specialist,
 Commissioning Advisory Group
 (NSCAG), Department of
 Health, London

Professor Jon Nicholl, Director,
 Medical Care Research Unit,
 University of Sheffield,
 School of Health and
 Related Research

Dr Ron Zimmern, Director,
 Public Health Genetics Unit,
 Strangeways Research
 Laboratories, Cambridge

HTA Commissioning Board

Members

Programme Director,
Professor Tom Walley,
 Director, NHS HTA Programme,
 Department of Pharmacology &
 Therapeutics,
 University of Liverpool

Chair,
Professor Jon Nicholl,
 Director, Medical Care Research
 Unit, University of Sheffield,
 School of Health and Related
 Research

Deputy Chair,
Dr Andrew Farmer,
 University Lecturer in General
 Practice, Department of
 Primary Health Care,
 University of Oxford

Dr Jeffrey Aronson,
 Reader in Clinical
 Pharmacology, Department of
 Clinical Pharmacology,
 Radcliffe Infirmary, Oxford

Professor Deborah Ashby,
 Professor of Medical Statistics,
 Department of Environmental
 and Preventative Medicine,
 Queen Mary University of
 London

Professor Ann Bowling,
 Professor of Health Services
 Research, Primary Care and
 Population Studies,
 University College London

Professor John Cairns,
 Professor of Health Economics,
 Public Health Policy,
 London School of Hygiene
 and Tropical Medicine,
 London

Professor Nicky Cullum,
 Director of Centre for Evidence
 Based Nursing, Department of
 Health Sciences, University of
 York

Professor Jon Deeks,
 Professor of Health Statistics,
 University of Birmingham

Professor Jenny Donovan,
 Professor of Social Medicine,
 Department of Social Medicine,
 University of Bristol

Professor Freddie Hamdy,
 Professor of Urology,
 University of Sheffield

Professor Allan House,
 Professor of Liaison Psychiatry,
 University of Leeds

Professor Sallie Lamb, Director,
 Warwick Clinical Trials Unit,
 University of Warwick

Professor Stuart Logan,
 Director of Health & Social
 Care Research, The Peninsula
 Medical School, Universities of
 Exeter & Plymouth

Professor Miranda Mugford,
 Professor of Health Economics,
 University of East Anglia

Dr Linda Patterson,
 Consultant Physician,
 Department of Medicine,
 Burnley General Hospital

Professor Ian Roberts,
 Professor of Epidemiology &
 Public Health, Intervention
 Research Unit, London School
 of Hygiene and Tropical
 Medicine

Professor Mark Sculpher,
 Professor of Health Economics,
 Centre for Health Economics,
 Institute for Research in the
 Social Services,
 University of York

Professor Kate Thomas,
 Professor of Complementary
 and Alternative Medicine,
 University of Leeds

Professor David John Torgerson,
 Director of York Trial Unit,
 Department of Health Sciences,
 University of York

Professor Hywel Williams,
 Professor of
 Dermato-Epidemiology,
 University of Nottingham

Diagnostic Technologies & Screening Panel

Members

Chair,

Dr Ron Zimmern, Director of the Public Health Genetics Unit, Strangeways Research Laboratories, Cambridge

Ms Norma Armston, Freelance Consumer Advocate, Bolton

Professor Max Bachmann, Professor of Health Care Interfaces, Department of Health Policy and Practice, University of East Anglia

Professor Rudy Bilous, Professor of Clinical Medicine & Consultant Physician, The Academic Centre, South Tees Hospitals NHS Trust

Ms Dea Birkett, Service User Representative, London

Dr Paul Cockcroft, Consultant Medical Microbiologist and Clinical Director of Pathology, Department of Clinical Microbiology, St Mary's Hospital, Portsmouth

Professor Adrian K Dixon, Professor of Radiology, University Department of Radiology, University of Cambridge Clinical School

Dr David Elliman, Consultant in Community Child Health, Islington PCT & Great Ormond Street Hospital, London

Professor Glyn Elwyn, Research Chair, Centre for Health Sciences Research, Cardiff University, Department of General Practice, Cardiff

Professor Paul Glasziou, Director, Centre for Evidence-Based Practice, University of Oxford

Dr Jennifer J Kurinczuk, Consultant Clinical Epidemiologist, National Perinatal Epidemiology Unit, Oxford

Dr Susanne M Ludgate, Clinical Director, Medicines & Healthcare Products Regulatory Agency, London

Mr Stephen Pilling, Director, Centre for Outcomes, Research & Effectiveness, Joint Director, National Collaborating Centre for Mental Health, University College London

Mrs Una Rennard, Service User Representative, Oxford

Dr Phil Shackley, Senior Lecturer in Health Economics, Academic Vascular Unit, University of Sheffield

Dr Margaret Somerville, Director of Public Health Learning, Peninsula Medical School, University of Plymouth

Dr Graham Taylor, Scientific Director & Senior Lecturer, Regional DNA Laboratory, The Leeds Teaching Hospitals

Professor Lindsay Wilson Turnbull, Scientific Director, Centre for MR Investigations & YCR Professor of Radiology, University of Hull

Professor Martin J Whittle, Clinical Co-director, National Co-ordinating Centre for Women's and Childhealth

Dr Dennis Wright, Consultant Biochemist & Clinical Director, The North West London Hospitals NHS Trust, Middlesex

Pharmaceuticals Panel

Members

Chair,

Professor Robin Ferner, Consultant Physician and Director, West Midlands Centre for Adverse Drug Reactions, City Hospital NHS Trust, Birmingham

Ms Anne Baileiff, Consultant Nurse in First Contact Care, Southampton City Primary Care Trust, University of Southampton

Professor Imti Choonara, Professor in Child Health, Academic Division of Child Health, University of Nottingham

Professor John Geddes, Professor of Epidemiological Psychiatry, University of Oxford

Mrs Barbara Greggains, Non-Executive Director, Greggains Management Ltd

Dr Bill Gutteridge, Medical Adviser, National Specialist Commissioning Advisory Group (NSCAG), London

Mrs Sharon Hart, Consultant Pharmaceutical Adviser, Reading

Dr Jonathan Karnon, Senior Research Fellow, Health Economics and Decision Science, University of Sheffield

Dr Yoon Loke, Senior Lecturer in Clinical Pharmacology, University of East Anglia

Ms Barbara Meredith, Lay Member, Epsom

Dr Andrew Prentice, Senior Lecturer and Consultant Obstetrician & Gynaecologist, Department of Obstetrics & Gynaecology, University of Cambridge

Dr Frances Rotblat, CPMP Delegate, Medicines & Healthcare Products Regulatory Agency, London

Dr Martin Shelly, General Practitioner, Leeds

Mrs Katrina Simister, Assistant Director New Medicines, National Prescribing Centre, Liverpool

Dr Richard Tiner, Medical Director, Medical Department, Association of the British Pharmaceutical Industry, London

Therapeutic Procedures Panel

Members

<p>Chair, Professor Bruce Campbell, Consultant Vascular and General Surgeon, Department of Surgery, Royal Devon & Exeter Hospital</p>	<p>Professor Matthew Cooke, Professor of Emergency Medicine, Warwick Emergency Care and Rehabilitation, University of Warwick</p> <p>Mr Mark Emberton, Senior Lecturer in Oncological Urology, Institute of Urology, University College Hospital</p> <p>Professor Paul Gregg, Professor of Orthopaedic Surgical Science, Department of General Practice and Primary Care, South Tees Hospital NHS Trust, Middlesbrough</p> <p>Ms Maryann L Hardy, Lecturer, Division of Radiography, University of Bradford</p>	<p>Dr Simon de Lusignan, Senior Lecturer, Primary Care Informatics, Department of Community Health Sciences, St George's Hospital Medical School, London</p> <p>Dr Peter Martin, Consultant Neurologist, Addenbrooke's Hospital, Cambridge</p> <p>Professor Neil McIntosh, Edward Clark Professor of Child Life & Health, Department of Child Life & Health, University of Edinburgh</p> <p>Professor Jim Neilson, Professor of Obstetrics and Gynaecology, Department of Obstetrics and Gynaecology, University of Liverpool</p>	<p>Dr John C Pounsford, Consultant Physician, Directorate of Medical Services, North Bristol NHS Trust</p> <p>Dr Karen Roberts, Nurse Consultant, Queen Elizabeth Hospital, Gateshead</p> <p>Dr Vimal Sharma, Consultant Psychiatrist/Hon. Senior Lecturer, Mental Health Resource Centre, Cheshire and Wirral Partnership NHS Trust, Wallasey</p> <p>Professor Scott Weich, Professor of Psychiatry, Division of Health in the Community, University of Warwick</p>
<p>Dr Mahmood Adil, Deputy Regional Director of Public Health, Department of Health, Manchester</p> <p>Dr Aileen Clarke, Consultant in Public Health, Public Health Resource Unit, Oxford</p>			

Disease Prevention Panel

Members

<p>Chair, Dr Edmund Jessop, Medical Adviser, National Specialist Commissioning Advisory Group (NSCAG), London</p> <p>Mrs Sheila Clark, Chief Executive, St James's Hospital, Portsmouth</p> <p>Mr Richard Copeland, Lead Pharmacist: Clinical Economy/Interface, Wansbeck General Hospital, Northumberland</p>	<p>Dr Elizabeth Fellow-Smith, Medical Director, West London Mental Health Trust, Middlesex</p> <p>Mr Ian Flack, Director PPI Forum Support, Council of Ethnic Minority Voluntary Sector Organisations, Stratford</p> <p>Dr John Jackson, General Practitioner, Newcastle upon Tyne</p> <p>Mrs Veronica James, Chief Officer, Horsham District Age Concern, Horsham</p> <p>Professor Mike Kelly, Director, Centre for Public Health Excellence, National Institute for Health and Clinical Excellence, London</p>	<p>Professor Yi Mien Koh, Director of Public Health and Medical Director, London NHS (North West London Strategic Health Authority), London</p> <p>Ms Jeanett Martin, Director of Clinical Leadership & Quality, Lewisham PCT, London</p> <p>Dr Chris McCall, General Practitioner, Dorset</p> <p>Dr David Pencheon, Director, Eastern Region Public Health Observatory, Cambridge</p> <p>Dr Ken Stein, Senior Clinical Lecturer in Public Health, Director, Peninsula Technology Assessment Group, University of Exeter, Exeter</p>	<p>Dr Carol Tannahill, Director, Glasgow Centre for Population Health, Glasgow</p> <p>Professor Margaret Thorogood, Professor of Epidemiology, University of Warwick, Coventry</p> <p>Dr Ewan Wilkinson, Consultant in Public Health, Royal Liverpool University Hospital, Liverpool</p>
--	--	--	--

Expert Advisory Network

Members

Professor Douglas Altman,
Professor of Statistics in
Medicine, Centre for Statistics
in Medicine, University of
Oxford

Professor John Bond,
Director, Centre for Health
Services Research, University of
Newcastle upon Tyne, School of
Population & Health Sciences,
Newcastle upon Tyne

Professor Andrew Bradbury,
Professor of Vascular Surgery,
Solihull Hospital, Birmingham

Mr Shaun Brogan,
Chief Executive, Ridgeway
Primary Care Group, Aylesbury

Mrs Stella Burnside OBE,
Chief Executive,
Regulation and Improvement
Authority, Belfast

Ms Tracy Bury,
Project Manager, World
Confederation for Physical
Therapy, London

Professor Iain T Cameron,
Professor of Obstetrics and
Gynaecology and Head of the
School of Medicine,
University of Southampton

Dr Christine Clark,
Medical Writer & Consultant
Pharmacist, Rossendale

Professor Collette Clifford,
Professor of Nursing & Head of
Research, School of Health
Sciences, University of
Birmingham, Edgbaston,
Birmingham

Professor Barry Cookson,
Director, Laboratory of
Healthcare Associated Infection,
Health Protection Agency,
London

Dr Carl Counsell, Clinical
Senior Lecturer in Neurology,
Department of Medicine &
Therapeutics, University of
Aberdeen

Professor Howard Cuckle,
Professor of Reproductive
Epidemiology, Department of
Paediatrics, Obstetrics &
Gynaecology, University of
Leeds

Dr Katherine Darton,
Information Unit, MIND –
The Mental Health Charity,
London

Professor Carol Dezateux,
Professor of Paediatric
Epidemiology, London

Dr Keith Dodd, Consultant
Paediatrician, Derby

Mr John Dunning,
Consultant Cardiothoracic
Surgeon, Cardiothoracic
Surgical Unit, Papworth
Hospital NHS Trust, Cambridge

Mr Jonathan Earnshaw,
Consultant Vascular Surgeon,
Gloucestershire Royal Hospital,
Gloucester

Professor Martin Eccles,
Professor of Clinical
Effectiveness, Centre for Health
Services Research, University of
Newcastle upon Tyne

Professor Pam Enderby,
Professor of Community
Rehabilitation, Institute of
General Practice and Primary
Care, University of Sheffield

Professor Gene Feder, Professor
of Primary Care Research &
Development, Centre for Health
Sciences, Barts & The London
Queen Mary's School of
Medicine & Dentistry, London

Mr Leonard R Fenwick,
Chief Executive, Newcastle
upon Tyne Hospitals NHS Trust

Mrs Gillian Fletcher,
Antenatal Teacher & Tutor and
President, National Childbirth
Trust, Henfield

Professor Jayne Franklyn,
Professor of Medicine,
Department of Medicine,
University of Birmingham,
Queen Elizabeth Hospital,
Edgbaston, Birmingham

Dr Neville Goodman,
Consultant Anaesthetist,
Southmead Hospital, Bristol

Professor Robert E Hawkins,
CRC Professor and Director of
Medical Oncology, Christie CRC
Research Centre, Christie
Hospital NHS Trust, Manchester

Professor Allen Hutchinson,
Director of Public Health &
Deputy Dean of SchARR,
Department of Public Health,
University of Sheffield

Professor Peter Jones, Professor
of Psychiatry, University of
Cambridge, Cambridge

Professor Stan Kaye, Cancer
Research UK Professor of
Medical Oncology, Section of
Medicine, Royal Marsden
Hospital & Institute of Cancer
Research, Surrey

Dr Duncan Keeley,
General Practitioner (Dr Burch
& Ptnrs), The Health Centre,
Thame

Dr Donna Lamping,
Research Degrees Programme
Director & Reader in Psychology,
Health Services Research Unit,
London School of Hygiene and
Tropical Medicine, London

Mr George Levy,
Chief Executive, Motor
Neurone Disease Association,
Northampton

Professor James Lindesay,
Professor of Psychiatry for the
Elderly, University of Leicester,
Leicester General Hospital

Professor Julian Little,
Professor of Human Genome
Epidemiology, Department of
Epidemiology & Community
Medicine, University of Ottawa

Professor Rajan Madhok,
Consultant in Public Health,
South Manchester Primary
Care Trust, Manchester

Professor Alexander Markham,
Director, Molecular Medicine
Unit, St James's University
Hospital, Leeds

Professor Alistaire McGuire,
Professor of Health Economics,
London School of Economics

Dr Peter Moore,
Freelance Science Writer, Ashtead

Dr Andrew Mortimore, Public
Health Director, Southampton
City Primary Care Trust,
Southampton

Dr Sue Moss, Associate Director,
Cancer Screening Evaluation
Unit, Institute of Cancer
Research, Sutton

Mrs Julietta Patnick,
Director, NHS Cancer Screening
Programmes, Sheffield

Professor Robert Peveler,
Professor of Liaison Psychiatry,
Royal South Hants Hospital,
Southampton

Professor Chris Price,
Visiting Professor in Clinical
Biochemistry, University of
Oxford

Professor William Rosenberg,
Professor of Hepatology and
Consultant Physician, University
of Southampton, Southampton

Professor Peter Sandercock,
Professor of Medical Neurology,
Department of Clinical
Neurosciences, University of
Edinburgh

Dr Susan Schonfield, Consultant
in Public Health, Hillingdon
PCT, Middlesex

Dr Eamonn Sheridan,
Consultant in Clinical Genetics,
Genetics Department,
St James's University Hospital,
Leeds

Professor Sarah Stewart-Brown,
Professor of Public Health,
University of Warwick,
Division of Health in the
Community Warwick Medical
School, LWMS, Coventry

Professor Ala Szczepura,
Professor of Health Service
Research, Centre for Health
Services Studies, University of
Warwick

Dr Ross Taylor,
Senior Lecturer, Department of
General Practice and Primary
Care, University of Aberdeen

Mrs Joan Webster,
Consumer member, HTA –
Expert Advisory Network

Feedback

The HTA Programme and the authors would like to know your views about this report.

The Correspondence Page on the HTA website (<http://www.hta.ac.uk>) is a convenient way to publish your comments. If you prefer, you can send your comments to the address below, telling us whether you would like us to transfer them to the website.

We look forward to hearing from you.